snbp20190930

0001437749-19-022592.txt : 20191113 0001437749-19-022592.hdr.sgml : 20191113 20191113080115 ACCESSION NUMBER: 0001437749-19-022592 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 49 CONFORMED PERIOD OF REPORT: 20190930 FILED AS OF DATE: 20191113 DATE AS OF CHANGE: 20191113 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Sun BioPharma, Inc. CENTRAL INDEX KEY: 0001029125 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 870543922 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-55242 FILM NUMBER: 191211719 BUSINESS ADDRESS: STREET 1: 712 VISTA BLVD #305 CITY: WACONIA STATE: MN ZIP: 55387 BUSINESS PHONE: 9524791196 MAIL ADDRESS: STREET 1: 712 VISTA BLVD #305 CITY: WACONIA STATE: MN ZIP: 55387 FORMER COMPANY: FORMER CONFORMED NAME: Cimarron Medical, Inc. DATE OF NAME CHANGE: 20150602 FORMER COMPANY: FORMER CONFORMED NAME: CIMARRON SOFTWARE INC DATE OF NAME CHANGE: 19961217 10-Q 1 snbp20190930_10q.htm FORM 10-Q snbp20190930_10q.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)
☑	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2019

or

☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ________ to ________.

Commission File No.: 000-55242

	Sun BioPharma, Inc.
	(Exact Name of Registrant as Specified in its Charter)

Delaware		87-0543922
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

712 Vista Blvd #305, Waconia, Minnesota
(Address of principal executive offices)

(952) 479-1196

(Registrant’s telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☑ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☑ No ☐ *

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☐	Accelerated filer ☐

Non-accelerated filer ☐	Smaller reporting company ☑

	Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☑

Securities registered pursuant to Section 12(b) of the Act: None

On November 8, 2019, there were 6,631,308 shares of the registrant’s common stock, par value $0.001, outstanding.

Sun BioPharma, Inc.
Index to Quarterly Report on Form 10-Q

			Page
PART I – FINANCIAL INFORMATION

	Item 1.	Financial Statements (unaudited).	3
	Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations.	14
	Item 3.	Quantitative and Qualitative Disclosure About Market Risk.	19
	Item 4.	Controls and Procedures.	19

PART II – OTHER INFORMATION

	Item 1.	Legal Proceedings.	20
	Item 1A.	Risk Factors.	20
	Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds.	20
	Item 3.	Defaults Upon Senior Securities.	20
	Item 4.	Mine Safety Disclosures.	20
	Item 5.	Other Information.	20
	Item 6.	Exhibits.	20

PART I – FINANCIAL INFORMATION

Item 1. Financial Statements.

Sun BioPharma, Inc.
Condensed Consolidated Balance Sheets

(In thousands, except share amounts)

	September 30, 2019			December 31, 2018
ASSETS	(Unaudited)
Current assets:
Cash	$	3,377		$	1,405
Prepaid expenses and other current assets		119			110
Income tax receivable		275			332
Total current assets		3,771			1,847
Other noncurrent assets		49			51
Total assets	$	3,820		$	1,898

LIABILITITES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable	$	261		$	1,064
Accrued expenses		223			212
Convertible notes payable, net of debt discounts		-			64
Term debt, current portion		204			286
Accrued interest		1			4
Total current liabilities		689			1,630
Unsecured promissory note payable		742			-
Total liabilities		1,431			1,630

Stockholders' equity:
Preferred stock, $0.001 par value; 10,000,000 authorized; no shares issued or outstanding as of September 30, 2019 and December 31, 2018		-			-
Common stock, $0.001 par value; 100,000,000 authorized; 6,624,166 and 5,077,483 shares issued and outstanding, as of September 30, 2019 and December 31, 2018, respectively		7			5
Additional paid-in capital		42,164			35,038
Accumulated deficit		(40,284	)		(35,058	)
Accumulated comprehensive income		502			283
Total stockholders' equity		2,389			268
Total liabilities and stockholders' equity	$	3,820		$	1,898

See accompanying notes to condensed consolidated financial statements.

Sun BioPharma, Inc.

Condensed Consolidated Statements of Operations and Comprehensive Loss
(In thousands, except share and per share amounts)

(Unaudited)

	Three Months Ended September 30,						Nine Months Ended September 30,
	2019			2018			2019			2018
Operating expenses:
General and administrative	$	622		$	467		$	1,505		$	1,779
Research and development		720			450			1,578			1,475
Operating loss		(1,342	)		(917	)		(3,083	)		(3,254	)

Other (expense) income:
Grant income		-			29			-			51
Interest expense		(3	)		(3	)		(2,187	)		(1,763	)
Other expense		(219	)		(89	)		(287	)		(362	)
Total other expense		(222	)		(63	)		(2,474	)		(2,074	)

Loss before income tax benefit		(1,564	)		(980	)		(5,557	)		(5,328	)

Income tax benefit		190			55			331			163

Net loss		(1,374	)		(925	)		(5,226	)		(5,165	)
Foreign currency translation adjustment		202			155			219			324
Comprehensive loss	$	(1,172	)	$	(770	)	$	(5,007	)	$	(4,841	)

Basic and diluted net loss per share	$	(0.23	)	$	(0.18	)	$	(0.97	)	$	(1.14	)
Weighted average shares outstanding - basic and diluted		6,009,904			5,060,594			5,385,986			4,522,606

See accompanying notes to condensed consolidated financial statements.

Sun BioPharma, Inc.

Condensed Consolidated Statements of Stockholders’ Equity (Deficit)

(In thousands)

(Unaudited)

	For the Nine Months Ended September 30, 2018
	Common Stock				Additional Paid-In			Accumulated			Accumulated Other Comprehensive			Total Stockholders'
	Shares		Amount		Capital			Deficit			Gain (Loss)			Equity (Deficit)
Balances as of January 1, 2018		3,842	$	4	$	25,625		$	(29,153	)	$	(165	)	$	(3,689	)
Sale of common stock and warrants		252		-		1,261			-			-			1,261
Stock-based compensation		-		-		1,792			-			-			1,792
Net loss		-		-		-			(1,753	)		-			(1,753	)
Foreign currency translation adjustment		-		-		-			-			69			69
Balances as of March 31, 2018		4,094	$	4	$	28,678		$	(30,906	)	$	(96	)	$	(2,320	)

Sale of common stock and warrants		216		-		1,080			-			-			1,080
Beneficial conversion feature		-		-		121			-			-			121
Conversion of convertible notes payable and accrued interest into common stock and warrants		751		1		3,257			-			-			3,258
Stock-based compensation		-		-		358			-			-			358
Net loss		-		-		-			(2,487	)		-			(2,487	)
Foreign currency translation adjustment		-		-		-			-			100			100
Balances as of June 30, 2018		5,061	$	5	$	33,494		$	(33,393	)	$	4		$	110

Sale of common stock and warrants		-		-		(28	)		-			-			(28	)
Stock-based compensation		-		-		146			-			-			146
Net loss		-		-		-			(925	)		-			(925	)
Foreign currency translation adjustment		-		-		-			-			155			155
Balances as of Septmber 30, 2018		5,061	$	5	$	33,612		$	(34,318	)	$	159		$	(542	)

	For the Nine Months Ended September 30, 2019
	Common Stock					Additional Paid-In			Accumulated			Accumulated Other Comprehensive			Total Stockholders'
	Shares			Amount		Capital			Deficit			Gain (Loss)			Equity (Deficit)
Balances as of January 1, 2019		5,077		$	5	$	35,038		$	(35,058	)	$	283		$	268
Beneficial conversion feature on convertible notes payable		-			-		353			-			-			353
Warrants issued with sale of convertible notes payable		-			-		419			-			-			419
Common stock converted into convertible notes payable		(7	)		-		(25	)		-			-			(25	)
Stock-based compensation		-			-		10			-			-			10
Net loss		-			-		-			(1,581	)		-			(1,581	)
Foreign currency translation adjustment		-			-		-			-			(32	)		(32	)
Balances as of March 31, 2019		5,070		$	5	$	35,795		$	(36,639	)	$	251		$	(588	)

Conversion of convertible notes payable and accrued interest into common stock		652			1		2,280			-			-			2,281
Stock-based compensation		-			-		412			-			-			412
Net loss		-			-		-			(2,271	)		-			(2,271	)
Foreign currency translation adjustment		-			-		-			-			49			49
Balances at June 30, 2019		5,722		$	6	$	38,487		$	(38,910	)	$	300		$	(117	)

Sale of common stock and warrants		902			1		3,141			-			-			3,142
Stock-based compensation		-			-		536			-			-			536
Net loss		-			-		-			(1,374	)		-			(1,374	)
Foreign currency translation adjustment		-			-		-			-			202			202
Balances at September 30, 2019		6,624		$	7	$	42,164		$	(40,284	)	$	502		$	2,389

See accompanying notes to condensed consolidated financial statements.

Sun BioPharma, Inc.

Condensed Consolidated Statements of Cash Flows
(In thousands)

(Unaudited)

	Nine Months Ended September 30,
	2019			2018
Cash flows from operating activities:
Net loss	$	(5,226	)	$	(5,165	)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation		958			1,202
Amortization of debt discount		2,061			1,687
Amortization of debt issuance costs		12			9
Non-cash interest expense		102			6
Changes in operating assets and liabilities:
Income tax receivable		44			(157	)
Prepaid expenses and other current assets		(12	)		23
Accounts payable		179			186
Accrued liabilities		15			(16	)
Net cash used in operating activities		(1,867	)		(2,225	)

Cash flows from financing activities:
Proceeds from the sale of convertible promissory notes and warrants, net of debt issuance costs of $7		810			-
Proceeds from sale of common stock and warrants, net of offering costs of $16 and $27 respectively		3,142			2,314
Repayment of demand note		(25	)		-
Repayments of term debt		(82	)		-
Net cash provided by financing activities		3,845			2,314

Effect of exchange rate changes on cash		(6	)		(2	)

Net change in cash		1,972			87
Cash at beginning of period		1,405			152
Cash at end of period	$	3,377		$	239

Supplemental disclosure of cash flow information:
Cash paid during period for interest	$	11		$	61

Supplemental disclosure of non-cash transactions:
Beneficial conversion feature on convertible notes	$	353		$	121
Warrants issued with convertible notes	$	419		$	-
Common stock converted into convertible notes payable	$	25		$	-
Conversion of convertible notes payable and accrued interest into common stock and warrants	$	-		$	2,908
Conversion of convertible notes payable and accrued interest into common stock	$	2,281		$	350
Issuance of unsecured promissory note in exchange for vendor accounts payable	$	742		$	-
Options granted in exchange for release from contingent payment obligations	$	-		$	1,094

See accompanying notes to condensed consolidated financial statements.

Sun BioPharma, Inc.
Notes to Condensed Consolidated Financial Statements

1.	Business

Sun BioPharma, Inc. together with its wholly-owned subsidiary Sun BioPharma Australia Pty Ltd. (collectively “we,” “us,” “our,” and the “Company”), exists for the primary purpose of advancing the commercial development of a proprietary polyamine analogue (the “compound”) for the treatment of patients with pancreatic cancer. We have exclusively licensed the worldwide rights to this compound, which has been designated as SBP-101, from the University of Florida Research Foundation, Inc. (“UFRF”).

2.	Risks and Uncertainties

The Company operates in a highly regulated and competitive environment. The development, manufacturing and marketing of pharmaceutical products require approval from, and are subject to ongoing oversight by, the Food and Drug Administration (“FDA”) in the United States, the Therapeutic Goods Administration in Australia, the European Medicines Agency in the European Union, and comparable agencies in other countries. Obtaining approval for a new pharmaceutical product is never certain, may take many years, and is normally expected to involve substantial expenditures.

We have incurred losses of $40.3 million since our inception in 2011. For the nine months ended September 30, 2019, we incurred a net loss of $5.2 million, which includes the amortization of discount on debt of $2.1 million. We also incurred negative cash flows from operating activities of $1.9 million during this period. During this same period, we raised $3.1 million from sales of common stock and warrants and $0.8 million from the sale of convertible promissory notes and warrants, as discussed in Note 4 titled “Liquidity and Business Plan”. The notes sold in January 2019, along with similar ones sold in December 2018 converted into common stock on June 30, 2019. As we continue to pursue development activities and seek commercialization of our initial product candidate, SBP-101, we expect to incur substantial losses, which are likely to generate negative net cash flows from operating activities. As of September 30, 2019, we had cash of $3.4 million, working capital (current assets less current liabilities) of $3.1 million and stockholders’ equity of $2.4 million. The Company’s principal sources of cash have historically included the issuance of convertible debt and equity securities.

The accompanying condensed consolidated financial statements have been prepared assuming that we will continue as a going concern, which contemplates the realization of assets and liquidation of liabilities in the normal course of business. The condensed consolidated financial statements do not include any adjustments relating to the recoverability or classification of assets or the amounts of liabilities that might result from the outcome of these uncertainties. Our current independent registered public accounting firm included a paragraph emphasizing this going concern uncertainty in their audit report regarding our 2018 financial statements dated March 22, 2019. Our ability to continue as a going concern, realize the carrying value of our assets and discharge our liabilities in the ordinary course of business is dependent upon a number of factors, including our ability to obtain additional financing, the success of our development efforts, our ability to obtain marketing approval for our SBP-101 product candidate in the United States, Australia, the European Union or other markets and ultimately our ability to market and sell our SBP-101 product candidate. These factors, among others, raise substantial doubt about our ability to continue operations as a going concern. See Note 4 titled “Liquidity and Business Plan.”

3.	Basis of Presentation

We have prepared the accompanying interim condensed consolidated financial statements in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and Regulation S-X of the Securities and Exchange Commission (“SEC”). Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. These interim condensed consolidated financial statements reflect all adjustments consisting of normal recurring accruals, which, in the opinion of management, are necessary to present fairly our consolidated financial position, consolidated results of operations and consolidated cash flows for the periods and as of the dates presented. Our fiscal year ends on December 31. The condensed consolidated balance sheet as of December 31, 2018 was derived from audited consolidated financial statements but does not include all disclosures required by U.S. GAAP. These interim condensed consolidated financial statements should be read in conjunction with the annual consolidated financial statements and the notes thereto included in our most recent filed Annual Report on Form 10-K and our subsequent filings with the SEC. The nature of our business is such that the results of any interim period may not be indicative of the results to be expected for the entire year.

Recently Adopted Accounting Pronouncements

In June 2018, the Financial Accounting Standards Board (the “FASB”) issued Accounting Standards Update (“ASU”) 2018-07, “Compensation – Stock Compensation (Topic 718).” ASU 2018-07 simplifies the accounting for nonemployee stock-based payment transactions. This ASU was adopted by the Company effective for the fiscal year beginning January 1, 2019. Historically, the ultimate stock-based compensation related to non-employee common stock options would fluctuate based on changes in the underlying option pricing model as the awards vest. Under the new guidance, the total compensation cost of non-employee options is determined at grant date. The Company has evaluated the impact of this new guidance on its financial statements and has determined that it has affected how the Company records stock-based compensation related to common stock options and other equity-based compensation, if any, granted to non-employees.

In February 2016, the FASB issued ASU 2016-02, “Leases,” which created a new Topic, Accounting Standards Codification (“ASC”) Topic 842 and established the core principle that a lessee should recognize the assets, representing rights-of-use, and liabilities to make lease payments, that arise from leases. For leases with a term of 12 months or less, a lessee is permitted to make an election under which such assets and liabilities would not be recognized, and lease expense would be recognized generally on a straight-line basis over the lease term. This standard was adopted by the Company for the year beginning January 1, 2019. The Company has evaluated the impact of this revised guidance on its financial statements and determined it had no material impact, as the Company has no leasing arrangements with terms greater than one year.

4.	Liquidity and Business Plan

We will need to obtain additional funds to continue our operations and execute our current business plans. We may seek to raise additional funds through various sources, such as equity and debt financings, or through strategic collaborations and license agreements. We can give no assurances that we will be able to secure additional sources of funds to support our operations, or if such funds are available to us, that such additional financing will be sufficient to meet our needs or on terms acceptable to us. This risk would increase if our clinical data is inconclusive or not positive or economic conditions worsen in the market as a whole or in the pharmaceutical or biotechnology markets individually.

In closings occurring in August and September 2019 the Company sold 902,067 shares of common stock and an equal number of warrants to purchase common stock in a private placement to certain accredited investors pursuant to a Securities Purchase Agreement. Net proceeds from these sales totaled approximately $3.1 million. The warrants are exercisable for a period of five years from the date of issuance at an initial exercise price of $4.00.

In closings occurring in December 2018 and January 2019 the Company sold $2.2 million principal amount of unsecured convertible promissory notes (the “Notes”) and warrants to purchase up to 1,243,498 shares of common stock in a private placement to certain investors. On June 30, 2019 the entire principal balance and accrued interest of $105,000 converted into 651,758 shares of common stock per the terms of the Notes at a conversion rate of $3.50. See Note 6 titled “Indebtedness” for a detailed discussion of the material terms of the Notes. The warrants are exercisable for a period of five years from the date of issuance at an initial exercise price of $4.50.

If we are unable to obtain additional financing when needed, we believe that will need to reduce our operations by taking actions that may include, among other things, reducing use of outside professional service providers, reducing staff or further reducing staff compensation, significantly modifying or delaying the development of our SBP-101 product candidate, licensing rights to third parties, including the right to commercialize our SBP-101 product candidate for pancreatic cancer or other applications that we would otherwise seek to pursue, or discontinuing operations entirely.

Our future success is dependent upon our ability to obtain additional financing, the success of our development efforts, our ability to obtain marketing approval for our SBP-101 product candidate in the United States or other markets and ultimately our ability to market and sell our SBP-101 product candidate. If we are unable to obtain additional financing when needed, if our clinical trials are not successful or if we are unable to obtain marketing approval, we would not be able to continue as a going concern and would be forced to cease operations and liquidate our company.

There can be no assurances that we will be able to obtain additional financing on commercially reasonable terms, or at all. The sale of additional convertible debt or equity securities would likely result in dilution to our current stockholders.

5.	Summary of Significant Accounting Policies

Principles of consolidation

The accompanying condensed consolidated financial statements include the assets, liabilities and expenses of the Company. All significant intercompany transactions and balances have been eliminated in consolidation.

Use of estimates

The preparation of condensed consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amount of expenses during the reporting period. Actual results could differ from those estimates.

Beneficial conversion features

For convertible debt where the rate of conversion is below fair market value for our common stock, the Company records a beneficial conversion feature and related debt discount that is presented as a direct deduction from the carrying amount of the related debt and as an increase to additional paid-in capital. The debt discount is amortized through interest expense over the life of the related debt.

Debt issuance costs

Costs associated with the issuance of debt instruments are capitalized and presented as a direct deduction from the carrying amount of the related debt liability. These costs are amortized through interest expense over the life of the related debt.

Research and development costs

Research and development costs include expenses incurred in the conduct of our second Phase 1 human clinical trial, for third-party service providers performing various testing and accumulating data related to our preclinical studies; sponsored research agreements; developing and scaling the manufacturing process necessary to produce sufficient amounts of the SBP-101 compound for use in our pre-clinical studies and human clinical trials; consulting resources with specialized expertise related to execution of our development plan for our SBP-101 product candidate; personnel costs, including salaries, benefits and share-based compensation; and costs to license and maintain our licensed intellectual property.

We charge research and development costs, including clinical trial costs, to expense when incurred. Our human clinical trials are, and will be, performed at clinical trial sites and are administered jointly by us with assistance from contract research organizations (“CROs”). Costs of setting up clinical trial sites are accrued upon execution of the study agreement. Expenses related to the performance of clinical trials generally are accrued based on contracted amounts and the achievement of agreed upon milestones, such as patient enrollment, patient follow-up, etc. We monitor levels of performance under each significant contract, including the extent of patient enrollment and other activities through communications with the clinical trial sites and CROs, and adjust the estimates, if required, on a quarterly basis so that clinical expenses reflect the actual effort expended at each clinical trial site and by each CRO.

All material CRO contracts are terminable by us upon written notice and we are generally only liable for actual effort expended by the CROs and certain non-cancelable expenses incurred at any point of termination.

We expense costs associated with obtaining licenses for patented technologies when it is determined there is no alternative future use of the intellectual property subject to the license.

Stock-based compensation

In accounting for stock-based incentive awards, we measure and recognize the cost of employee and non-employee services received in exchange for awards of equity instruments based on the fair value of those awards on the grant date. Calculating stock-based compensation expense requires the input of highly subjective assumptions, which represent our best estimates and involve inherent uncertainties and the application of management’s judgment. Compensation cost is recognized ratably using the straight-line attribution method over the vesting period, which is considered to be the requisite service period. Compensation expense for performance-based stock option awards is recognized when “performance” has occurred or is probable of occurring.

The fair value of stock-based awards is estimated at the date of grant using the Black-Scholes option pricing model. The determination of the fair value of stock-based awards is affected by our stock price, as well as assumptions regarding a number of complex and subjective variables. Risk free interest rates are based upon U.S. Treasury rates appropriate for the expected term of each award. Expected volatility rates are based primarily on the volatility rates of a set of guideline companies, which consist of public and recently public biotechnology companies. The assumed dividend yield is zero, as we do not expect to declare any dividends in the foreseeable future. The expected term of options granted is determined using the “simplified” method. Under this approach, the expected term is presumed to be the mid-point between the average vesting date and the end of the contractual term. Forfeitures of unvested stock options are recognized as they occur.

Foreign currency translation adjustments

The functional currency of Sun BioPharma Australia Pty Ltd is the Australian Dollar. Accordingly, assets and liabilities, and equity transactions of Sun BioPharma Australia Pty Ltd are translated into U.S. dollars at period-end exchange rates. Revenues and expenses are translated at the average exchange rate in effect for the period. The resulting translation gains and losses are recorded as a component of accumulated comprehensive loss presented within the statements of stockholders’ equity (deficit). During the nine-month periods ended September 30, 2019 and 2018, any reclassification adjustments from accumulated other comprehensive loss to operations were inconsequential.

Comprehensive loss

Comprehensive loss consists of our net loss and the effects of foreign currency translation.

Net loss per share

Basic net loss per share is computed by dividing net loss by the weighted-average number of common shares outstanding during the period. Diluted net loss per share is based on the weighted average of common shares outstanding during the period plus dilutive potential common shares calculated using the treasury stock method. Such potentially dilutive shares are excluded when the effect would be anti-dilutive or reduce a net loss per share. The Company’s potential dilutive shares, which include convertible debt, outstanding common stock options, and warrants, have not been included in the computation of diluted net loss per share for all periods as the result would be anti-dilutive.

The following table sets forth the potential shares of common stock that were not included in the calculation of diluted net loss per share as their effects would have been anti-dilutive as of:

	September 30,
	2019		2018
Employee and non-employee stock options		1,711,511		1,130,710
Estimated common shares issuable upon conversion of notes payable and accrued interest		-		2,222
Common stock issuable under common stock purchase warrants		3,411,544		1,265,979
		5,123,055		2,398,911

6.	Indebtedness

Notes

On June 30, 2019, all $2.2 million aggregate principal balance of Notes outstanding plus $105,000 of accrued interest was converted at a conversion rate of $3.50 per share of common stock into 651,758 shares of common stock per the terms of the Notes. The Notes were issued in December 2018 and January 2019 and bore interest at a rate of 10.0% per year. Both the relative value of the Warrants and the beneficial conversion feature of the Notes were recorded as a debt discount at the times the Notes were sold which was presented as a direct deduction from the carrying value of the Notes. The discount was fully amortized through interest expense immediately prior to the conversion on June 30, 2019.

Term debt

Effective April 5, 2019, the terms of our unsecured loan (the “Term Debt”) payable to the Institute for Commercialization of Public Research, Inc. (the “Institute”) were amended to extend the maturity date from May 1, 2019 to December 31, 2019. The Institute agreed to the amendment in exchange for a warrant to purchase 5,555 shares of common stock at an exercise price of $4.50. The warrant expires five years from issuance. The fair market value of the warrant was nominal and as such has not been given any accounting treatment. The amendment requires the continuation of monthly payments of principal and interest totaling $10,000. The unpaid principal balance at September 30, 2019 was $204,000.

Unsecured Promissory Notes

On May 17, 2019 the Company executed an unsecured promissory note with a vendor that relieved the Company’s immediate obligation to pay the outstanding vendor invoices. The outstanding vendor invoices totaling approximately $742,000 were removed from the Company’s accounts payable as consideration for the promissory note. The promissory note is unsecured, does not bear interest and the balance is payable in full on the earlier of (1) December 31, 2020 or (2) the date the Company’s stock is registered on a national exchange.

7.	Commitments and Contingencies

License agreement

Subsequent to the end of the quarter, on October 3, 2019, the Company entered into a second amendment to its License Agreement No. A9672 with the University of Florida Research Foundation, Inc. (“UFRF”). The license agreement continues to entitle the Company to a worldwide exclusive license from UFRF for the polyamine analogue compound (“SBP-101”). The second amendment (i) eliminated the Company’s obligation to make any future milestone and minimum royalty payments to UFRF; (ii) clarified the obligation of the Company to make certain payments to UFRF in the event the Company sub-licenses SBP-101 to another party; (iii) reduced the period during which the Company is required to pay royalties on future commercial sales of SBP-101 to the shorter of ten years or the expiration of the period of regulatory exclusivity on a country-by-country basis; and (iv) extended the deadline for the first commercial sale of SBP-101 to December 31, 2025 before UFRF may exercise its termination rights under the license agreement.

8.	Stockholders’ Deficit

Shares of common stock reserved for future issuance were as follows as of September 30, 2019:

	Total Reserved
Stock options outstanding		1,711,511
Shares available for grant under equity incentive plan		52,849
Common shares issuable under outstanding common stock purchase warrants		3,411,544
		5,175,904

Private Placement

During the quarter ended September 30, 2019, we issued an aggregate of 902,067 shares of our common stock and warrants to purchase an aggregate of up to the same number of additional shares of common stock pursuant to closings under 2019 Securities Purchase Agreements. Total proceeds from the sale of common stock and warrants was approximately $3.1 million. See Note 4, titled “Liquidity and Management’s Plans.

9.	Stock-based Compensation

2016 Omnibus Incentive Plan

The Sun BioPharma, Inc. 2016 Omnibus Incentive Plan (the “2016 Plan”) was adopted by our Board of Directors in March 2016 and approved by our stockholders in May 2016. The 2016 Plan permits the granting of incentive and non-statutory stock options, restricted stock, stock appreciation rights, performance units, performance shares and other stock awards to eligible employees, directors and consultants. We grant options to purchase shares of common stock under the 2016 Plan at no less than the fair market value of the underlying common stock as of the date of grant. Options granted under the 2016 Plan have a maximum term of ten years. Under the 2016 Plan, a total of 1,500,000 shares of common stock were initially reserved for issuance. As of September 30, 2019, options to purchase 1,447,151 shares of common stock were outstanding under the 2016 Plan 52,849 shares remained available for future awards.

2011 Stock Option Plan

Our Board of Directors ceased making awards under the Sun BioPharma, Inc. 2011 Stock Option Plan (the “2011 Plan”) upon the receipt of stockholder approval for the 2016 Plan. Awards outstanding under the 2011 Plan remain outstanding in accordance with and pursuant to the terms thereof. Options granted under the 2011 Plan have a maximum term of ten years and generally vest over zero to two years for employees. As of September 30, 2019, options to purchase 264,360 shares of common stock remained outstanding under the 2011 Plan.

Stock-based Compensation Expense

General and administrative (“G&A”) and research and development (“R&D”) expenses include non-cash stock-based compensation expense as a result of our issuance of stock options. The terms and vesting schedules for stock-based awards vary by type of grant and the employment status of the grantee. The awards granted through September 30, 2019 vest based upon time-based and performance conditions. There was approximately $0.6 million unamortized stock-based compensation expense related to options granted to employees and non-employees as of September 30, 2019 which will be amortized over the next eleven quarters.

Stock-based compensation expense for each of the periods presented is as follows (in thousands):

	Nine Months Ended September 30,
	2019		2018
General and Administrative	$	573	$	1,404
Research and Development		385		892
	$	958	$	2,296

A summary of stock option activity for the nine months ended September 30, 2019 is as follows:

	Shares Available for Grant			Shares Underlying Options			Weighted Average Exercise Price Per Share		Aggregate Intrinsic Value
Balance at December 31, 2018		732,149			1,032,211		$	8.90	$	169,495
Granted		(700,100	)		700,100			3.41
Exercised		-			-			-
Cancelled		-			-			-
Forfeitures		20,800			(20,800	)		15.10

Balance at September 30, 2019		52,849			1,711,511		$	6.58	$	1,674,675

Information about stock options outstanding, vested and expected to vest as of September 30, 2019, is as follows:

			Outstanding, Vested and Expected to Vest						Options Vested and Excercisable
Per Share Exercise Price			Shares		Weighted Average Remaining Contractual Life (Years)		Weighted Average Exercise Price		Options Excercisable		Weighted Average Remaining Contractual Life (Years)

$0.875	-	$1.10		26,360		3.25	$	1.029		26,360		3.25
$2.275	-	$2.50		38,000		4.37	$	2.464		38,000		4.37
$2.95	-	$3.175		740,800		8.50	$	3.011		398,125		7.52
$4.50	-	$8.10		538,300		8.04	$	6.742		506,500		8.18
$10.00	-	$10.10		54,000		7.80	$	10.007		54,000		7.80
	$15.10			314,051		6.66	$	15.100		307,051		6.76

Totals				1,711,511		7.88	$	6.581		1,330,036		7.43

Key assumptions

The estimated grant-date fair values of the stock options were calculated using the Black-Scholes valuation model, based on the following assumptions for the three months ended September 30, 2019:

	2019
Common stock fair value	4.50	-	5.00
Risk-free interest rate	1.55%	-	1.57%
Expected dividend yield		0%
Expected Option life (years)	5.0	-	5.5
Expected stock price volatility		72%

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations.

This Quarterly Report and other publicly available documents, including any documents incorporated herein and therein by reference contain, and our officers and representatives may from time to time make, “forward-looking statements,” including within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. When used in the following discussion, the words “anticipates,” “intends,” “believes,” “expects,” “intends,” “plans,” ”seeks,” “estimates,” “likely,” “may,” “would,” “will,” and similar expressions, as they relate to us or our management, are intended to identify such forward-looking statements. Examples of forward-looking statements include, among others, statements we make regarding (i) our plans to complete Phase 1b; and (ii) our estimates of additional funds that may be required to complete Phase 1b and obtain necessary approvals.

Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially and adversely from the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: (i) our ability to obtain additional funding to complete Phase 1 clinical trial; (ii) progress and success of our Phase 1 clinical trial; (iii) our ability to demonstrate the safety and effectiveness of our SBP-101 product candidate; (iv) our ability to obtain regulatory approvals for our SBP-101 product candidate in the United States, the European Union or other international markets; (v) the market acceptance and level of future sales of our SBP-101 product candidate; (vi) the cost and delays in product development that may result from changes in regulatory oversight applicable to our SBP-101 product candidate; (vii) the rate of progress in establishing reimbursement arrangements with third-party payors; (viii) the effect of competing technological and market developments; (ix) the costs involved in filing and prosecuting patent applications and enforcing or defending patent claims; and (x) such other factors as discussed in Part I, Item 1A under the caption “Risk Factors” in our most recent Annual Report on Form 10-K, any additional risks presented in our Quarterly Reports on Form 10-Q and our Current Reports on Form 8-K.

Any forward-looking statement made by us in this Quarterly Report is based on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement or reasons why actual results would differ from those anticipated in any such forward-looking statement, whether written or oral, whether as a result of new information, future developments or otherwise.

Overview

The Company exists for the primary purpose of advancing the commercial development of a proprietary polyamine analogue for pancreatic cancer and for a potential additional indication in certain other solid tumor cancers. We have exclusively licensed the worldwide rights to this compound, which has been designated as SBP-101, from the UFRF.

In August 2015, the U.S. FDA granted an Investigational New Drug (“IND”) approval for our SBP-101 product candidate. From January 2016 through September 2017, we enrolled twenty-nine patients into six cohorts, or groups, in the dose-escalation phase of a Phase 1 safety trial and published results in the Spring of 2018. The Company’s second trial, a Phase 1a/1b combination of SBP-101 with gemcitabine and nab-paclitaxel in patients previously untreated for metastatic pancreatic ductal adenocarcinoma (“PDA”), began dosing patients in June of 2018. The Phase 1a portion of this study will have a total of 4 dosing levels, cohorts, and determine a recommended dose (and schedule) of SBP-101 to be given in combination with standard treatment. The Company completed enrollment of an expanded cohort 2 early in the quarter ended September 30, 2019. Following review by the Data Safety Monitoring Board (“DSMB”) of cohort 2 data (data for 6 of 7 patients enrolled was available for review at this DSMB meeting), approval was received to advance to the third planned dose level of SBP-101. Enrollment in cohort 3 began in the middle of July 2019 and was completed in October 2019. Encouraging signals of efficacy were noted in the second cohort. Six of 6 subjects (100%) had significant decreases in Tumor Marker CA19-9 levels during treatment, with changes from baseline ranging from 75% to 95%. The CA19-9 level changes were accompanied by Response Evaluation Criteria in Solid Tumors (“RECIST”) tumor assessments of 4 partial responses and 2 subjects with stable disease. Subsequent to the review of cohort 2 data by the DSMB a new RECIST tumor assessment on one of the 6 subjects converted from stable disease to partial response, resulting in interim efficacy RECIST tumor assessments of 5 partial responses and 1 subject with stable disease at dose level 2. The Company is currently evaluating the appropriate next phase of clinical trial. A previously planned expansion to a Phase 1b at the recommended dose of SBP-101 may be modified to a larger, randomized phase 2 trial for patients with PDA. We estimate that that we have sufficient funding to complete the current Phase 1 clinical trial in PDA. Additional clinical trials will likely be required for FDA or other similar approvals if the results of the current clinical trial of our SBP-101 product candidate remain positive. The cost and timing of additional clinical trials are highly dependent on the nature and size of the trials. However, it is estimated that the next steps in the approval process could cost between $30 and $40 million.

During the three months ended September 30, 2019 the Company obtained the results of a preclinical study related to a potential second indication for SBP-101, the treatment of patients with chronic and recurrent acute pancreatitis. Based on the results of this preclinical study the Company will not be pursuing this indication but will begin exploration of SBP-101 as a treatment for other solid cancer tumors as funding becomes available.

Financial Overview

We have incurred losses of $40.3 million since inception. For the nine months ended September 30, 2019, we incurred a net loss of $5.2 million, which included amortization of debt discount of $2.1 million. We also incurred negative cash flows from operating activities of $1.9 million for this period. We expect to continue to incur substantial losses, which will generate negative net cash flows from operating activities, as we continue to pursue research and development activities and commercialize our SBP-101 product candidate.

Our cash was approximately $3.4 and $1.4 million as of September 30, 2019 and December 31, 2018, respectively.

The increase of $2.0 million in cash for the nine months ended September 30, 2019 was primarily due the sale of common stock and warrants in the third quarter for net proceeds of $3.1 million and the sale of convertible notes and warrants in the first quarter for net proceeds of $0.8 million offset in part by negative cash flow from operations in the nine months of $1.9 million.

We will need to obtain additional funds to continue our operations and execute our current business plans, including completing our current Phase 1 clinical trial, planning for required future trials and pursuing regulatory approvals in the United States, the European Union and other international markets. We historically have financed our operations principally from the sale of convertible debt and equity securities. While we have been successful in the past in obtaining the necessary capital to support our operations, and have similar future plans to obtain additional financing, there is no assurance that we will be able to obtain additional financing under commercially reasonable terms and conditions, or at all. This risk would increase if our clinical data is inconclusive or not positive or economic conditions worsen in the market as a whole or in the pharmaceutical or biotechnology markets individually.

If we are unable to obtain additional financing when needed, we will likely need to reduce our operations by taking actions that may include, among other things, reducing use of outside professional service providers, reducing staff or further reducing staff compensation, significantly modifying or delaying the development of our SBP-101 product candidate, licensing rights to third parties, including the right to commercialize our SBP-101 product candidate for pancreatic cancer, or other applications that we would otherwise seek to pursue, or discontinue operations entirely.

Results of Operations

Comparison of the results of operations (in thousands):

	Nine Months Ended September 30,									Nine Months Ended September 30,
	2019			2018			Percent Change			2019			2018			Percent Change
Operating Expenses
General and administrative	$	622		$	467			33.2	%	$	1,505		$	1,779			-15.4	%
Research and development		720			450			60.0	%		1,578			1,475			7.0	%
Operating loss		(1,342	)		(917	)		46.3	%		(3,083	)		(3,254	)		-5.3	%

Other expenses, net		(222	)		(63	)		252.4	%		(2,474	)		(2,074	)		19.3	%
Income tax benefit		190			55			245.5	%		331			163			103.1	%

Net Loss	$	(1,374	)	$	(925	)		48.5	%	$	(5,226	)	$	(5,165	)		1.2	%

General and administrative (“G&A”) expenses and research and development (“R&D”) expenses include non-cash share-based compensation expense because of our issuance of stock options. We expense the fair value of equity awards over their vesting periods. The terms and vesting schedules for share-based awards vary by type of grant and the employment status of the grantee. The awards granted through September 30, 2019 vest upon performance and time-based conditions. We expect to record additional non-cash share-based compensation expense in the future, which may be significant.

The following table summarizes the stock-based compensation expense in our statements of comprehensive loss for the nine months ended September 30, 2019 and September 30, 2018 (in thousands):

	Nine Months Ended September 30,
	2019		2018
General and administative	$	573	$	1,404
Research and Development		385		892
Total Stock based compensation	$	958	$	2,296

General and administrative expense

Our G&A expenses increased 33.2% to $0.6 million in the third quarter of 2019 up from $0.5 million in the third quarter of 2018. G&A decreased 15.4% to $1.5 million in the nine months ended September 30, 2019, down from $1.8 in the six months ended September 30, 2018. The increase in the quarter ended September 30, 2019 is primarily associated with higher stock compensation expense offset in part by reduced headcount versus the same quarter in the prior year. For the nine-months ended September 30, 2019 the decrease is due to a combination of lower salary expense and lower stock compensation expense.

Research and development expense

Our R&D expenses increased 60.0% to $0.7 million in the third quarter of 2019 up from $0.4 million in the second quarter of 2018. R&D increased 7.0% to $1.6 million in the nine months ended September 30, 2019, up from $1.5 million in the nine months ended September 30, 2018. The increase in the quarter ended September 30, 2019 was due primarily to incremental expenses associated with a manufacturing study, increased cost of the clinical trial and higher stock compensation expense. The increase in the nine-months ended September 30, 2019 was due to manufacturing and preclinical studies, offset in part by reduced stock compensation expense.

Other expense, net

Other income and expense, net, was a net expense of $2.5 million and $2.1 million for the nine months ended September 30, 2019 and 2018, respectively. The increase in other expense is due to higher interest expense resulting from the amortization of debt discount.

Income tax benefit

Income tax benefit was $331,000 for the nine months ended September 30, 2019 versus $163,000 during the nine months ended September 30, 2018. Our income tax benefit is derived primarily from refundable tax credits associated with our R&D activities conducted in Australia and the increased tax benefit is due to higher R&D spending during the nine months ended September 30, 2019.

Liquidity and Capital Resources

The following tables summarize our liquidity and capital resources as of September 30, 2019 and December 31, 2018 and our cash flow data for the nine months ended September 30, 2019 and 2018 and are intended to supplement the more detailed discussion that follows (in thousands):

Liquidity and Capital Resources
	September 30, 2019		December 31, 2018
Cash	$	3,377	$	1,405
Working capital (deficiency)*	$	3,082	$	(1,073	)

* excludes $1,289 of unamortized debt discount at December 31, 2018

Cash Flow Data
	Nine Months Ended September 30,
	2019			2018
Cash Provided by (Used in):
Operating Activities	$	(1,867	)	$	(2,225	)
Investment Activities		-			-
Financing Activities		3,845			2,314
Effect of exchange rate changes on cash		(6	)		(2	)
Net (decrease) increase in cash	$	1,972		$	87

Working Capital

Our total cash was $3.4 million and $1.4 million as of September 30, 2019 and December 31, 2018 respectively. We had $0.7 million in current liabilities and working capital of $3.1 million as of September 30, 2019, compared to $1.6 million in current liabilities and a working capital deficit of $1.1 million (excluding $1.3 million of unamortized debt discount) as of December 31, 2018. The decrease in current liabilities was due to the reduction in vendor payables of $742,000 which were moved to an unsecured, non-interest-bearing promissory note payable which is due on December 31, 2020 and is therefore classified as a long-term liability. The unamortized debt discount as of December 31, 2018 was fully amortized as of June 30, 2019 just prior to the conversion of that debt into common stock of the company.

Cash Flows

Net Cash Used in Operating Activities

Net cash used in operating activities was $1.9 million in the nine months ended September 30, 2019 compared to $2.2 million in the nine months ended September 30, 2018. The net cash used in each of these periods primarily reflects the net loss for these periods and is partially offset by the effects of changes in operating assets and liabilities.

Net Cash Provided by Financing Activities

Net cash provided by financing activities was $3.8 million and $2.3 million for the nine months ended September 30, 2019 and September 30, 2018, respectively. The cash provided for the nine months ended September 30, 2019 represents the net proceeds of $3.1 million from the sale of common stock and warrants in August and September of 2019 and the net proceeds of $0.8 million from the sale of convertible notes and warrants during the first quarter of 2019 offset in part by payments made on a demand note and term debt. The cash provided in the nine months ended September 30, 2018 represents $2.3 million net proceeds from sales of equity securities and warrants.

Capital Requirements

As we continue to pursue our operations and execute our business plan, including the completion of our current Phase 1 clinical trial for our initial product candidate, SBP-101, in pancreatic cancer, planning for required future trials and pursuing regulatory approvals in the United States, the European Union and other international markets, we expect to continue to incur substantial and increasing losses, which will continue to generate negative net cash flows from operating activities.

Our future capital uses and requirements depend on numerous current and future factors. These factors include, but are not limited to, the following:

●

the progress of clinical trials required to support our applications for regulatory approvals, including our current Phase 1a clinical trial, a human clinical trial in Australia and the United States;

●

our ability to demonstrate the safety and effectiveness of our SBP-101 product candidate;

●

our ability to obtain regulatory approval of our SBP-101 product candidate in the United States, the European Union or other international markets;

●

the cost and delays in product development that may result from changes in regulatory oversight applicable to our SBP-101 product candidate;

●

the market acceptance and size of future market opportunity of our SBP-101 product candidate;

●

the rate of progress in establishing reimbursement arrangements with third-party payors;

●

the effect of competing technological and market developments; and

●

the costs involved in filing and prosecuting patent applications and enforcing or defending patent claims.

To date, we have used primarily convertible debt and equity financings to fund our ongoing business operations and short-term liquidity needs, and we expect to continue this practice for the foreseeable future.

We expect that we will increase our projected expenditures once we have additional capital on hand in order to continue our efforts to grow our business and complete our Phase 1a clinical trial for our SBP-101 product candidate. Accordingly, we expect to make additional expenditures in performing our Phase 1a clinical trial and related support activities. With sufficient capital, we also expect to invest in additional R&D efforts of follow-on products or secondary indications. However, we do not have any definitive plans as to the exact amounts or particular uses at this time, and the exact amounts and timing of any expenditure may vary significantly from our current intentions. We will likely need to obtain additional funds to continue our operations and execute our business plans, planning for required future trials and pursuing regulatory approvals in the United States, the European Union and other international markets. We historically have financed our operations principally from the sale of convertible debt and equity securities. While we have been successful in the past in obtaining the necessary capital to support our operations, and have similar future plans to obtain additional financing, there is no assurance that we will be able to obtain additional financing under commercially reasonable terms and conditions, or at all. This risk would increase if our clinical data is inconclusive or not positive or economic conditions worsen in the market as a whole or in the pharmaceutical or biotechnology markets individually.

As of September 30, 2019, we did not have any existing credit facilities under which we could borrow funds. We historically have financed our operations principally from the sale of convertible debt and equity securities.

If we are unable to obtain additional financing when needed, we will likely need to reduce our operations by taking actions which may include, among other things, reducing use of outside professional service providers, reducing staff or further reducing staff compensation, significantly modifying or delaying the development of our SBP-101 product candidate, licensing rights to third parties, including the right to commercialize our SBP-101 product candidate for patients with pancreatic cancer or other applications that we would otherwise seek to pursue, or discontinuing operations entirely.

To the extent that we raise additional capital through the sale of equity or convertible debt securities, the interests of our current stockholders would be diluted, and the terms may include liquidation or other preferences that adversely affect the rights of our current stockholders. If we issue preferred stock, it could affect the rights of our stockholders or reduce the value of our common stock. Specific rights granted to future holders of preferred stock may include voting rights, preferences as to dividends and liquidation, conversion and redemption rights, sinking fund provisions, and restrictions on our ability to merge with or sell our assets to a third party. Debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. Any of these events could adversely affect our ability to achieve our regulatory approvals and commercialization goals and harm our business.

Our future success is dependent upon our ability to obtain additional financing, the success of our current Phase 1 clinical trial and required future trials, our ability to obtain marketing approval for our SBP-101 product candidate in the United States, the European Union and other international markets. If we are unable to obtain additional financing when needed, if our Phase 1 clinical trial is not successful, if we do not receive regulatory approval required for future trials or if once these studies are concluded, we do not receive marketing approval for our SBP-101 product candidate, we would not be able to continue as a going concern and would be forced to cease operations. The interim financial statements included in this report have been prepared assuming that we will continue as a going concern and do not include any adjustments relating to the recoverability or classification of assets or the amounts of liabilities that might result from the outcome of these uncertainties.

Indebtedness

As of September 30, 2019, we had $0.9 million indebtedness outstanding.

As of December 31, 2018, the Company had $1.6 million aggregate principal amount of indebtedness outstanding.

The change in the six months ended September 30, 2019 was due to the conversion of $2.2 million of convertible notes and $105,000 of accrued interest to common stock on September 30, 2019 and a new unsecured promissory note payable entered into for the resolution of the balance owed a single vendor previously reflected in Accounts Payable.

One $25,000 convertible promissory note was paid in full on January 4, 2019.

Included in the $0.9 million of indebtedness is $204,000 outstanding in an unsecured loan that accrues interest of 4.125% per year and is scheduled to mature on December 31, 2019. In accordance with the terms of this loan we commenced monthly payments of $10,000 on May 1, 2018.

Critical Accounting Policies and Estimates

Our significant accounting policies are set forth in the notes accompanying the condensed consolidated financial statements included in this document. The accounting policies used in preparing our interim fiscal 2019 condensed consolidated financial statements are the same as those described in our Annual Report on Form 10-K for the fiscal year ended December 31, 2018.

Off-Balance Sheet Arrangements

We do not have any off-balance sheet arrangements.

Item 3.

Quantitative and Qualitative Disclosure About Market Risk.

As a smaller reporting company, we are not required to provide disclosure pursuant to this item.

Item 4.

Controls and Procedures.

Evaluation of Disclosure Controls and Procedures

Our management is responsible for establishing and maintaining adequate internal control over financial reporting for the Company. As of the date of this filing, management has not identified any material weaknesses, but believes that it does have a significant deficiency in that it has insufficient personnel resources within the accounting function to fully segregate the duties over financial transaction processing and reporting. Management has mitigated this deficiency primarily through greater involvement in the review and monitoring of financial transaction processing and reporting by executive and senior management.

We believe that our internal control system provides reasonable assurance to our management and Board of Directors regarding the preparation and fair presentation of published financial statements. All internal controls over financial reporting, no matter how well designed, have inherent limitations, including the possibility of human error and the circumvention or overriding of controls. Therefore, even effective internal controls over financial reporting can provide only reasonable assurance with respect to financial statement preparation and presentation. Further, because of changes in conditions, the effectiveness of internal controls over financial reporting may vary over time.

As of the end of the period covered by this quarterly report, the Company’s management conducted an evaluation, under the supervision and with the participation of our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures, pursuant to Rules 13a-15 and 15d-15 of the Exchange Act. Based on such evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that, as of September 30, 2019, our disclosure controls and procedures were effective in ensuring that information relating to the Company required to be disclosed in the reports that we file or submit under the Securities Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, including ensuring that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure.

Changes to Internal Control Over Financial Reporting

We have not identified any change in our internal control over financial reporting during our most recently completed fiscal quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

PART II – OTHER INFORMATION

Item 1.

Legal Proceedings.

None

Item 1A.

Risk Factors.

There have been no material changes to the risk factors described in our Annual Report on Form 10-K for the fiscal year ended December 31, 2018.

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds.

On October 10, 2019, we sold 7,142 shares of common stock and a warrant to purchase up to 7,142 additional shares of common stock for total gross proceeds of approximately $25,000. The warrants is exercisable for a period of five years from the date of issuance at an initial exercise price of $4.00 per share. The exercise price of the warrant and the number of the shares issuable upon exercise of the warrant are subject to customary adjustments prior to exercise upon the occurrence of certain events affecting all outstanding shares of common stock.

The foregoing securities were issued in reliance on an exemption from registration set forth in Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”) to a limited number of persons who were “accredited investors,” as defined in Rule 501 of Regulation D of the SEC, without the use of any general solicitations or advertising to market or otherwise offer the securities for sale. None of the shares, warrant or shares of common stock issued upon exercise of the warrant have been registered under the Securities Act or applicable state securities laws and none may be offered or sold in the United States absent registration under the Securities Act, or an exemption from such registration requirements. Neither this quarterly report on Form 10-Q nor any exhibit attached hereto shall constitute an offer to sell or the solicitation of an offer to buy any securities.

Item 3.

Defaults Upon Senior Securities.

None.

Item 4.

Mine Safety Disclosures.

Not applicable.

Item 5.

Other Information.

None.

Item 6.

Exhibits.

Unless otherwise indicated, all documents incorporated into this quarterly report on Form 10-Q by reference to a document filed with the SEC pursuant to the Exchange Act are located under SEC file number 000-55242.

Exhibit No.	Description	Manner of Filing
3.1	Restated Certificate of Incorporation, as amended through November 8, 2017 (incorporated by reference to Exhibit 3.1 to current report on Form 8-K filed November 15, 2017)	Incorporated by Reference

3.2	Bylaws, as amended through May 12, 2016 (incorporated by reference to Exhibit 3.2 to quarterly report on Form 10-Q for the quarter ended June 30, 2016)	Incorporated by Reference

4.1	Form of Warrants issued August 23, August 30, September 20, and October 10, 2019 (incorporated by reference to Exhibit 10.2 to current report on Form 8-K filed August 29, 2019)	Incorporated by Reference

10.1	Form of Securities Purchase Agreement, by and among the Investors (incorporated by reference to Exhibit 10.1 to current report on Form 8-K filed August 29, 2019).	Incorporated by Reference

10.1	Second Amendment to License Agreement No. A9672 between Sun Biopharma, Inc. and University of Florida Research Foundation, Inc., dated as of October 3, 2019 (incorporated by reference to Exhibit 10.1 to Form 8-K filed on October 9, 2019).	Incorporated by Reference

31.1	Certification of Chief Executive Officer Pursuant to Rule 13a-14(a) or 15d-14(a) Under the Securities Exchange Act of 1934, as Amended, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002	Filed Electronically

31.2	Certification of Chief Financial Officer Pursuant to Rule 13a-14(a) or 15d-14(a) Under the Securities Exchange Act of 1934, as Amended, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002	Filed Electronically

32.1	Certification of Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002	Filed Electronically

32.2	Certification of Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002	Filed Electronically

101	Financial statements from the quarterly report on Form 10-Q of Sun BioPharma, Inc. for the quarter ended September 30, 2019, formatted in XBRL: (i) the Balance Sheets, (ii) the Statements of Operations and Comprehensive Loss, (iii) the Statements of Stockholders’ Equity (Deficit), (iv) the Statements of Cash Flows, and (v) the Notes to Financial Statements.	Filed Electronically

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	SUN BIOPHARMA, INC.

Date: November 13, 2019	/s/ Michael T. Cullen, MD
	Michael T. Cullen, MD, MBA President and Chief Executive Officer
	(Duly Authorized Officer)

Date: November 13, 2019	/s/ Susan Horvath
	Susan Horvath Chief Financial Officer
	(Principal Financial Officer and Principal Accounting Officer)

EX-31.1 2 ex_162921.htm EXHIBIT 31.1 ex_162921.htm

Exhibit 31.1

CERTIFICATION PURSUANT TO RULE 13a-14(a) OR 15d-14(a) UNDER THE SECURITIES

EXCHANGE ACT OF 1934, AS AMENDED, AS ADOPTED PURSUANT TO
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Michael T. Cullen, certify that:

1.	I have reviewed this Quarterly Report on Form 10-Q of Sun BioPharma, Inc.;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.	The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Dated: November 13, 2019	/s/ Michael T. Cullen, MD
	Michael T. Cullen, MD, MBA
	President and Chief Executive Officer
	(Principal Executive Officer)

EX-31.2 3 ex_162922.htm EXHIBIT 31.2 ex_162922.htm

Exhibit 31.2

CERTIFICATION PURSUANT TO RULE 13a-14(a) OR 15d-14(a) UNDER THE SECURITIES

EXCHANGE ACT OF 1934, AS AMENDED, AS ADOPTED PURSUANT TO
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Susan Horvath, certify that:

1.	I have reviewed this Quarterly Report on Form 10-Q of Sun BioPharma, Inc.;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

5.	The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Dated: November 13, 2019	/s/ Susan Horvath
	Susan Horvath
	Chief Financial Officer
	(Principal Financial Officer and Principal Accounting Officer)

EX-32.1 4 ex_162923.htm EXHIBIT 32.1 ex_162923.htm

Exhibit 32.1

CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

I, Michael T. Cullen, hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1)

the Quarterly Report on Form 10-Q of Sun BioPharma, Inc. for the quarter ended September 30, 2019 (the “Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)

the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of Sun BioPharma, Inc.

Dated: November 13, 2019

	/s/ Michael T. Cullen, MD
	Michael T. Cullen, MD, MBA
	President and Chief Executive Officer
	(Principal Executive Officer)

EX-32.2 5 ex_162924.htm EXHIBIT 32.2 ex_162924.htm

Exhibit 32.2

CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

I, Susan Horvath, hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1)

(2)

the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of Sun BioPharma, Inc.

Dated: November 13, 2019

	/s/ Susan Horvath
	Susan Horvath
	Chief Financial Officer
	(Principal Financial Officer and Principal
	Accounting Officer)

EX-101.INS 6 snbp-20190930.xml XBRL INSTANCE DOCUMENT false --12-31 Q3 2019 2019-09-30 10-Q 0001029125 6631308 Yes false Non-accelerated Filer Sun BioPharma, Inc. false true Common Stock, $0.001 par value snbp <div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:9pt;margin-right:0pt;margin-top:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Beneficial </div></div><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">c</div></div><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">onversion </div></div><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">f</div></div><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">eature</div></div><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">s</div></div></div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">For convertible debt where the rate of conversion is below fair market value for our common stock, the Company records a beneficial conversion feature and related debt discount that is presented as a direct deduction from the carrying amount of the related debt and as an increase to additional paid-in capital. The debt discount is amortized through interest expense over the life of the related debt.</div></div></div></div></div></div></div></div></div></div></div> 7000 25000 25000 25000 105000 2908000 2281000 350000 <div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:9pt;margin-right:0pt;margin-top:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Debt issuance costs</div></div></div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">Costs associated with the issuance of debt instruments are capitalized and presented as a direct deduction from the carrying amount of the related debt liability. These costs are amortized through interest expense over the life of the related debt.</div></div></div></div></div></div></div></div></div></div></div> 29000 51000 353000 121000 102000 6000 P10Y <div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="margin-right: 10%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; min-; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: center;">Total Reserved</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 83%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Stock options outstanding</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,711,511</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Shares available for grant under equity incentive plan</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">52,849</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Common shares issuable under outstanding common stock purchase warrants</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,411,544</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5,175,904</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </table></div> 700100 1094000 742000 3100000

261000

1064000

223000

212000

502000

283000

42164000

35038000

121000

353000

1792000

358000

146000

10000

412000

536000

28000

419000

573000

1404000

385000

892000

958000

2296000

2061000

1687000

12000

9000

1711511

1130710

2222

3411544

1265979

5123055

2398911

3820000

1898000

3771000

1847000

3377000

1405000

152000

239000

1972000

87000

4.50

1243498

902067

5555

3411544

1500000

52849

5175904

0.001

100000000

6624166

5077483

6624166

5077483

7000

5000

-1172000

-770000

-5007000

-4841000

64000

651758

2200000

3.50

0.1

10000

<div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; min-width: 700px;"> <tr style="vertical-align: top;"> <td style="width: 36pt;"> <div style=" margin: 0pt; text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">9</div></div><div style="display: inline; font-weight: bold;">.</div><div style="display: inline; font-weight: bold;"> </div></div> </td> <td> <div style=" margin: 0pt; text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">S</div><div style="display: inline; font-weight: bold;">tock</div><div style="display: inline; font-weight: bold;">-based</div><div style="display: inline; font-weight: bold;"> Compensation</div></div> </td> </tr> </table> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:9pt;margin-right:0pt;margin-top:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div> Omnibus Incentive Plan</div></div></div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">The Sun BioPharma, Inc. <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div> Omnibus Incentive Plan (the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">“2016</div> Plan”) was adopted by our Board of Directors in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 2016 </div>and approved by our stockholders in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> May 2016. </div>The <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div> Plan permits the granting of incentive and non-statutory stock options, restricted stock, stock appreciation rights, performance units, performance shares and other stock awards to eligible employees, directors and consultants. We grant options to purchase shares of common stock under the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div> Plan at <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> less than the fair market value of the underlying common stock as of the date of grant. Options granted under the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div> Plan have a maximum term of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">ten</div> years. Under the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div> Plan, a total of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,500,000</div> shares of common stock were initially reserved for issuance. As of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> September 30, 2019, </div>options to purchase <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,447,151</div> shares of common stock were outstanding under the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div> Plan <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">52,849</div> shares remained available for future awards.</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:9pt;margin-right:0pt;margin-top:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2011</div> Stock Option Plan</div></div></div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">Our Board of Directors ceased making awards under the Sun BioPharma, Inc. <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2011</div> Stock Option Plan (the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">“2011</div> Plan”) upon the receipt of stockholder approval for the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div> Plan. Awards outstanding under the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2011</div> Plan remain outstanding in accordance with and pursuant to the terms thereof. Options granted under the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2011</div> Plan have a maximum term of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">ten</div> years and generally vest over <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">zero</div> to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">two</div> years for employees. As of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> September 30, 2019, </div>options to purchase <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">264,360</div> shares of common stock remained outstanding under the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2011</div> Plan.</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:9pt;margin-right:0pt;margin-top:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Stock</div></div><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">-based Compensation</div></div><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;"> Expense</div></div></div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">General and administrative (“G&A”) and research and development (“R&D”) expenses include non-cash stock-based compensation expense as a result of our issuance of stock options. The terms and vesting schedules for stock-based awards vary by type of grant and the employment status of the grantee. The awards granted through <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> September 30, 2019 </div>vest based upon time-based and performance conditions. There was approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$0.6</div> million unamortized stock-based compensation expense related to options granted to employees and non-employees as of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> September 30, 2019 </div>which will be amortized over the next <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">eleven</div> quarters.</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"></div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Stock-based compensation expense for each of the periods presented is as follows (in thousands):</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"> </div> <div> <table cellpadding="0pt" cellspacing="0pt" style="margin-right: auto; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; min-width: 700px;"> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: center;">Nine Months Ended September 30,</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">2019</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">2018</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 62%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">General and Administrative</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">573</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,404</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Research and Development</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">385</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">892</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">958</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,296</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </table> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">A summary of stock option activity for the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">nine</div> months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> September 30, 2019 </div>is as follows:</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"> </div> <div> <table border="0" cellpadding="0" cellspacing="0" style="; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Shares</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Available</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">for Grant</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Shares</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Underlying</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Options</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Weighted Average</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Exercise Price</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Per Share</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Aggregate</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Intrinsic Value</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 52%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Balance at December 31, 2018</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">732,149</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,032,211</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8.90</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">169,495</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Granted</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(700,100</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">700,100</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3.41</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Exercised</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Cancelled</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Forfeitures</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">20,800</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(20,800</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">15.10</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Balance at September 30, 2019</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">52,849</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,711,511</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6.58</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,674,675</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </table> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Information about stock options outstanding, vested and expected to vest as of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> September 30, 2019, </div>is as follows:</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"> </div> <div> <table border="0" cellpadding="0" cellspacing="0" style="; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 5%;"> </td> <td style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 4%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; width: 5%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="10" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 35%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: center;">Outstanding, Vested and Expected to Vest</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 18%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: center;">Options Vested and Excercisable</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom;"> <td colspan="3" rowspan="1" style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 9%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Per Share Exercise Price</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Shares</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Weighted Average</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Remaining Contractual Life</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">(Years)</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Weighted Average</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Exercise Price</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Options</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Excercisable</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Weighted Average</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Remaining Contractual Life</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">(Years)</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="width: 5%;"> </td> <td style="width: 4%;"> </td> <td style="width: 5%;"> </td> <td style="width: 1%;"> </td> <td style="width: 1%;"> </td> <td style="width: 14%;"> </td> <td style="width: 1%;"> </td> <td style="width: 1%;"> </td> <td style="width: 1%;"> </td> <td style="width: 14%;"> </td> <td style="width: 1%;"> </td> <td style="width: 1%;"> </td> <td style="width: 1%;"> </td> <td style="width: 15%;"> </td> <td style="width: 1%;"> </td> <td style="width: 1%;"> </td> <td style="width: 1%;"> </td> <td style="width: 14%;"> </td> <td style="width: 1%;"> </td> <td style="width: 1%;"> </td> <td style="width: 1%;"> </td> <td style="width: 14%;"> </td> <td style="width: 1%;"> </td> </tr> <tr style="background-color: rgb(204, 238, 255);"> <td style="width: 5%; font-family: "Times New Roman", Times, serif; font-size: 10pt; text-align: right;">$0.875</td> <td style="width: 4%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 5%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1.10</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">26,360</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3.25</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.029</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">26,360</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3.25</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255);"> <td style="width: 5%; font-family: "Times New Roman", Times, serif; font-size: 10pt; text-align: right;">$2.275</td> <td style="width: 4%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 5%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$2.50</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">38,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4.37</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.464</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">38,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4.37</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(204, 238, 255);"> <td style="width: 5%; font-family: "Times New Roman", Times, serif; font-size: 10pt; text-align: right;">$2.95</td> <td style="width: 4%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 5%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$3.175</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">740,800</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8.50</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3.011</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">398,125</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7.52</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255);"> <td style="width: 5%; font-family: "Times New Roman", Times, serif; font-size: 10pt; text-align: right;">$4.50</td> <td style="width: 4%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 5%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$8.10</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">538,300</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8.04</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6.742</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">506,500</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8.18</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(204, 238, 255);"> <td style="width: 5%; font-family: "Times New Roman", Times, serif; font-size: 10pt; text-align: right;">$10.00</td> <td style="width: 4%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 5%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$10.10</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">54,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7.80</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10.007</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">54,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7.80</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="width: 5%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 4%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$15.10</div></td> <td nowrap="nowrap" style="width: 5%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">314,051</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6.66</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">15.100</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">307,051</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6.76</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="width: 5%;"> </td> <td style="width: 4%;"> </td> <td style="width: 5%;"> </td> <td style="width: 1%; padding-bottom: 1px;"> </td> <td style="width: 1%; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 1%; padding-bottom: 1px;"> </td> <td style="width: 1%; padding-bottom: 1px;"> </td> <td style="width: 1%; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 1%; padding-bottom: 1px;"> </td> <td style="width: 1%; padding-bottom: 1px;"> </td> <td style="width: 1%; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 15%; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 1%; padding-bottom: 1px;"> </td> <td style="width: 1%; padding-bottom: 1px;"> </td> <td style="width: 1%; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 1%; padding-bottom: 1px;"> </td> <td style="width: 1%; padding-bottom: 1px;"> </td> <td style="width: 1%; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 1%; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="3" rowspan="1" style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 5%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">Totals</div></div></div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,711,511</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7.88</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6.581</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,330,036</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7.43</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </table> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Key assumptions </div></div></div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">The estimated grant-date fair values of the stock options were calculated using the Black-Scholes valuation model, based on the following assumptions for the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> September 30, 2019:</div></div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"> </div> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin-right: 20%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 80%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="3" rowspan="1" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 12%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">2019</div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 80%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Common stock fair value</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 7%; font-family: "Times New Roman", Times, serif; font-size: 10pt; text-align: right;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> 4.50</div></td> <td style="width: 5%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> -</div></td> <td nowrap="nowrap" style="width: 7%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5.00</div></td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 80%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Risk-free interest rate</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 7%; font-family: "Times New Roman", Times, serif; font-size: 10pt; text-align: right;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> 1.55%</div></td> <td style="width: 5%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 7%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.57%</div></td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 80%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Expected dividend yield</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 7%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="width: 5%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">0%</div></td> <td nowrap="nowrap" style="width: 7%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> </tr> <tr style="background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 80%;">Expected Option life (years)</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 7%; font-family: "Times New Roman", Times, serif; font-size: 10pt; text-align: right;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5.0</div></td> <td style="width: 5%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 7%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5.5</div></td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 80%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Expected stock price volatility</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 7%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="width: 5%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">72%</div></td> <td nowrap="nowrap" style="width: 7%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> </tr> </table> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"></div></div>

-0.23

-0.18

-0.97

-1.14

<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:9pt;margin-right:18pt;margin-top:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Net loss per share</div></div></div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">Basic net loss per share is computed by dividing net loss by the weighted-average number of common shares outstanding during the period. Diluted net loss per share is based on the weighted average of common shares outstanding during the period plus dilutive potential common shares calculated using the treasury stock method. Such potentially dilutive shares are excluded when the effect would be anti-dilutive or reduce a net loss per share. The Company’s potential dilutive shares, which include convertible debt, outstanding common stock options, and warrants, have <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> been included in the computation of diluted net loss per share for all periods as the result would be anti-dilutive.</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">The following table sets forth the potential shares of common stock that were <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> included in the calculation of diluted net loss per share as their effects would have been anti-dilutive as of:</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"> </div> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin-right: 20%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: center;">September 30,</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">2019</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">2018</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 62%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Employee and non-employee stock options</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,711,511</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,130,710</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Estimated common shares issuable upon conversion of notes payable and accrued interest</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,222</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Common stock issuable under common stock purchase warrants</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,411,544</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,265,979</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5,123,055</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,398,911</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </table> </div></div></div></div></div></div></div></div></div></div></div>

-6000

-2000

P2Y270D

600000

622000

467000

1505000

1779000

-1564000

-980000

-5557000

-5328000

-190000

-55000

-331000

-163000

275000

332000

742000

179000

186000

15000

-16000

-44000

157000

12000

-23000

3000

2187000

1763000

11000

61000

1000

4000

1431000

1630000

3820000

1898000

689000

1630000

204000

3845000

2314000

-1867000

-2225000

-40300000

-5226000

-1374000

-925000

-5165000

-1753000

-2487000

-925000

-1581000

-2271000

-1374000

-222000

-63000

-2474000

-2074000

-1342000

-917000

-3083000

-3254000

49000

51000

202000

155000

219000

324000

69000

100000

155000

-32000

49000

202000

-219000

-89000

-287000

-362000

7000

16000

27000

0.001

10000000

119000

110000

2200000

810000

3142000

3100000

2314000

800000

82000

25000

720000

450000

1578000

1475000

-40284000

-35058000

<div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="margin-right: 20%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; min-; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: center;">September 30,</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">2019</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">2018</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 62%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Employee and non-employee stock options</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,711,511</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,130,710</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Estimated common shares issuable upon conversion of notes payable and accrued interest</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,222</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Common stock issuable under common stock purchase warrants</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,411,544</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,265,979</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5,123,055</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,398,911</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </table></div>

<div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0pt" cellspacing="0pt" style="margin-right: auto; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; min-; min-width: 700px;"> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: center;">Nine Months Ended September 30,</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">2019</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">2018</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 62%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">General and Administrative</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">573</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,404</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Research and Development</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">385</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">892</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">958</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,296</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </table></div>

<div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; min-; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 5%;"> </td> <td style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 4%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; width: 5%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="10" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 35%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: center;">Outstanding, Vested and Expected to Vest</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 18%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: center;">Options Vested and Excercisable</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom;"> <td colspan="3" rowspan="1" style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 9%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Per Share Exercise Price</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Shares</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Weighted Average</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Remaining Contractual Life</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">(Years)</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Weighted Average</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Exercise Price</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Options</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Excercisable</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Weighted Average</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Remaining Contractual Life</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">(Years)</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="width: 5%;"> </td> <td style="width: 4%;"> </td> <td style="width: 5%;"> </td> <td style="width: 1%;"> </td> <td style="width: 1%;"> </td> <td style="width: 14%;"> </td> <td style="width: 1%;"> </td> <td style="width: 1%;"> </td> <td style="width: 1%;"> </td> <td style="width: 14%;"> </td> <td style="width: 1%;"> </td> <td style="width: 1%;"> </td> <td style="width: 1%;"> </td> <td style="width: 15%;"> </td> <td style="width: 1%;"> </td> <td style="width: 1%;"> </td> <td style="width: 1%;"> </td> <td style="width: 14%;"> </td> <td style="width: 1%;"> </td> <td style="width: 1%;"> </td> <td style="width: 1%;"> </td> <td style="width: 14%;"> </td> <td style="width: 1%;"> </td> </tr> <tr style="background-color: rgb(204, 238, 255);"> <td style="width: 5%; font-family: "Times New Roman", Times, serif; font-size: 10pt; text-align: right;">$0.875</td> <td style="width: 4%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 5%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1.10</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">26,360</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3.25</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.029</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">26,360</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3.25</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255);"> <td style="width: 5%; font-family: "Times New Roman", Times, serif; font-size: 10pt; text-align: right;">$2.275</td> <td style="width: 4%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 5%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$2.50</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">38,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4.37</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.464</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">38,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4.37</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(204, 238, 255);"> <td style="width: 5%; font-family: "Times New Roman", Times, serif; font-size: 10pt; text-align: right;">$2.95</td> <td style="width: 4%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 5%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$3.175</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">740,800</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8.50</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3.011</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">398,125</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7.52</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255);"> <td style="width: 5%; font-family: "Times New Roman", Times, serif; font-size: 10pt; text-align: right;">$4.50</td> <td style="width: 4%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 5%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$8.10</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">538,300</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8.04</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6.742</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">506,500</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8.18</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(204, 238, 255);"> <td style="width: 5%; font-family: "Times New Roman", Times, serif; font-size: 10pt; text-align: right;">$10.00</td> <td style="width: 4%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 5%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$10.10</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">54,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7.80</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10.007</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">54,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7.80</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="width: 5%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 4%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$15.10</div></td> <td nowrap="nowrap" style="width: 5%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">314,051</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6.66</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">15.100</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">307,051</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6.76</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="width: 5%;"> </td> <td style="width: 4%;"> </td> <td style="width: 5%;"> </td> <td style="width: 1%; padding-bottom: 1px;"> </td> <td style="width: 1%; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 1%; padding-bottom: 1px;"> </td> <td style="width: 1%; padding-bottom: 1px;"> </td> <td style="width: 1%; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 1%; padding-bottom: 1px;"> </td> <td style="width: 1%; padding-bottom: 1px;"> </td> <td style="width: 1%; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 15%; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 1%; padding-bottom: 1px;"> </td> <td style="width: 1%; padding-bottom: 1px;"> </td> <td style="width: 1%; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 1%; padding-bottom: 1px;"> </td> <td style="width: 1%; padding-bottom: 1px;"> </td> <td style="width: 1%; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 1%; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="3" rowspan="1" style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 5%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">Totals</div></div></div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,711,511</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7.88</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6.581</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,330,036</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7.43</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </table></div>

<div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="margin-right: 20%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; min-; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 80%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="3" rowspan="1" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 12%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">2019</div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 80%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Common stock fair value</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 7%; font-family: "Times New Roman", Times, serif; font-size: 10pt; text-align: right;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> 4.50</div></td> <td style="width: 5%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> -</div></td> <td nowrap="nowrap" style="width: 7%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5.00</div></td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 80%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Risk-free interest rate</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 7%; font-family: "Times New Roman", Times, serif; font-size: 10pt; text-align: right;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> 1.55%</div></td> <td style="width: 5%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 7%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.57%</div></td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 80%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Expected dividend yield</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 7%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="width: 5%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">0%</div></td> <td nowrap="nowrap" style="width: 7%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> </tr> <tr style="background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 80%;">Expected Option life (years)</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 7%; font-family: "Times New Roman", Times, serif; font-size: 10pt; text-align: right;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5.0</div></td> <td style="width: 5%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 7%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5.5</div></td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 80%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Expected stock price volatility</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 7%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="width: 5%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">72%</div></td> <td nowrap="nowrap" style="width: 7%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> </tr> </table></div>

958000

1202000

P0Y

P2Y

0.72

0.0155

0.0157

52849

732149

20800

700100

169495

1674675

1447151

264360

1032211

1711511

8.90

6.58

15.10

3.41

0.875

2.275

2.95

4.50

15.10

26360

38000

398125

506500

54000

307051

1330036

1711511

26360

38000

740800

538300

54000

314051

1.10

2.50

3.175

8.10

10.10

4.50

P10Y

P5Y

P5Y182D

P3Y91D

P4Y135D

P7Y189D

P8Y65D

P7Y292D

P6Y277D

P7Y156D

1.029

2.464

3.011

6.742

10.007

15.10

6.581

P3Y91D

P4Y135D

P8Y182D

P8Y14D

P7Y292D

P6Y240D

P7Y321D

3842000

4094000

5061000

5077000

5070000

5722000

6624000

751000

652000

902067

252000

216000

902000

1000

3257000

3258000

1000

2280000

2281000

1261000

1080000

1000

3141000

3142000

2389000

268000

4000

25625000

-29153000

-165000

-3689000

4000

28678000

-30906000

-96000

-2320000

5000

33494000

-33393000

4000

110000

5000

33612000

-34318000

159000

-542000

5000

35038000

-35058000

283000

5000

35795000

-36639000

251000

-588000

6000

38487000

-38910000

300000

-117000

7000

42164000

-40284000

502000

204000

286000

742000

P5Y

6009904

5060594

5385986

4522606

xbrli:shares xbrli:pure iso4217:USD iso4217:USD xbrli:shares 0001029125 2011-01-01 2019-09-30 0001029125 snbp:LicensingAgreementWithUniversityOfFloridaResearchFoundationMember 2011-12-22 2011-12-22 0001029125 snbp:SunBiopharmaInc2016OmnibusIncentivePlanMember 2016-05-31 2016-05-31 0001029125 2018-01-01 2018-03-31 0001029125 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-01-01 2018-03-31 0001029125 us-gaap:AdditionalPaidInCapitalMember 2018-01-01 2018-03-31 0001029125 us-gaap:CommonStockMember 2018-01-01 2018-03-31 0001029125 us-gaap:RetainedEarningsMember 2018-01-01 2018-03-31 0001029125 2018-01-01 2018-09-30 0001029125 us-gaap:ConvertibleDebtSecuritiesMember 2018-01-01 2018-09-30 0001029125 us-gaap:StockCompensationPlanMember 2018-01-01 2018-09-30 0001029125 us-gaap:WarrantMember 2018-01-01 2018-09-30 0001029125 us-gaap:GeneralAndAdministrativeExpenseMember 2018-01-01 2018-09-30 0001029125 us-gaap:ResearchAndDevelopmentExpenseMember 2018-01-01 2018-09-30 0001029125 2018-04-01 2018-06-30 0001029125 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-04-01 2018-06-30 0001029125 us-gaap:AdditionalPaidInCapitalMember 2018-04-01 2018-06-30 0001029125 us-gaap:CommonStockMember 2018-04-01 2018-06-30 0001029125 us-gaap:RetainedEarningsMember 2018-04-01 2018-06-30 0001029125 2018-07-01 2018-09-30 0001029125 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-07-01 2018-09-30 0001029125 us-gaap:AdditionalPaidInCapitalMember 2018-07-01 2018-09-30 0001029125 us-gaap:CommonStockMember 2018-07-01 2018-09-30 0001029125 us-gaap:RetainedEarningsMember 2018-07-01 2018-09-30 0001029125 snbp:UnsecuredConvertiblePromissoryNotesMember 2018-12-01 2019-01-31 0001029125 2019-01-01 2019-03-31 0001029125 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-03-31 0001029125 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-03-31 0001029125 us-gaap:CommonStockMember 2019-01-01 2019-03-31 0001029125 us-gaap:RetainedEarningsMember 2019-01-01 2019-03-31 0001029125 2019-01-01 2019-09-30 0001029125 us-gaap:ConvertibleDebtSecuritiesMember 2019-01-01 2019-09-30 0001029125 us-gaap:StockCompensationPlanMember 2019-01-01 2019-09-30 0001029125 us-gaap:WarrantMember 2019-01-01 2019-09-30 0001029125 us-gaap:EmployeeStockOptionMember 2019-01-01 2019-09-30 0001029125 us-gaap:EmployeeStockOptionMember snbp:SunBiopharmaInc2011StockOptionPlanMember srt:MaximumMember 2019-01-01 2019-09-30 0001029125 us-gaap:EmployeeStockOptionMember snbp:SunBiopharmaInc2011StockOptionPlanMember srt:MinimumMember 2019-01-01 2019-09-30 0001029125 us-gaap:GeneralAndAdministrativeExpenseMember 2019-01-01 2019-09-30 0001029125 us-gaap:ResearchAndDevelopmentExpenseMember 2019-01-01 2019-09-30 0001029125 snbp:SunBiopharmaInc2011StockOptionPlanMember 2019-01-01 2019-09-30 0001029125 snbp:ExercisePriceRange1Member 2019-01-01 2019-09-30 0001029125 snbp:ExercisePriceRange2Member 2019-01-01 2019-09-30 0001029125 snbp:ExercisePriceRange3Member 2019-01-01 2019-09-30 0001029125 snbp:ExercisePriceRange4Member 2019-01-01 2019-09-30 0001029125 snbp:ExercisePriceRange5Member 2019-01-01 2019-09-30 0001029125 snbp:ExercisePriceRange6Member 2019-01-01 2019-09-30 0001029125 2019-04-01 2019-06-30 0001029125 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-04-01 2019-06-30 0001029125 us-gaap:AdditionalPaidInCapitalMember 2019-04-01 2019-06-30 0001029125 us-gaap:CommonStockMember 2019-04-01 2019-06-30 0001029125 us-gaap:RetainedEarningsMember 2019-04-01 2019-06-30 0001029125 snbp:TermDebtMember 2019-04-05 2019-04-05 0001029125 2019-05-17 2019-05-17 0001029125 snbp:ConversionFromDebtToCommonStockMember 2019-06-30 2019-06-30 0001029125 2019-07-01 2019-09-30 0001029125 srt:MaximumMember 2019-07-01 2019-09-30 0001029125 srt:MinimumMember 2019-07-01 2019-09-30 0001029125 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-07-01 2019-09-30 0001029125 us-gaap:AdditionalPaidInCapitalMember 2019-07-01 2019-09-30 0001029125 us-gaap:CommonStockMember 2019-07-01 2019-09-30 0001029125 us-gaap:RetainedEarningsMember 2019-07-01 2019-09-30 0001029125 us-gaap:PrivatePlacementMember 2019-07-01 2019-09-30 0001029125 us-gaap:PrivatePlacementMember 2019-08-01 2019-09-30 0001029125 us-gaap:EmployeeStockOptionMember snbp:SunBiopharmaInc2016OmnibusIncentivePlanMember 2016-05-31 0001029125 2017-12-31 0001029125 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-12-31 0001029125 us-gaap:AdditionalPaidInCapitalMember 2017-12-31 0001029125 us-gaap:CommonStockMember 2017-12-31 0001029125 us-gaap:RetainedEarningsMember 2017-12-31 0001029125 2018-03-31 0001029125 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-03-31 0001029125 us-gaap:AdditionalPaidInCapitalMember 2018-03-31 0001029125 us-gaap:CommonStockMember 2018-03-31 0001029125 us-gaap:RetainedEarningsMember 2018-03-31 0001029125 2018-06-30 0001029125 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-06-30 0001029125 us-gaap:AdditionalPaidInCapitalMember 2018-06-30 0001029125 us-gaap:CommonStockMember 2018-06-30 0001029125 us-gaap:RetainedEarningsMember 2018-06-30 0001029125 2018-09-30 0001029125 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-09-30 0001029125 us-gaap:AdditionalPaidInCapitalMember 2018-09-30 0001029125 us-gaap:CommonStockMember 2018-09-30 0001029125 us-gaap:RetainedEarningsMember 2018-09-30 0001029125 2018-12-31 0001029125 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 0001029125 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0001029125 us-gaap:CommonStockMember 2018-12-31 0001029125 us-gaap:RetainedEarningsMember 2018-12-31 0001029125 snbp:WarrantsInConnectionWith2018ConvertibleNotesPayableMember 2019-01-31 0001029125 2019-03-31 0001029125 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-03-31 0001029125 us-gaap:AdditionalPaidInCapitalMember 2019-03-31 0001029125 us-gaap:CommonStockMember 2019-03-31 0001029125 us-gaap:RetainedEarningsMember 2019-03-31 0001029125 snbp:WarrantsInConnectionWithTermDebtMember 2019-04-05 0001029125 snbp:UnsecuredPromissoryNoteMember 2019-05-17 0001029125 2019-06-30 0001029125 snbp:WarrantsInConnectionWithSecuritiesPurchaseAgreementMember 2019-06-30 0001029125 snbp:ConversionFromDebtToCommonStockMember 2019-06-30 0001029125 snbp:The2018NotesMember us-gaap:ConvertibleDebtMember 2019-06-30 0001029125 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-06-30 0001029125 us-gaap:AdditionalPaidInCapitalMember 2019-06-30 0001029125 us-gaap:CommonStockMember 2019-06-30 0001029125 us-gaap:RetainedEarningsMember 2019-06-30 0001029125 2019-09-30 0001029125 us-gaap:EmployeeStockOptionMember snbp:SunBiopharmaInc2016OmnibusIncentivePlanMember 2019-09-30 0001029125 snbp:WarrantsInConnectionWithThePrivatePlacementMember 2019-09-30 0001029125 snbp:TermDebtMember 2019-09-30 0001029125 snbp:SunBiopharmaInc2011StockOptionPlanMember 2019-09-30 0001029125 snbp:SunBiopharmaInc2016OmnibusIncentivePlanMember 2019-09-30 0001029125 srt:MaximumMember 2019-09-30 0001029125 srt:MinimumMember 2019-09-30 0001029125 snbp:ExercisePriceRange1Member 2019-09-30 0001029125 snbp:ExercisePriceRange2Member 2019-09-30 0001029125 snbp:ExercisePriceRange3Member 2019-09-30 0001029125 snbp:ExercisePriceRange4Member 2019-09-30 0001029125 snbp:ExercisePriceRange5Member 2019-09-30 0001029125 snbp:ExercisePriceRange6Member 2019-09-30 0001029125 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-09-30 0001029125 us-gaap:AdditionalPaidInCapitalMember 2019-09-30 0001029125 us-gaap:CommonStockMember 2019-09-30 0001029125 us-gaap:RetainedEarningsMember 2019-09-30 0001029125 2019-11-08

EX-101.SCH 7 snbp-20190930.xsd XBRL TAXONOMY EXTENSION SCHEMA 000 - Document - Document And Entity Information link:calculationLink link:definitionLink link:presentationLink 001 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited) link:calculationLink link:definitionLink link:presentationLink 002 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) link:calculationLink link:definitionLink link:presentationLink 003 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) link:calculationLink link:definitionLink link:presentationLink 004 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited) link:calculationLink link:definitionLink link:presentationLink 005 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:calculationLink link:definitionLink link:presentationLink 006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) (Parentheticals) link:calculationLink link:definitionLink link:presentationLink 007 - Disclosure - Note 1 - Business link:calculationLink link:definitionLink link:presentationLink 008 - Disclosure - Note 2 - Risks and Uncertainties link:calculationLink link:definitionLink link:presentationLink 009 - Disclosure - Note 3 - Basis of Presentation link:calculationLink link:definitionLink link:presentationLink 010 - Disclosure - Note 4 - Liquidity and Business Plan link:calculationLink link:definitionLink link:presentationLink 011 - Disclosure - Note 5 - Summary of Significant Accounting Policies link:calculationLink link:definitionLink link:presentationLink 012 - Disclosure - Note 6 - Indebtedness link:calculationLink link:definitionLink link:presentationLink 013 - Disclosure - Note 7 - Commitments and Contingencies link:calculationLink link:definitionLink link:presentationLink 014 - Disclosure - Note 8 - Stockholders' Deficit link:calculationLink link:definitionLink link:presentationLink 015 - Disclosure - Note 9 - Stock-based Compensation link:calculationLink link:definitionLink link:presentationLink 016 - Disclosure - Significant Accounting Policies (Policies) link:calculationLink link:definitionLink link:presentationLink 017 - Disclosure - Note 5 - Summary of Significant Accounting Policies (Tables) link:calculationLink link:definitionLink link:presentationLink 018 - Disclosure - Note 8 - Stockholders' Deficit (Tables) link:calculationLink link:definitionLink link:presentationLink 019 - Disclosure - Note 9 - Stock-based Compensation (Tables) link:calculationLink link:definitionLink link:presentationLink 020 - Disclosure - Note 2 - Risks and Uncertainties (Details Textual) link:calculationLink link:definitionLink link:presentationLink 021 - Disclosure - Note 4 - Liquidity and Business Plan (Details Textual) link:calculationLink link:definitionLink link:presentationLink 022 - Disclosure - Note 5 - Summary of Significant Accounting Policies (Details Textual) link:calculationLink link:definitionLink link:presentationLink 023 - Disclosure - Note 5 - Summary of Significant Accounting Policies - Anti-dilutive Securities (Details) link:calculationLink link:definitionLink link:presentationLink 024 - Disclosure - Note 6 - Indebtedness (Details Textual) link:calculationLink link:definitionLink link:presentationLink 025 - Disclosure - Note 7 - Commitments and Contingencies (Details Textual) link:calculationLink link:definitionLink link:presentationLink 026 - Disclosure - Note 8 - Stockholders' Deficit (Details Textual) link:calculationLink link:definitionLink link:presentationLink 027 - Disclosure - Note 8 - Stockholders' Deficit - Common Stock Reserved for Future Issuance (Details) link:calculationLink link:definitionLink link:presentationLink 028 - Disclosure - Note 9 - Stock-based Compensation (Details Textual) link:calculationLink link:definitionLink link:presentationLink 029 - Disclosure - Note 9 - Stock-based Compensation - Stock-based Compensation Expense (Details) link:calculationLink link:definitionLink link:presentationLink 030 - Disclosure - Note 9 - Stock-based Compensation - Summary of Option Activity (Details) link:calculationLink link:definitionLink link:presentationLink 031 - Disclosure - Note 9 - Stock-based Compensation - Options Outstanding (Details) link:calculationLink link:definitionLink link:presentationLink 032 - Disclosure - Note 9 - Stock-based Compensation - Assumptions Used in Calculating Fair Value of Options (Details) link:calculationLink link:definitionLink link:presentationLink EX-101.CAL 8 snbp-20190930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 9 snbp-20190930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 10 snbp-20190930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Document And Entity Information Expected dividend yield Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate Unsecured promissory note payable Unsecured Long-term Debt, Noncurrent Note To Financial Statement Details Textual Significant Accounting Policies Share-based Payment Arrangement, Option, Exercise Price Range [Table Text Block] Note 5 - Summary of Significant Accounting Policies Note 8 - Stockholders' Deficit Risk-free interest rate Note 9 - Stock-based Compensation Note 5 - Summary of Significant Accounting Policies - Anti-dilutive Securities (Details) Note 8 - Stockholders' Deficit - Common Stock Reserved for Future Issuance (Details) Warrants In Connection with Term Debt [Member] Represents warrants in connection with term debt. Note 9 - Stock-based Compensation - Stock-based Compensation Expense (Details) Note 9 - Stock-based Compensation - Summary of Option Activity (Details) Note 9 - Stock-based Compensation - Options Outstanding (Details) Note 9 - Stock-based Compensation - Assumptions Used in Calculating Fair Value of Options (Details) Notes To Financial Statements Foreign Currency Transactions and Translations Policy [Policy Text Block] Notes To Financial Statements [Abstract] Expected stock price volatility Other noncurrent assets us-gaap_ShareBasedCompensation Stock-based compensation us-gaap_DebtConversionConvertedInstrumentSharesIssued1 Debt Conversion, Converted Instrument, Shares Issued Term Debt [Member] Represents information related to term debt. us-gaap_LiabilitiesCurrent Total current liabilities snbp_DebtConversionConversionOfPromissoryNotesAndAccruedInterestIntoCommonStock Conversion of convertible notes payable and accrued interest into common stock and warrants Represents the conversion of promissory notes and accrued interest into common stock in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. Expected Option life (years) (Year) Earnings Per Share, Policy [Policy Text Block] us-gaap_DebtConversionOriginalDebtAmount1 Debt Conversion, Original Debt, Amount Beneficial conversion feature on convertible notes Represents the intrinsic value of convertible debt with conversion feature in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period. Debt Conversion Description [Axis] Debt Conversion, Name [Domain] Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Amortization of debt discount Amortization of Debt Discount (Premium) Comprehensive Income, Policy [Policy Text Block] Beneficial Conversion Feature, Policy [Policy Text Block] Disclosure of accounting policy for beneficial conversion feature. Share-based Payment Arrangement, Option, Activity [Table Text Block] snbp_SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfSharesAvailableForGrantGrantsInPeriod Granted, shares available for grant (in shares) Represents the number of available shares granted during the period. Foreign currency translation adjustment Foreign currency translation adjustment Research and Development Expense, Policy [Policy Text Block] Exercise Price Range 5 [Member] Represents the fifth exercise price range. us-gaap_AssetsCurrent Total current assets Share-based Payment Arrangement [Policy Text Block] Stockholders' Equity Note Disclosure [Text Block] Convertible notes payable, net of debt discounts Aggregate intrinsic value Income tax receivable Term debt, current portion Common stock, $0.001 par value; 100,000,000 authorized; 6,624,166 and 5,077,483 shares issued and outstanding, as of September 30, 2019 and December 31, 2018, respectively Warrants in Connection with Securities Purchase Agreement [Member] Represents warrants in conjunction with securities purchase agreement. Adjustments to reconcile net loss to net cash used in operating activities: Balance, weighted average exercise price per share (in dollars per share) Common stock, shares authorized (in shares) The 2018 Notes [Member] Represents information related to convertible promissory 2018 notes. Forfeited, weighted average exercise price per share (in dollars per share) Common stock, shares issued (in shares) Common stock, par value (in dollars per share) Granted, weighted average exercise price per share (in dollars per share) Accrued expenses us-gaap_CommonStockCapitalSharesReservedForFutureIssuance Common Stock, Capital Shares Reserved for Future Issuance (in shares) Statistical Measurement [Domain] Maximum [Member] Accrued interest Grant income The aggregate amount of income from grants not considered a component of the entity's core operations. Minimum [Member] Warrants In Connection with 2018 Convertible Notes Payable [Member] Represents warrants in connection with 2018 convertible notes payable. Accounts payable us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance Balance, shares underlying options (in shares) Balance, shares underlying options (in shares) Statistical Measurement [Axis] Preferred stock, $0.001 par value; 10,000,000 authorized; no shares issued or outstanding as of September 30, 2019 and December 31, 2018 Issuance of unsecured promissory note in exchange for vendor accounts payable The issuance of an unsecured promissory note in exchange for vendor accounts payable. Preferred stock, shares issued (in shares) Cash paid during period for interest us-gaap_PolicyTextBlockAbstract Accounting Policies Prepaid expenses and other current assets Preferred stock, shares authorized (in shares) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant Shares available for grant under equity incentive plan (in shares) Balance, shares available for grant (in shares) Balance, shares available for grant (in shares) Preferred stock, par value (in dollars per share) Supplemental disclosure of non-cash transactions: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period Current liabilities: us-gaap_Assets Total assets Supplemental disclosure of cash flow information: Plan Name [Axis] Plan Name [Domain] Sun BioPharma, Inc. 2016 Omnibus Incentive Plan [Member] Represents company's 2016 Omnibus Incentive Plan stock option plan that permits the granting of incentive and non-statutory stock options, restricted stock, stock appreciation rights, performance units, performance shares and other stock awards to eligible employees, directors and consultants. us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount Cash flows from operating activities: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Statement [Line Items] Options granted in exchange for release from contingent payment obligations The amount of options granted in exchange for release from contingent payment obligations. Additional paid-in capital Share-based Payment Arrangement [Text Block] Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] AOCI Attributable to Parent [Member] Stockholders' equity: snbp_DebtConversionAccruedInterestAmount Debt Conversion, Accrued Interest, Amount The amount of the acrrued interest being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. Other expense us-gaap_NonoperatingIncomeExpense Total other expense Award Type [Domain] Current assets: Basis of Presentation and Significant Accounting Policies [Text Block] Net loss Net loss Net Income (Loss) Attributable to Parent, Total Net loss Award Type [Axis] Private Placement [Member] us-gaap_Liabilities Total liabilities us-gaap_NetCashProvidedByUsedInFinancingActivities Net cash provided by financing activities Exercise Price Range 1 [Member] Represents the first exercise price range. Sale of Stock [Axis] Sale of Stock [Domain] Exercise Price Range 2 [Member] Represents the second exercise price range. Share-based Payment Arrangement [Member] us-gaap_OperatingIncomeLoss Operating loss Convertible Debt Securities [Member] Exercise Price Range 3 [Member] Represents the third exercise price range. us-gaap_NetCashProvidedByUsedInOperatingActivities Net Cash Provided by (Used in) Operating Activities, Total Net cash used in operating activities Share-based Payment Arrangement, Option [Member] Other (expense) income: Warrant [Member] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Effect of exchange rate changes on cash us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease Net change in cash Antidilutive Securities [Axis] Antidilutive Securities, Name [Domain] Schedule of Common Stock Reserved for Future Issuance [Table Text Block] Tabular disclosure for common stock reserved for future issuance. Commitments and Contingencies Disclosure [Text Block] snbp_RoyaltyTerm Royalty Term Royalties are to be paid in period of time lasting up to 10 years from the first commercial sale of licensed product. Licensing Agreement with University of Florida Research Foundation [Member] An exclusive license agreement entered into with the University of Florida Research Foundation (UFRF). us-gaap_PaymentsOfStockIssuanceCosts Proceeds from issuance of common stock and warrants, issuance costs Long-term Debt, Type [Axis] Long-term Debt, Type [Domain] us-gaap_ProceedsFromIssuanceOrSaleOfEquity Proceeds from Issuance or Sale of Equity, Total Proceeds from sale of common stock and warrants, net of offering costs of $16 and $27 respectively Proceeds from Issuance of Private Placement Retained Earnings [Member] Convertible Debt [Member] Additional Paid-in Capital [Member] Common Stock [Member] us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments Loss before income tax benefit us-gaap_IncomeTaxExpenseBenefit Income tax benefit us-gaap_IncreaseDecreaseInAccruedLiabilities Accrued liabilities Equity Components [Axis] Equity Component [Domain] us-gaap_LongTermDebt Long-term Debt, Total Accounts payable us-gaap_IncreaseDecreaseInAccountsPayable Increase (Decrease) in Accounts Payable, Total us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 Class of Warrant or Right, Exercise Price of Warrants or Rights Class of Warrant or Right [Axis] Class of Warrant or Right [Domain] Exercise Price Range 6 [Member] Represents the sixth exercise price range. us-gaap_ClassOfWarrantOrRightOutstanding Common shares issuable under outstanding common stock purchase warrants (in shares) us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights Class of Warrant or Right, Number of Securities Called by Warrants or Rights General and administrative Conversion from Debt to Common Stock [Member] Represents the information pertaining to the conversion from debt to common stock snbp_DebtConversionConversionOfPromissoryNotesAndAccruedInterestIntoCommonStockAndWarrants Conversion of convertible notes payable and accrued interest into common stock Represents the conversion of promissory notes and accrued interest into common stock and warrants in a noncash (or part noncash) transaction. "Part noncash" refers to the portion of the transaction not resulting in cash receipts or cash payments in the period. snbp_CommonStockConvertedIntoConvertibleNotesPayableShares Common stock converted into convertible notes payable (in shares) Represents number of common stock converted into convertible notes payable. Proceeds from the sale of convertible promissory notes, offering costs snbp_CommonStockConvertedIntoConvertibleNotesPayableValue Common stock converted into convertible notes payable Common stock converted into convertible notes payable Represents the value of common stock converted into convertible notes payable. Cash Cash and Cash Equivalents, at Carrying Value, Ending Balance Cash at beginning of period Cash at end of period us-gaap_DebtInstrumentConvertibleConversionPrice1 Debt Instrument, Convertible, Conversion Price Share-based compensation expense us-gaap_RepaymentsOfLongTermDebt Repayments of term debt Warrants in Connection with the Private Placement [Member] Represents the information pertaining to the warrants in connection with a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts. Non-cash interest expense Noncash interest expense incurred by the entity during the period. Exercise Price Range 4 [Member] Represents the fourth exercise price range. Amendment Flag General and Administrative Expense [Member] Accounting Policies [Abstract] Significant Accounting Policies [Text Block] us-gaap_ComprehensiveIncomeNetOfTax Comprehensive loss Use of Estimates, Policy [Policy Text Block] us-gaap_DebtInstrumentPeriodicPayment Debt Instrument, Periodic Payment, Total us-gaap_SharesOutstanding Balances (in shares) Balances (in shares) Common stock, shares outstanding (in shares) Title of 12(g) Security Preferred stock, shares outstanding (in shares) Debt Issuance Costs [Policy Text Block] Disclosure of accounting policy for debt issuance costs. Current Fiscal Year End Date us-gaap_DebtInstrumentInterestRateStatedPercentage Debt Instrument, Interest Rate, Stated Percentage Proceeds from the sale of convertible promissory notes and warrants, net of debt issuance costs of $7 Proceeds from Convertible Debt us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets Prepaid expenses and other current assets Research and Development Expense [Member] Document Fiscal Period Focus Document Fiscal Year Focus Consolidation, Policy [Policy Text Block] Document Period End Date Income Statement Location [Axis] Income Statement Location [Domain] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Entity Emerging Growth Company Document Type EX-101.PRE 11 snbp-20190930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 12 R15.htm IDEA: XBRL DOCUMENT

Note 8 - Stockholders' Deficit

9 Months Ended

Sep. 30, 2019

Notes to Financial Statements

Stockholders' Equity Note Disclosure [Text Block]

8 .	S tock holders’ Deficit

of common stock reserved for future

issuance were as follows as of

September

2019:

	Total Reserved
Stock options outstanding		1,711,511
Shares available for grant under equity incentive plan		52,849
Common shares issuable under outstanding common stock purchase warrants		3,411,544
		5,175,904

Private Placement

During the quarter ended

September 30, 2019,

we issued an aggregate of

902,067

shares of our common stock and warrants to purchase an aggregate of up to the same number of additional shares of common stock pursuant to closings under

2019

Securities Purchase Agreements. Total proceeds from the sale of common stock and warrants was approximately

$3.1

million. See Note

titled “Liquidity and Management’s Plans.

XML 13 R11.htm IDEA: XBRL DOCUMENT

Note 4 - Liquidity and Business Plan

9 Months Ended

Sep. 30, 2019

Notes to Financial Statements

Substantial Doubt about Going Concern [Text Block]

4.	Liquidity and Business Plan

We will need to obtain additional funds to continue our operations and execute our current business plans. We

may

seek to raise additional funds through various sources, such as equity and debt financings, or through strategic collaborations and license agreements. We can give

assurances that we will be able to secure additional sources of funds to support our operations, or if such funds are available to us, that such additional financing will be sufficient to meet our needs or on terms acceptable to us. This risk would increase if our clinical data is inconclusive or

not

positive or economic conditions worsen in the market as a whole or in the pharmaceutical or biotechnology markets individually.

In closings occurring in

August

and

September 2019

the Company sold

902,067

shares of common stock and an equal number of warrants to purchase common stock in a private placement to certain accredited investors pursuant to a Securities Purchase Agreement. Net proceeds from these sales totaled approximately

$3.1

million. The warrants are exercisable for a period of

five

years from the date of issuance at an initial exercise price of

$4.00.

In closings occurring in

December 2018

and

January 2019

the Company sold

$2.2

million principal amount of unsecured convertible promissory notes (the “Notes”) and warrants to purchase up to

1,243,498

shares of common stock in a private placement to certain investors. On

June 30, 2019

the entire principal balance and accrued interest of

$105,000

converted into

651,758

shares of common stock per the terms of the Notes at a conversion rate of

$3.50.

See Note

titled “Indebtedness” for a detailed discussion of the material terms of the Notes. The warrants are exercisable for a period of

five

years from the date of issuance at an initial exercise price of

$4.50.

If we are unable to obtain additional financing when needed, we believe that will need to reduce our operations by taking actions that

may

include, among other things, reducing use of outside professional service providers, reducing staff or further reducing staff compensation, significantly modifying or delaying the development of our SBP-

101

product candidate, licensing rights to

third

parties, including the right to commercialize our SBP-

101

product candidate for pancreatic cancer or other applications that we would otherwise seek to pursue, or discontinuing operations entirely.

Our future success is dependent upon our ability to obtain additional financing, the success of our development efforts, our ability to obtain marketing approval for our SBP-

101

product candidate in the United States or other markets and ultimately our ability to market and sell our SBP-

101

product candidate. If we are unable to obtain additional financing when needed, if our clinical trials are

not

successful or if we are unable to obtain marketing approval, we would

not

be able to continue as a going concern and would be forced to cease operations and liquidate our company.

There can be

assurances that we will be able to obtain additional financing on commercially reasonable terms, or at all. The sale of additional convertible debt or equity securities would likely result in dilution to our current stockholders.

XML 14 R19.htm IDEA: XBRL DOCUMENT

Note 8 - Stockholders' Deficit (Tables)

9 Months Ended

Sep. 30, 2019

Notes Tables

Schedule of Common Stock Reserved for Future Issuance [Table Text Block]

	Total Reserved
Stock options outstanding		1,711,511
Shares available for grant under equity incentive plan		52,849
Common shares issuable under outstanding common stock purchase warrants		3,411,544
		5,175,904

XML 15 R6.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Cash flows from operating activities:
Net loss	$ (5,226,000)	$ (5,165,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation	958,000	1,202,000
Amortization of debt discount	2,061,000	1,687,000
Amortization of debt issuance costs	12,000	9,000
Non-cash interest expense	102,000	6,000
Changes in operating assets and liabilities:
Income tax receivable	44,000	(157,000)
Prepaid expenses and other current assets	(12,000)	23,000
Accounts payable	179,000	186,000
Accrued liabilities	15,000	(16,000)
Net cash used in operating activities	(1,867,000)	(2,225,000)
Cash flows from financing activities:
Proceeds from the sale of convertible promissory notes and warrants, net of debt issuance costs of $7	810,000
Proceeds from sale of common stock and warrants, net of offering costs of $16 and $27 respectively	3,142,000	2,314,000
Repayment of demand note	(25,000)
Repayments of term debt	(82,000)
Net cash provided by financing activities	3,845,000	2,314,000
Effect of exchange rate changes on cash	(6,000)	(2,000)
Net change in cash	1,972,000	87,000
Cash at beginning of period	1,405,000	152,000
Cash at end of period	3,377,000	239,000
Supplemental disclosure of cash flow information:
Cash paid during period for interest	11,000	61,000
Supplemental disclosure of non-cash transactions:
Beneficial conversion feature on convertible notes	353,000	121,000
Warrants issued with convertible notes	419,000
Common stock converted into convertible notes payable	25,000
Conversion of convertible notes payable and accrued interest into common stock and warrants		2,908,000
Conversion of convertible notes payable and accrued interest into common stock	2,281,000	350,000
Issuance of unsecured promissory note in exchange for vendor accounts payable	742,000
Options granted in exchange for release from contingent payment obligations		$ 1,094,000

XML 16 R2.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
Current assets:
Cash	$ 3,377	$ 1,405
Prepaid expenses and other current assets	119	110
Income tax receivable	275	332
Total current assets	3,771	1,847
Other noncurrent assets	49	51
Total assets	3,820	1,898
Current liabilities:
Accounts payable	261	1,064
Accrued expenses	223	212
Convertible notes payable, net of debt discounts		64
Term debt, current portion	204	286
Accrued interest	1	4
Total current liabilities	689	1,630
Unsecured promissory note payable	742
Total liabilities	1,431	1,630
Stockholders' equity:
Preferred stock, $0.001 par value; 10,000,000 authorized; no shares issued or outstanding as of September 30, 2019 and December 31, 2018	0	0
Common stock, $0.001 par value; 100,000,000 authorized; 6,624,166 and 5,077,483 shares issued and outstanding, as of September 30, 2019 and December 31, 2018, respectively	7	5
Additional paid-in capital	42,164	35,038
Accumulated deficit	(40,284)	(35,058)
Accumulated comprehensive income	502	283
Total stockholders' equity	2,389	268
Total liabilities and stockholders' equity	$ 3,820	$ 1,898

XML 17 R32.htm IDEA: XBRL DOCUMENT

Note 9 - Stock-based Compensation - Options Outstanding (Details)	9 Months Ended
	Sep. 30, 2019 $ / shares shares
Options outstanding (in shares) \| shares	1,711,511
Options outstanding, weighted average remaining contractual life (Year)	7 years 321 days
Options outstanding, weighted average exercise price (in dollars per share)	$ 6.581
Options excercisable (in shares) \| shares	1,330,036
Options excercisable, weighted average remaining contractual life (Year)	7 years 156 days
Exercise Price Range 1 [Member]
Per share exercise price, lower limit (in dollars per share)	$ 0.875
Per share exercise price, upper limit (in dollars per share)	$ 1.10
Options outstanding (in shares) \| shares	26,360
Options outstanding, weighted average remaining contractual life (Year)	3 years 91 days
Options outstanding, weighted average exercise price (in dollars per share)	$ 1.029
Options excercisable (in shares) \| shares	26,360
Options excercisable, weighted average remaining contractual life (Year)	3 years 91 days
Exercise Price Range 2 [Member]
Per share exercise price, lower limit (in dollars per share)	$ 2.275
Per share exercise price, upper limit (in dollars per share)	$ 2.50
Options outstanding (in shares) \| shares	38,000
Options outstanding, weighted average remaining contractual life (Year)	4 years 135 days
Options outstanding, weighted average exercise price (in dollars per share)	$ 2.464
Options excercisable (in shares) \| shares	38,000
Options excercisable, weighted average remaining contractual life (Year)	4 years 135 days
Exercise Price Range 3 [Member]
Per share exercise price, lower limit (in dollars per share)	$ 2.95
Per share exercise price, upper limit (in dollars per share)	$ 3.175
Options outstanding (in shares) \| shares	740,800
Options outstanding, weighted average remaining contractual life (Year)	8 years 182 days
Options outstanding, weighted average exercise price (in dollars per share)	$ 3.011
Options excercisable (in shares) \| shares	398,125
Options excercisable, weighted average remaining contractual life (Year)	7 years 189 days
Exercise Price Range 4 [Member]
Per share exercise price, lower limit (in dollars per share)	$ 4.50
Per share exercise price, upper limit (in dollars per share)	$ 8.10
Options outstanding (in shares) \| shares	538,300
Options outstanding, weighted average remaining contractual life (Year)	8 years 14 days
Options outstanding, weighted average exercise price (in dollars per share)	$ 6.742
Options excercisable (in shares) \| shares	506,500
Options excercisable, weighted average remaining contractual life (Year)	8 years 65 days
Exercise Price Range 5 [Member]
Per share exercise price, lower limit (in dollars per share)	$ 10
Per share exercise price, upper limit (in dollars per share)	$ 10.10
Options outstanding (in shares) \| shares	54,000
Options outstanding, weighted average remaining contractual life (Year)	7 years 292 days
Options outstanding, weighted average exercise price (in dollars per share)	$ 10.007
Options excercisable (in shares) \| shares	54,000
Options excercisable, weighted average remaining contractual life (Year)	7 years 292 days
Exercise Price Range 6 [Member]
Per share exercise price, lower limit (in dollars per share)	$ 15.10
Options outstanding (in shares) \| shares	314,051
Options outstanding, weighted average remaining contractual life (Year)	6 years 240 days
Options outstanding, weighted average exercise price (in dollars per share)	$ 15.10
Options excercisable (in shares) \| shares	307,051
Options excercisable, weighted average remaining contractual life (Year)	6 years 277 days

XML 18 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 19 R27.htm IDEA: XBRL DOCUMENT

Note 8 - Stockholders' Deficit (Details Textual) - USD ($)	2 Months Ended	3 Months Ended	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2019	Sep. 30, 2019	Sep. 30, 2018
Proceeds from Issuance of Private Placement			$ 3,142,000	$ 2,314,000
Warrants in Connection with the Private Placement [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	902,067	902,067	902,067
Private Placement [Member]
Stock Issued During Period, Shares, New Issues	902,067	902,067
Proceeds from Issuance of Private Placement	$ 3,100,000	$ 3,100,000

XML 20 R23.htm IDEA: XBRL DOCUMENT

Note 5 - Summary of Significant Accounting Policies (Details Textual)	3 Months Ended	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2019
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate	0.00%	0.00%

XML 21 R26.htm IDEA: XBRL DOCUMENT

Note 7 - Commitments and Contingencies (Details Textual)	Dec. 22, 2011
Licensing Agreement with University of Florida Research Foundation [Member]
Royalty Term	10 years

XML 22 R22.htm IDEA: XBRL DOCUMENT

Note 4 - Liquidity and Business Plan (Details Textual) - USD ($)		2 Months Ended		3 Months Ended	9 Months Ended
	Jun. 30, 2019	Sep. 30, 2019	Jan. 31, 2019	Sep. 30, 2019	Sep. 30, 2019	Sep. 30, 2018
Proceeds from Issuance of Private Placement					$ 3,142,000	$ 2,314,000
Proceeds from Convertible Debt					$ 810,000
Conversion from Debt to Common Stock [Member]
Debt Conversion, Accrued Interest, Amount	$ 105,000
Debt Conversion, Converted Instrument, Shares Issued	651,758
Debt Instrument, Convertible, Conversion Price	$ 3.50
Unsecured Convertible Promissory Notes [Member]
Proceeds from Convertible Debt			$ 2,200,000
Warrants in Connection with the Private Placement [Member]
Warrants and Rights Outstanding, Term		5 years		5 years	5 years
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 4		$ 4	$ 4
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		902,067		902,067	902,067
Warrants In Connection with 2018 Convertible Notes Payable [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights			1,243,498
Warrants in Connection with Securities Purchase Agreement [Member]
Warrants and Rights Outstanding, Term	5 years
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 4.50
Private Placement [Member]
Stock Issued During Period, Shares, New Issues		902,067		902,067
Proceeds from Issuance of Private Placement		$ 3,100,000		$ 3,100,000

XML 23 R18.htm IDEA: XBRL DOCUMENT

Note 5 - Summary of Significant Accounting Policies (Tables)

9 Months Ended

Sep. 30, 2019

Notes Tables

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]

	September 30,
	2019		2018
Employee and non-employee stock options		1,711,511		1,130,710
Estimated common shares issuable upon conversion of notes payable and accrued interest		-		2,222
Common stock issuable under common stock purchase warrants		3,411,544		1,265,979
		5,123,055		2,398,911

XML 24 R7.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Cash Flows (Unaudited) (Parentheticals) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Proceeds from the sale of convertible promissory notes, offering costs	$ 7
Proceeds from issuance of common stock and warrants, issuance costs	$ 16	$ 27

XML 25 R3.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares	Sep. 30, 2019	Dec. 31, 2018
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	10,000,000	10,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	100,000,000	100,000,000
Common stock, shares issued (in shares)	6,624,166	5,077,483
Common stock, shares outstanding (in shares)	6,624,166	5,077,483

ZIP 26 0001437749-19-022592-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001437749-19-022592-xbrl.zip M4$L#!!0 ( "= ;4]>6)658H4 $IN!P 1 ?<_)0"@2&) M& 08/"0Q?_W7W0. F0 !\@2,W6V5@D@9F>GGY-3S_^^7^>9Y;TR%S/=.R? MKY26?"4Q6W<,TY[\?/7MH7G]1:YEO\+\20&![]*?Y\]74]^=O7K]^>GIJX3-)B9_0[\\)JPD'JO3[.?Q%WQAD'[!M!^9YV>_PG_#E]HK+WE.1U7Z MF]#&GXA>L$S[^X:G\>>1YL5(MC53][)AHI\0)"4-DNW8=C#+GL/PW=?^8LY> MPT-->(JYIAZ]YYEZ]D3P0\8TGCV:IR;Q GMD.O.IYLZTEN[,:$_D85N.WW"7 MV!UKWH@@@B\S-L_SYVX.,/!+QN;YG$D,8)(44%_>__+1!*1./ 0I>CKPFA-- MFZ]#$_Z0 5'@N[G;-GP-OUXE&,Y8H=3PN=YK_F/\Z!HQ/+7I664X'+ZF7^-' MO:SG8$SE]?_[[=<'?<17^C"0%/YNSN<6N7O-Q@"O?7,^8;<#_^Q\M;2+ICNVS9_\+ M#F7\$:%85L(_ATTD%=/X^4IOJNK5N[%F>>R?K]?&60Y_2\+"_VAZNF;]SC3W M@VV\![%99B9%N7K7;"HJ;#6?*V_0Y;3O'3V8Q8_< P\YQD?XSBNU0ICW?]I\ MRMP!\^9$L,K/*%^]PV^SYHP'7)^1@[,+9H=\/OYM>M;4H.MS?@5Z*C75X.J= M(C?_)ST)CK(<^X/MF_[B%KYW->L3"(OG_V:+,I/ I #;,/,:E)SLO["YX_KP^X.O^>7H2VE?O?N= M>2D ,@==G?H#J*$)_/J+ZSSY4P!ZKMFE=D;II*3%AE%7IP;=P-Q;H,&)XY:; M$@349]"AFJXS*[35:+ D"*G15Z?^PB:F!W1C^Y^U62EJ!V)_"&SIQG3N2=DV MI$^VWDI.G!Y[=>:'*;.L7=#D'N04L+LTU5WK4K B U3F6LW]U M-62FA\5LY%BE5@C"&-4IGR U#!\=?WQS ^> L:F;&F#8#D\3'QGPD,ON'SC144\V1X_O.[$WB&XN-_3?# MY6?7G$S]Y .^,Z>/R/%-S3(G]AM\YVWQ-3\Q&E,"J6.4>(U^A.]\F%3G[RTE ME81#O(8QHN&2?U<(D5X3.&+!71?$C&L"!]=C-0'&VP1']+>TB>VE;7R_*DC> M2@D^EI)?A+* ON.KTF;SM_;(FQ<'9RD33#,'$L '&NF4;3M&&P.1)82_HZ92N 4PP Z#Q;QC5G[I.,)G" M<#Z@TO,E]CQG-@SKP$II?LL6VCP-S_);K-TV\VV\@<>-QEZ C[\%?#C\-RQX:-W_6QZS<2\ MO['9B+G),W>SG;23P5+./7?W95D.D;#32G;'Q+^(DPJ9_'D+Z[?5Q,)"5W4S M\(RK=VIWYX418 =?UV"YKL'Z4:;?;N>L1'KVWMBF]?,5GB@C[^31\+T;X25) M;7@NZ[B.A=X]R+Q/]BV7>%N9:2B?#,#1XJ9[/! MNA[, E(X=Z!\7/S995/03N8C^V2#[F99Z\L3*=6O;Q,1YHF+0Q+A>]#22WT( MZ(2%X_NDZ*^YD9&UC!X(M^2?Z7%N%M]L\Z^ O6>>[IIS9,%0KL2:%RP:?.>K MLU')+1W+7(3FXT21$T@IL*I<'"S_NAO? Y2FYSGN@G!X;1LK8W%,QPLHZ]WJ MMSNE*?&8T&8IL'S%W,VESZ$\R-N,?0 ^"A;@@7^#5:V!2-G74NGE(D0=*,= M2 +VZG%3CECZ>;AI(]]6B9I/GA?@;?*MX_G>ONYIO"0]0W>@&%&,6*<1A7L: M)9-DAJ()Q!#()N'PV^;P(Q$N:: 6=).<3D^F/R4O5(Q)9\Q=6QA#Y%+0!;S@ MLLCY10XN])@=U 5GF=K(M."X0KXU+]Q/FO?2W&K;-&I"^?Z"VI@?RCX[MC/' MH(35")-(Y_;S=6Y'&90VF@M//5A.O=6HZ2AYCA"T@&.;)F?N'1&SP1CIJ'EN MB\,@IK"U!_/F(::KE$$,V'0N,*ZIT['U;IPXU"+=_=O$L)D59^Z>1KR:1UQ@ MJ+:7L.\"V<$75LH"5W.)55&5@RT,-E+7O&EDE'\(1=I>>](;Y.Z)(JM+T+/G MW@&X,GCMY7I#W_5*@/;%66B6#V+3G:W#HV#TIZHF_\3(P;OQ-1YP)N0>(__* MKZ:.KB][B4W)/S?3XG-RK7Q#P=>"%D2'3J:Q"X' MXZL#]K(4L?::U5_-!DLA9R81MVW77_MN*B7&P"K3CN&]H15>XT M)+4]@/]TNS]5PD12R.&#]H_5TD&!TQ_W'SODV?UPK+ MGCK!T/DQS7>D5:J00[OZ+-+N#].>PH1^^DG;<<%@XC,HC;ZB-+J*LG::3*/% M=IY7(2 MH_M>C&$"'00&K 0T:0OQ(L1+AGCIJHU!9RADRXDLE;K)EC!CAL>_<54 B;LB>5LY!)I19T=-'5;G30,NITZB>]LHY: M+\I<.C6"N!3WPW E;6N$NH;"!DI_S5Y=% +76MULF]ZE3D M86=Y W0@:!/K_V9[F/4-^YX*C4,.61G[7\PV'/=:I]R>*!)XWV#'W#NY?B=Q M)[%AA8MBT*3VN-W-#=I4>_S*>/.-YGYM^-OVK/NV!T MF+O;77D-YC+ ''@EV[$_S*>-P1IM[+&2[*RGG7"?EY_P#OY:9;7L:7>$K0 V M<_,/VEVY/=@%-@PNI!#!KT[.&SL'ZG26JH829O9)P)/S5IZIFFJXO%WS\N1< M]1C%,!UZL;5%88$T/CE/?9\-F>R4W2>7"@\]Q;(W4?C6*+USI? #)R'W:T;< ME>4F][<&J+X8"BD@ _NE3G$U7.-N,G!0RIURBF5O*F61ZU*I#X5G.^:^8-"" M9_KL@;F/ILZX>^T+TYV)3:,4*AQQ/.'1Z><;4/VA6AJW^V"A?CC?A+=\M?P" M\7;(LXQR-#U^XF7OJM]SLYM ^JT>:@6EE;4'LKIS/K*Z)+GM)*N[YR.K M"Z=0=[OYU^_;47/;LK%[1"THK:U/TU#,Q8'ZW7;+\YZ+8?R K(Z-_SP[,EM)UF=&_58>W1LXJ!<67T& M'(1B,HP_3E9 .[X?KE1][IHL:6_;(+&=. M'%X0![FA)._:@^ZY$,*>*,B]S!RL!@F>E HV+2'WM#5#H;'MH(\CZT8QD5K[>2>]-H#=24JDR8I-G&! D2Y MKFAE,!P4G'B/(D/Y9\1VOZ]DS)]=NVMC@DQJP M<5^,;3R8$]LMNA@XRGM/NJVNG4K8U,7I.7C/8N6VJH M^LX\LS1J.%*[EUNI.;?]QW&ZH53<7K%L0=Y4=SUI8^/%=(W.<\AL MI/LI*D=-[1['W'6C60!PZ+#VX!T:PS6HPR7UO-1B&0ESF?#&W(*53/B]AK7 MW]DD5(>N_GD%HZF^_M1Y:TB_7U_?++XVW/U%_A@C8 M)52F/4;>04JA-IK+!IS4;Y-Z9WH@FJ2/\%AZ2X[<<41.;GOS?PBZ+VR"UY(( M[$/S^##\OQ3EA8T\EU83@135K93P>M_TL"A%>CL>/MRF-J(E7=/>PU9;BP8. MN9 ,9Y6NC[ :V_%3ZP$J0Z-/ OJ*UK9*#6/'\6ULURVY&(.'##!:2#&!$4TA M+UC,9YFD'O5/W85+7#:VL(-B&.F!Z2 MF.9*S(9W8&7')R'I/6 *CZ526VFE5.O7*2SE6$IIM![SXXY;QD*+Q!2Y, M,*:$ :N%RZ'QD<]FCNFG@_.C8\+=.PKLF\'F;X#B]!"C&@VOM8C]58AO^W\!F9&@U4AR&$OMC;!,DJ.P!NWAI+MBN-P[\([W")Y,GIX_7 M#S?I,ZS)(T S!_DV1_LC??:Z?OB6'N#X:$ $I&R'XT\I]QMIJDM@('FOG_BA M_5;B+6!3O[_Z"H MY#*@AH,6N?GXJ^B;PPL .*D8S,*S+&W<$PF@1^;Y+>D;-2FDLPX(\$E@DI./ M+\-W>*G\!-PZ'GG(C9$ .H+3Q#,JG EFF%D@P:&!]U=%.<G+@!]WG!K7II6#!A9I@7><>U*9::EXZKI@^?:T1"<&74^]FAP'A#$@?60CES@57BOE>UN%?S]?*OV"S*:Z3T'ODK)=UEQ"@:,2UIY$:VQ7/K&'3#ZJ_Y MG*\?TCYGJ2K%/NBHJ24C5X-8U$:6Z4U#T02"@BTO.;AXT> XZWFHZ;CCR>7) MW7\S+F#I\KD!WX9>4,0#G36]IC-N!A[(5YS)6C:[0=$PT[XSB;IR14K3:X33 MN29\27X_^MUK+7D674SAM^'5C(2BL!JOI9)&'XA)?^I)!) 'P,=H I$^1_GL MAU*0EJK9$D./.9(#[Y7+*8J<3AR':VCBJO D?I]XCXUP]VBG6)A#\+1T0$:/ M):[#\'Y"PBP?G+Z)0*(2Q]O/QU#[\M%PYY)[2V:2%W+0)ELILI!.;QIE:Y-2 MVM]ECR8JT\(60$+[D^*OAD+2I*^A,Q1O*&DMC(F G'?ISJWF8:H7_8"(IT"#ED/JW M@" TF]!FE>>^62CC>:Q]XS_NV?"6'X&KC+L%T%_-E2'7$^I MCJKYR;2#(IQ;:#46F#-WXS!2^L[]@@+SPS-S==!S]W!&9_&/7OBKI^3*H3\R MATO&8GN?[%O'MKEMA1U(0/W"-(\@[.\MC?O)M\9K]X6P!4LO/ M)E#43KLS'&Q!6_$U'Q^!58JV07XRX%!6Y5[_C/!V?$[-SY+J=I,)*\='U5W@ MTVD8#S5%S/35I:12QKC&U2([ M_Q+"=P[-8?D^$$9!&%"OY5Z"Y/G,;%06 W^F^0T'5W#N]?K,7 M!QM@,"N%]@+,6@6@>0P#G-.W3T!XQBS$&SJ\(ZJ,3Y\5P/79V7@K?809KX>] M?OH>*0Y1_F:;U#G57R#]?+0F3\^N6YF*@$Y\^,5,HQ!)T01/K8-)JIKTV;A28PQZ)J1-O M>L&H&1*/)U5' DG<(U';/(1E#C)Y04A(8@'$8:"'. AC_(V 8^A'& M-/0=!19R;]P?6-+L,RA'7O LL&],9PYSSC2P]J=80TQMM$!FE^!L*OTNT.Y7990CNO@F;&Q9'=PE M\-V[#GRP>2@^;2?LYU;UXXTI_7 M-*R37W>LJ2BK(4_Y4.P!;IF&0)W\'M=-BD4\.K1EPLDZW=P*\$W8_352/ YR M"T>+=?)K #8[@XYR,' IDG7!_[O#M7%H[JF#8]T;BQ'%B"]FQ-I*G?$&.8AQP$'O';@::ALW**MA>!C[AF>GM MU*VV[,S;/42]7"=!K[-RY-XT=1I,C'[GSV,5W/!-9GRB2L)(E4EOII)IE%!^ M4>+/]) WBV^V^5? WC-/=\UYW/5O^00V,,!WOCH9W78WY'UT\GV?>(V32/LH MM\A-"+H#R0T\8N&WO*]"G7 RV- &6UUQ]V]=USH:#A'#?S1?C(CAOY 8_MZ+ M[07P"6AP!'()"\^*>/L+M[)),V\L:RH,:ISNKKHZF&TY*T >ZW8?'X(?U-9* M&2'3LJBD_V3BL@E6O O++\&1(:K.#D< 3D9.XH)V;@555%GY09&[#; H4D!C M46PLY<]S"!C85#X5[-$CDTNBNE%Z;'=(+JZLDL#3']JM;AK:.0-=3O$K=,Y- M%+BC!(@*5%U7:8"AF@**V[!K$,W#J$->LR8\^]'F\\AU3@=/@/*H1)M9;7.! MM6K]>,JL@G/#TDO(N&OSCS"4-*9$HKWJ"$Z16_*/:P1']7ZD&R=,[J 2B^@= M?Z3 @7!CHZS@V"L^8C:#<[W)"_='S#-F<=%Z/TT#O+0CHY84FH1F!?4>H,YU M82%[;EFOO ?':B.,;$>^C1M8A..8+C;W,# FGH)B*>6#ZL.%55G2RTC09SP[ M#CL.J#T.[Y=,D=BN$TRFRYV*"HJ9LQDS3-@Q>!S$'\9H.V$]NA@)U>10I11$ MKCODXE7U!60Y8LX_<82PO;;97A_BXL,5<-@U,+@E=1OKDCRE]_#2, #9H >8 M9F,YFKU>A)RV&#T6Z8*:<^X'BV0(NG],/_!Y\L=MG(01MG"GIFS!")82Y]I% M"7:K\\4CI>>T-PS%-R8OD+USTF,5H#BW[2X1&$:P:?(^UBM M(/TUM26456%$6[5,D0.KAD7=NW#;-% HI"LIXRHL5%3!:KJ-;K=;Q'!#HP-A M#M-*L!AU508OE@Q*.U,0QQ&^*->JDHY(8Y @*3!XSA=1O1F&S7,K ?MWH4C\ MSORT)1$!C=:#[> UA15UW*)*J555EEPMB,IL:0*KLRGM,E$,WL>BDI041.M: MTF^8(.A%5@SFW,;BADK'6HG43/AN>>K#]<86$I4EKZ:Z*9ST\*"W3DF!/==, M(^-@E3Q!IZ*V9.W-0Q=P]"]>K%=KP6AA,:8<-.*:X[D=YRO@.K=&!Z M2R)IG*HYY A+E2\=5)&W)]2CYG*MIDU>$_1V4)2DY@+)4LK^JPH\64F8JVC( MM)8C+J>8'K:Y@E6KZ55';5WS"33T'6,5B(GI\5(Z5)Z IY"#@10=70H4_,ZY M<%^_E5]&,23B/I8W^U0,=$-AV*JB-7(B$S*R/=NI2J>%E[@),Y]"#OL"^\>S M1>_A/(:%U"?9:6,Q:I9C$!Y D*"CFVR#,.7Z5\>>^&$=R3A#.P%G=GU))1VW ML9ZI"6=9AIFO2AXJ-JUI$RYXK693OP][4F5%<% YS<2?69@H7CHSO\#Z>DA* M+IPK2XHYXVZ<;(?VA7T$U%[##&2PJ>>3@ OE"5'6 8W@;M$/N7%&TB(NC"(X(JL&A7^JE)83D8 M*:X'(V%!&.'T*!+E_Q#8THWIW%-YG?!FJ#9;&-Y1'=^#D+@%6P.-:"E](Y9N MWH5W>;R/,)QCWU-P@>-Z%46N_$;5,Q'HM; 1\L,\+F&D@]T4&)Q5"!UOP[A^ M1W8"&B.*XKWK^,4%]?*D%JMC3%H)"0]1AZT],:,EH$)]J7:AV L0C'N3>I'2 M+XWHC@SP#<>'9*&U!LXW1J#0$8+'AY6OPNNV90O2<"C>UQ5O6X%M\?PEQ9U& M&V$ "](8OH?.H\#R,="F)?T[7%7J3:GDIF6MH9KG\6YI M_J8KNT0CWO2%:!R^9H2A6(3WEG07(CYJ%'MZ[%)NE :K>Z;*J=6UE,PLDIGL M4WPBC& W2]X0N9H(ND97EM?8>7U\W77C5K MR+BF3,<79\F;*E#;Z?0;2C== '031I,W&*=GS0HB/-3&H#/,0H_+9AKO[OVH MF18Y<)"VPO*^7 .=55=KH MW !<2JB3G=.V[/>)CFC*FBQ-']&">7C%".AEYIP:$B?./^'9""R ZBIF9VH MT.!\IT^HE]9Q&>J&%%#P$:^N7=[&F8UC#A<-E<_!'OSZF1^/'A^9NYZ1-1)?&S_I.3@07DPOB ^^*M6K77:;1[ MZ2RO')LV-N)J)3^$V7A.9N-#UH71GG<^N\+"+YT*W1A5#)GT@6=S"0-WFX'[ M"U=G/++=P(8]GN_R],!4NZ1?Z /^_W7:>,,7W:@Q%'XPV".SG#GO+I0(+,X6X]R!&'ZP/*C3)W(WQ);D9%[E0OYDOGX;)Z(*E"6BYYH6-? M(S>CPE# <*C(M(K2#T^B-E-:DZP8OEQNAP,]11-?,"2^.9V]DTXVX"FS ML'AIQ!*9K621(OW9P/(5P,DL;+.5VI&PV6!=/%)'!R(G6N6D4GYIH3QLXP4R MZ#4@IE0#K&0JMDED/W8LRWGRI%?47LT)/& .[ZK7DP6QP],DY*G$T[[/&0SIGUE_BQ134+)G8Q>@8K __V4V*Q!F23Z>6KAR,S]CG[C=X=>I)'R@G.:74UEBUFAV70MY/8G(;&401;H(!3\F M:B8#AA1W3BQX$!6?Y#0T#\^(G00UU9V:!F=$3>6$\TC3OT]<[ C=!%)PW#>$ M;DRJEM3V /[3[?YTGB)<"DW&GOICM69 0,]Z6BZ3CF:"A):N#;EQR/M31%A M=408UL4#]W9L!Z;W8]H H[-*90!6$!73;Z_Y;M,(L9TG5YO_?,7_O3K=;IV8 MANH @Z#C/#I6&AVY<_Z4?!!EV^V2GCUG95LW!?LE>0GS?GD)(]1K65N[#*@G M$UJE%G1TV=8>=.LGV;).$D)Q"PXY"8<,ANJ%'B>L PW9.; ,G&DZ M5W'KK%CGDT*IA1Q?I@S3A=SK*5/:0NL*9JD!LZ@-==B[4';95'_C%"$G*Y"> M ()KR0MF,PS<6PD#E+ EX2/6P:XNF\2&<5*(F/$K<5ZF^_CS;PLE2X7WG&$\ MSRZUK.H>Q%,KBU5E?6)?KC&C[")<854;\=6L8\7>S;,VS MVH>K:'#IA3M_R\(PO/ (J7Y;;2B=];+6)W?2BNL+0<$%8_QDH&$U769#T'"M M:7CGB-5+)^9!:[C>14G0L:#C,Z-CI3=L=(8U#%"L0>CU"XN43J-\& 'W"R_] M(4XEPJ9;%Q^O^K+<4#(:"M94?OQT%E13!Q@NG7+/C'#/C'KJ ,.E4W"[U;FH MH_3)Z.5D$]>IA=M>I+BRV'R"/ W&S_0"H_YG@^C&6)P.A(;*$ O-2U)/-:*; M.L @:%?0[KG"(&CWC&A7' O$L:#&QP)Q9;!^++C%V";+$L<"H9XN7CW5B&[J M (.@74&[YPJ#H-TSHEUQ+!#'@AH?"\1MP?JQX*/CCIF)79F+ID_62#F<45FY MD^FQ>E654^7&H(X!'J+THN"1NO#(J[HRR3K>J0I'C:.Y=M-"!^?\F_BY/]H8L7K!=/%"?[+$MF?U_8?.8$O)Q)\X_F:C:AO2(_,PS*D MV"*//<^9CA]\A[[&$OC.>!7R:JKQ-U+[)\KQ'T BG6$Y_KB8XX^[.7J/5@0U MA*M3 JYJK@1V0-BQD*,4@2&N8JO(YU'&-EI=NUMQ?=$0R@SD$!AW2:'^KZ50 M_Y 0ZOAU04]=I=1:B%)J1:V]\R)695 S8@TMD12=ZI15GMD^XRQHM-0]PU4F M6;6O)!6X5KRTI7I]G67(F=1M7UW<\4\R!9J/G(5 M$ 1WA@17G\8<7]A,,VT@/^D67G4UW0\T2_K5')\0IE>_,\WU?A+\*/CQQ?%C M/4P-P0(OC@7RFH]52/GG?C83='^&=%\?T2],L=KX2M+7DF7\W#OX['>?I8Q( MVN.5'193$60O?3'UI9F7OC-'64RV0-LYF'PI> YO#*P'N_!(&;DU"(-$MHC/ M*NR3O)N#%15;NWH91]FQ4X4._:!LSX5[&=%ENPB9BXXJ4WN-=J^&>9(B/E)0 M<-%&"FH-0R(%_1XZOA1U#RV5"RD,3"EA 4?%$4?!FVQ 7$8:BMH7!A"!=& MPH71;BE;R[?44&+6 89+E]K]SKF4+^^GSH5S@Q\@BYU^IW+L""?C&4 M+"3QJC$A]QI=84P($CY?$H:34@W[T;S 4 Q%;LG"BR&\&,F2&+)P8PBQG6UY M=$0,J*#@Z,'Y3N]C/\"_)IK-"&\&L(09X."U7 %NF*R&9!PF=+PKU6 MKR?H]VSH5S@V('$RT=B5R!14*) XBDN"N+> MH>TKR76>^-]*;%D2[7T MS?M;.@^;_Q@6[0I_MX&_#2<86>P LN,DYY-R*SJ^,ZG15Y1&MXY%2U8%JSL0.N7!M _Z6QIKI2H^:%C?P@'GHN1M+T[\W'_2I8\'+.(:&KT@SQV!60QII'CP. MG_'9L6-9SA.^F=RTL>/2K\<71?[492R%_!D\.?4D9AL Y?$!D![8W&>S$7,E ML!XD55:&;\Z,3I=R&\5=J&M^OI*O))U95BA6X\_>7-.CS^$ZPFE=CC)5_C$# MUGW%/5&_"9MJDR!'T0Y3AOJD+\O1A8!4S.&?=3-^+)?]0"YQ"WXL()0B,&RY MT\A($3B!\9-SK10O5"UR0W(0,9Q,DT#&WWA-4%%XQ]&)N$873[?.#*1]J->6 M"N_\;FOZ%191J>"V+EYXIVROUVKR>$Z8Z[3$S7Y%7(Y",2?+K6UM#J&N*.?O M)8G.+Z;WO3D&VQEV!\@?CA"2"\< (3KK(CJ55K?[HY"=ARM[=5$2$ZBCOY$Z MA+5Y<)'YX7G.=/24 #@FG$,-:6$RRQ BL_ZIT1K%2YW2&&AQ9A 02QED.;6QLV25,L^.99MP5 M.'=-G4F/CJ7YIF7Z"V&BU4[]OCP!V5>%C;:CC5:;8(R<>]U_O@Z\YD33YF_> MFYYN.5[@LKOQK3.;,]NCN_,OC"[9;QW/]QZFFLMN\!+]7EO,@ :]KS#9C062 MZ]U__HZ9&[UCZM>V\=ZT A1V.D /;WYA8]BC/_ "JBGW MF[(2_CELMN4KR6"Z"6CW?K[Z]/GCE60:/U_IW7:W.^AT.U=28)O\?=-S.JK2 M;P:>T9PSM_D\&TWM6[IMQ2V\M5;@%LSU4,EJL8%%A%M\PJE$%5JX - M4$KL1:_,*H;]"O="*;$7_>*K4%I*YT"KN'= BUB)BJV%TNP!VWEZETAD1=) M7I^DB@U2Q46ILB97BPM1,:(8\5)&W%_S1H9]XANR3(;+SSS&2!DLO\'305V" M%S\S7P+U[TD@\"02=7DF0V$3YA+#%_\,/-\<+S@0).J!U%8Q)YD>2/+9G!33 M:,&][AAH&#\*7V*0(=\^9C0U.$-K$R;9 87C.6-\GP)$2.E(3N![OF;3($;@ M1N&.,*/I&"TI4H+9H*2B'J,II6C*P%D=)_/:.&?>LE5K0"1@.F M-@%2TR9(4%63XP/C#@TV\ALIQ.G)^)XP;K4!,,("-!=#7>'3%+:@@C!/V_%3 M/#)B@,%P%0;\0=CDY,J#98$BC'R"P@!9V*:0'F!W/!H ,!18>=O1$C(CDAE? M4Y''/&S58SX%'OM3SFDQ"48<.4[3DS_5?!X$73WUK!%.R.G;"8<3BNF&G.N% MM$)<0#29YF -U_WF# AGZ0>YA!CD0J[=*IRV)PL[+A%KW#N/^.)*?=Y;O)6I MG(."WNV#0WKLFCR"/SA_J)?"']7'W->+^@4UU9V:!F=$36=^C=PKE*93\37R M;&XY"\;HB&D[=I-%7Z2.H.=WG5P+&'H77H6XQM6[1*D(0<1%B5B!(T5_SW9, MM2#B,\T:JIU2C*L+I+W3IN<%Y*L)YO E=^1ZH0/+=GQX8JXMZ '4IIJNNP$Y MO'BVD="A0OP3!4G6"I+VV!N M^B)J'KCZ5/-8?*DI=&-91]%92*%2"SJZL&HW.GA:[73J)["RG&%"#0L^.5%5 M4+77;0S[PPOEDW,^)0ON/UZMT]JP_XEKG78;BMINR-V-*7WUX']1%5APR@DY M16VTAX/&L([W'P\*^:#Z[ MLV\U;WIM&_C/A[\"\U&S,$>M;(93LYW,L>DK.0E.5^^:/5F6$PLH =,A5[,Y MTVEU-3F)3K :]5"K":^>'YC[:.ILF3283"O\C%YWSV?&]9/F&AXUL4K^COF& MGQW_=P:0ZL[$!I8P[BGD^*/CAE_A32&#I(BJBB6D ML08H!35@WP:NRVR0)ZX&P^CT(! R?>3AR]Z^R7AJ7R3CB1'%B'N.N'^HW-DG MXX4R2])#H27Y2S$E:08FE%#V?1$#JZ99$U6FVP0VR7O,4HL0ZHREA\"6;DSG M'G303).NX2T7!M"D>W\A_0K&OLD3F^(?;.F]8UF:VY*N=1V.+V"K6HL&-@_ M]!V,%("'1EBUQ61AKA<#$\D/=R_4.45FQFR9:,=YX($C?6L]M."(A # 9'Z8 M?M7$6GXLM-"H#*K7DKZP1V9C\P0"X1GU9IA%EQ@4AL#515F J3$PMR=,KXO: M(429AE_C5"]*7TJ0Y40S[1 -CA=-Z#+$%$X'GRG)S+&!#NR;FT4DP!<.H%5+M 4Q;3#;/* GD+7.L:9=?P*]N9K**M"YI_1.KU\AT&5<"QTY]S"N=.5NM:@N[$+HR(-Y0?P+6 MG;%?@;$_@@2X!1A-.P"Q?1>S^ T#?<3X+>=*W":PX$LL%E. MJ+3S_97=;K5XZ*R.*UWE/P-[[7W@))Y7YC.S$<*)"SD M84X!UN[D,J':S]GCY)0[035H*FJSK6R"*I<_VFUU!ZBP/@Y[S_B_GVQT,P3 MZO=A,D(6!7:;2C_QYX82=X.\0GU7[_J=-6@W@W((R OS3F^8:QXH*^;F\0$O MPTZ]82[&E4'OX(!CDLJO2P_4ODC?=#39"OH*+(> OASF-VBN I@O"?YV@;(# M_O-%<6?M@%$$G@,MHMPVY%X,*NN&Z"$6<>^RN68:[]F8N2XS0MT$-M4=NI"N MN:MVSXUIYZYIFQ0M MUQ5EANU_)/M^J:$7" )7+#]S"^*S67XE8A3\U:$J12 M]JF:2S"'!*F4-:KF[K"J#%892\?1SG@)&?<#:KMYGDOWR5<&JH\ MTZ0@@OJYVESIK!S_X-A'G3;Z'T?#LR_*=A <]D .?;D M*W-G[]DH'S5_X*^?;,]W W224;!?]%(4X;?A@)PKQ50Y+3&2P*3!_*SYU$%A MZ?$K'D;F*<"D:J=]K"BR7>M3'JZ#O>_,,U-LPI':O=QDV-S:@A2CJ:_7T\V-_$E'L)\[;K'W+P\R^6;K0%R:::/$*(R!36U97G2,5%@+.PRG MP!HIMJ1)4\"_A=$:DS 2 S&/<1C,-ZE(+[,?3=>Q4=CRV""#/3++F>,7#5BU M'8PUW>?!-_@N0/.=4>B0,Y;F%/^DLX!DA#1W'2/ NL NQN]@P> Y?/4(OV! M" ^HPI@B+QC]B:%)&/QA3QP:C JX *U(HT6#HGP^.@Z']KT;3*3DY;-C2Z^6 MT4+ZVX_OKY%!;K:G."5?G$PEF=E8'@UCN;B MKWP(7$"I9DN_,<,$P0J8O9Y0!%HX3?P S.?8C1C#FLL+T.##)M^/* PFL'W7 MQ$"ONQ$R .$V1A56YR9ED(U=C&JS88]@',X^C2HBD6;:(B6E?.T[0^I82-0% MDJ\:(:.7@.)8U!4--MFT'QWKD?8=RZM386R*:C-,U+7>V187/V[1W12+_YOQ M.MNF31&0<8P><.'QM_^'CMQJI[ "R[>07SR ATE.X")@;![Q4"51:4J:;CZ& M@8[5AP=*%!YXTKC 1HH[GQ)TDNB>4 VM=%MJ%JFL=%_@H;G:S '[\N]$\7F/ MI"/VNL"6#!6!K+:4+)!;$G ='#2<)39M-J'P)TG7O*DTMIRG,-HQC&)$2:[# M _R07PWT2FN8R9MQZP_36_8927SG:;,H+!@V!P.'3:\2^OVAG8UOCDE/LS(Z M)B0;;TC5!+[^(+<&^6!2-#. RB%==A(!-3TS/<]Q%V$ENG3+$,TC(@\\CW=@ M^ S/5+"65*45.'#Z%NYTPHCZU023S4"G"L)[@SU?&(B,>RO49:%QQ6U$OC / MC/IJA+WT?\$.U0"CZZ).L\"$I AST$6P09H+LJ-:X-XSG0MC]*BD@ OI(LH M2+>4J09Q@-\=;DVS#M@*&=-@]<+TB= )+"#.G"8^P[+8.Y.EAQ M"KBY;QY_N8JLI"/5GUAHB'(S%(1XR@CE-E2D MF?!H8IG?&5BO\/2$ E^!.6.1CWJTB-AO2=<5B?XBAL!4,SC4U2BC=JN3H_T= M]SOU5=+F.+3T2@^]DF'ZC87B)OHND8?S4V6 9^LD(OLM>2I562F9J-W4"@N4 MO6[.L0\1\*<>JE4D!CI+@!'@.RX>+JW%LBT0*C8J&4>6?5JYD4V6R(OR&.P8 M)_IS/<,=QQNCZ3K?$-Y*#!VO'N]Q2M6DR!4S-FW ,76)6F9%+9LIS?$BGBQX MV(P9M]JH:Q1H.\M:"FY*S.)>%/A.9VYL:I/?>C:WR!W$6WRE9'8J\0W5?_Q+ M@O\B-PN![1Q2BT$3C]Q6OWH,EP3MD$/D;7X!OP MT$A17")R2.WF.E*6@#V)$PXAS,>SJM1QB59"M5DK:4V M+YN,B,(J4-2_:2XPI*IF&6*X51&MD)6X@;$Y![.P<9OKDGQYU*R 1498@JGQ MH#$%><4=-!D\33FP:%>OH%NLZX5P)?35J=;(R]]+Q&SIA+'W3*:XH/5V9GIFAKS>#- M<4'GN9;)+E9 !PV]@@S^5&B6@T*HT?)))0 ]Q50"\@TI M!%<'G\C1D#+$L7(4+&4$4FUUF3$[)/)$USFC!:8P.X?#="MYFMZ>;KI^&[UR M6\U\K.1S#UQ@@LR^67P#%?S)_ABQVO7R_+9G#:7<@+/VH)..)RX.T^'64JZ" M4GZ80%OI'',M=]%Q\6#[TLU/2U$&*WFSQ8$ZW&)*;8R^S([97*2:F)2\%4BB#R4UJ:757M'0ZDXB&]G=P L:;2 M[J\QW(X@E0KI[>2&@36'ZX2V.T0E,K?R::FK](X#4KO95OYXB,QA'M5V&Y7X M\"CXZ@M#DXL946V_]2"LE74,\C&K]+OMHZUC$TCYJ#TL2)TE2#T,9MN,6EZD MG^(*UXO7=7.#SJ5G[XUM6C]?^6[ KEX?%\;KV'S' .1/]BWWWF7!FV<@5 IO M67+MY@>'-]7.8$U_5D4;U\OB*91W<9LLG<)GRMJ#O'CIP^[!)G1N*$YY4'2N MB/J]6*U[)%8K!V-Q5NL>B=7*P5N:U?*C$91S M+S_ZO:ET!\I1[-7-RKF77ZOHP"!UEB#MJYQ[[;QLD#VWOQR,A25&KYUG@5<* M;VER;>>3JZKV3T8;.XF,7F[)H MS6J]#9KA<&?T\GC?B=5ZN[&:8\?A''SHPV0TMS=ZM=*8S0-A9TC+ M%>+)+UFPDKY[>$#+5@R__*A.53Z1X"N%#'F7R? >X/V<9!7G W=+]HJ]U.2?#\)<^WHT_1O?ML8#WWIN>;CE>X+(=2O2'N96JR*T\Z_R_ M"FZG7VQN9731+)(I]PG?2]5V;T@@"5O FA-&H1D4:&[ZGO0T=2QKT72>P,BF M4 ;3,#&29DME^);T2H<7&5Y.8DQ',FK@B362P0&IWP(O_S_M20&-C86*\[JA'O@@J!1"#->.0WW3SD* []3L7KX',8 M!0+OP[D#!W"L!>R/C;%RFN5, B:]6H4( R2QF6,Z=S,"Q7>9YD>#ST&G4+P6 MH1_6@<6*,(=3QR!5E_)T*'"2/>M6X''4@NC@09$."327(?OOXY6,*R[DUU1.6P($5_8H9L:PE!3:OOGN]C&[NB:63+I>1 M.>-.0&TOFM'-/9UTE9V RCCU4G'9W%KTZ5+TUW&L*AS/[\9?M>=]+_1S34I5 M5M=7>'#P3X.B<@$&&ZHO=B\61>4JZN9&JJA*!O->"(K*!87D5D9NJYT7@J(] M[L&2,2!YF-SH$JSMBDOX17.):YCKE^R]%/;;$CB47\+ULC%TT#BFNC/>L0*B M&U7? 9V\V_J%!6PH,O6X1L0E%^1<;+1M%!0]CJ+F6/ M%0O7J[N4/4Q077+%=9>R1XN_RQ4AN3$7+^BP?9!C4D^NM1PIO>(#$%=/V=#X MYW*=7:5B.)7\N)'+1M%!8TKS/(9U8;VC!:?F^0'/<^$%I&QNP[/S7/$AI&Q^ M>[6LBYR+E2";,%3JJNMR,'308.*ZR]BC12777<8>)KPYN>*ZR]BC!4+G2I!^ MKHP]V;7ML6*N\_OK-#,O%XM&WI:$N5R;J?SJ-Y)*"FH?:K="Z8>,\>O!><^]<$NS&O[!(USUS'Z98 M9[1(J--*=YMV/T>F-8$ZF\\CUS*;'@[N7;V36[*L), O!-1A%I(1'K6VD!Q! M5\5"Z 'O.O"GCFO^S4LREM^)))6G >9W%BG:V3C_?K 60?:P0EB1,7;$Z4#. MA7,+@'S2W8$K@,2!8!9!9/O(8)(@V*G! M7ZZ6S06,YMH!F *M_G)3BDH"@ZU<0W-ECZYT^;6)E!5C.G/*G: JT+P]OSFW MLB;6MD/EZ(P9WD?7F=TN*QZO-:LS8MABDTC!>XB,OG7?;"J/S(S$>/=Q=P"L M59B1EKO",/W\$"1*'4VO,G<)>ZRUG/F7>Q$W6-N28P";9?TEP=NIT$L2@LCR MNQO?N^8C6![WEJ;3J7W?.GZY^]Q65A(PB\%SL#4,5OT4<;++@V:QT"(F@E\= M;CMU#W*/"^W5X(^*5[WFG=ECU>FJ@8-^/1==[N24ZZM8*Z%YL#6X'/,9O5^+ ML%NZ* MU.3TI C#SLW[(BG?P=G-15)R_EVAW(:DG4)VHNRN:]MXOTRV.XQ_--_ST5]I MV;P1BKT +E<"(/]^L%L5P.6J N0W#._V!]6AN$2A@/PHJDY_E7\. _&]8YEZ M05F>T*#JT3HLBQ'%B"]FQ/T3Z:,4_L0W6!;AS7#YF?*MDP]@&8"5_'LJI5!Q M50G>C3I*H*9V&8F,=AT]^WE9TJ+5450K83/^XH8YC$M[;]E',^R/@5V#L'-$ MV /D^!GV'L,I4QB[GVI>%5TCTCTSI@%L@*3#X-3% M@^9<BH 3\PM!\C;=" MXEV?<4/G+HN7Z/F!83+OK>3-L9X 4H$;D\_$9;QTP-N(C*(Y/'@W*C^1;D<^ MQY.9AT(/_\&R$]C#D'J18'>1\=C4L6I$LKD2#G*:'BEZ6&>"MCCPJ$-,B*'F M*HIHW5D$XKVE#F+8$P;6#]@+N[KQ]I=SQGLR F*1X5P?NZPD-H0],SU(]FM, M,BRLWZY;%YVW2'^>8]O,X@(EV6[(TRP-FZ@WI!&SV=@,^^70;4)SI/%N:S.4 M.Q2-\C;LR^[QVA]A<9"PI;UI4U\AWB4IK!H"WS$JU!+PCI:(T(7H-8$4H?HK>#IQ0>HL%^HD MBJ-XZ5HKMU_NO'2M%8E'*@#/>CBOHX\U-L>UCIB,_, M@?,G""$+J8APEEP(B$_F2@Q D+ V#_73"SV9"&V2TA!4(%R6JA^4@(+6P[MM M)5K<^E/7"293*G,4V&&WOI JR%S)(RO<=4Z/O"\@G]_CK;N0!<:P07\%)E!< M0Z)6:G\%H'*9BY2G>=B,V^'=_N(IV')GQQ9UL"7LDSCB_='X(P:G>,)*!GP$ M%! W_0Y@"@D62[!KD!RX/X0K0$U,2)P3X0>0$[PJ( D'(O(G4&E 5M@"&TTE M$D&,GE_RE&-3^2EZ%55JSJ[!J+BG2#M<.?$6BC"TW:3"5A:-L&X\:SZUH)RC MZ"+)P"%%8A7;FU10+/:+H00&N>Z A812C3B:=Q-$:1$J?5X(#80%" @4I4R? MVH[E3% T<,WD\[:('.&\M)B+W7(K:4::PJ5F 1 V;TP]#K!)'%F5H9[(-%ZP M3-V?82]L?"A<=6XQL"K_+NA:Y/["50=C.A8\$2G]GN$98*>0AV%^ '%'5@>= M%7?H-A#V!WE[/,0P/WZXW96[JS[G0]S_^<,S M[QK+K^EG\R J#Q=-$ 7G[5#Z56_6KNIKRKDEJ?*/&>)RW]*@V75ER3P,FKC4[ M+(6LF<3;MFV/BMP*_BC!'^JE\,=![,HD&Z!R.B/J%]14=VH:G!$UE9*ETDC3 MOT]<]'HW@10<]PVA6Y4[#4EM#^ _W>Y/E4A<*327>NJ/U:K4 F?E#[.YY2P8 M=R7@T9]%7W@88B@YU7!5N6AY,P(J XP7#X1*W"DZ"OR^1/Q011D MMTNZL4(%63NE&%Z=T!WNS+'YM:XGF1B C1X;\L7KE [BA?=C-D;H@E'#0W3# M\ 2ZUT)O*+SM"QTJQ$^&^&F>O]BI)^'4 89+)UZUH:KJ^1/PF1XLZZ8W;T-M M22?'I;*DN D]^=L\<'6*>WS27%>S?7&^5,HZBLY""I5:T-&%5;O1P=-JIU,_ M@97E#!-J6/#)2?A$::B];F/8'UXHGYSS*5EP_QJSM(%9#"= 4^-"V'_SBH[. M_]V&HK8;N$UDW%Q;,$0XPQ>F.Q,;4Y-@#M,Q*"5BITC SG$C M =/A?_#S2@ @?I,9 J@%OI-!!/M2U3%B (\C:>MB>YTPS"4[J/ X?>(O(J3P M,W8(_PU>G7K2!\J)>!%!AH(!19R9B%H4U'3.U/3"HQ;/4H37.0SR%YX]27$; MUV&"MDOI;>)F:L.-Z@\U=A54Y2SKM^MW^!<>,4''I2]].G(-+T9K<+=SELJV M;@HV5:HKD5DMU*NXT#Y^X,?@#*ZR1,B'X)"3<US Z;L.3%P' M&/:\4Z[S2:%FE^/#[J#^,D4$D AFJ0.SJ UUV+M0=MDMBN3 41YYP239XZ[V M'OR&.0S4=.>.$N+O+$'0LY2A$8XAM713Z/*]=H=>UNQ1=I6^)I M$CTR&]*_F$<%?&V#J@3K877@?Q5/A*Z46@M12JVH]4QJR,6+&]2,6'EAFS2= MZJ3.R4(Y2QK=O=A<3%;M*S JGD*!>'6T=98CGF'](@; QI1X#_+(")3("CP5 MX>PD0\XDQFAU<=6&&_&SP'D*!$%P9TAP_R:G 2BE:Y#_,\WU?A+\*/CQQ?%C/4P-P0(OC@7N3<'*RJV=B5AC[)CITI+ M^4%I;2W,_3)BL781,A>=L:3V&NW>!11MKR?UU &&2Z?@=DNM86**H-^#)X]V M+YR0E9:LUK!:J*!D(8F%+7%ZZJD##)=.P9=A2Y3R86POP7P*'X;:4H4/0_@P MDCX,M=45/@PAM;.D]J AR\+N$!1\MA3<:;7[@G[/AGZ%#R/W"-CJ]"Z@ -:+ MH60AB84M(2CXHBCX,FR)"XC#4%M#X<(0+HR$"Z/=4OK;_(LUE)AU@.'2I7:_ M(S<&PO 0)'R^)#S8[J 5]%L?^A5.C/Q;0+F.S>@$)0M)7)" AX.&<@DWV?4D MGSK <.DDW&]U:UA,^05&8G0BJTYX,807@RAB()))A-#.)(UN>]!H"R>&(.'S M)>%!ZQ(:.-63=H03HT)"[K7ZG0NPH%\,)0M)O&I,R+U&5Q@3@H3/EX3AI%3# M[BTO,!1#D5NR\&((+T:R)(8LW!A";&=;'AT1 RHH^)PIN-\:"/H]'_H57HP\ M0B;#[0+"F5\,*0M1+(P)0<$71<&784P('$RT=B5R!14*) XBDN"N+>H>TKR76>^-]*;%D2[7TS?M;.@^;_Q@6[0I_MX&_#2<86>P MLN,DYY-R*SJ^,ZG15Y1&MXY%2U8%JSL0.N7,V)ILW?/.A39@06NQL_3#67W6@>,VZ=V9S9GN:;CDW?>M>! M/W5<@-/X9L,>/OB._OUNCK_?6YKMW2P^/#-7-SUV[YHZ^Z+9$_85:.S&@N?> M_>=_2-(_"\^W'-J[UGWST?077W$)\7B2#DB##U_8& CC#U56ADU9@?^%?PZ; M;?E*,HV?K_1F]^I=(4J*MM"GC;-AXUS@-UOJPVE,ZR?3U#XR 4%%[S\D8&&U3J&W@@:/G16 MXJ43\Z U%"F)@H[/GHZ5WK#1&5Y _ZN*BM83C9Q MDCH18KIX]50CNJD# M#()V!>V>*PR"=L^(=L6Q0!P+:GPL$+<%Z\>"CXX[9J8?9.60UEXY5%%%Y4#5 M7$^FQTJMY^AB1I4;@SH&>&1E8 DC3O#(*7CD55V99!UON8F++S>F3_#&T?M. MU8\S#JP^Q#E*G*,.28JGO7/91@/B]Y?\NSC9'[IXP0.;^V'U IFJ%Z02U,7) M_M#U46MCFIVX/&I7;0SJ6 Q!5!$67%(?+A'-3BZ%48[=QT%P#)\!VS@(9KDT M9JD[$U2F#GK]#OQ_#:L]U*^P_-9"[]L+Q]]KBQFS_>LGS362XV']/YKDVO." M&?]N]R+R_;H5D0^WS>54JA8,UWIL42UU1I91OUC MJ-EUZZ;RJXI.J[OM4BV-B&XUYZD,058Y;O8+T#P*Q9S*5NVV-D7"1^>%YSG3LW0'@F' 8-:2%R:PS3'L\!B?4- KFI8A&>9NJ>$&RL1B-9 O( M^MJ.L?3A?D7),L=,>K5@FNN=1TSL91EJ<&01$D@89SFTL?'219AFQS/-N"MP MCBW-I$?'TGS3,OV%,-%JIWY?GH#LJ\)&V\-&V^6.=_<[V97[WLQ;XV+WM@;3 M35BV]_-5LQW>XG;;W>Z@-U"OI, V^>NFYW14I=\,/./JW; [D&4YL;3,Z7<# M<; $<; =Q'8>B(HJJP>"\=IUL4<[;M3-(GOOZ#__8IYOVI-[("S'4(H@_P]Z M[^MBSJZ?3:_Y83:WG 5C"4KXC<*9_\#&\9^U&7_L(;!O3&<.@,RT3[8.PRDK M/>;#MZBU/+WRFVF;LV#&OT]B<"@/KM[=R[]OP]-N.'@IV-6>\[ [!.RJ]<;N M1\UTJ0=D0M9$YLK[T)'T1?/9?M)DT.XF6/5YY%IF:C4U:ZW2,A-&M]-4=G6@/DHE/=A,[^^:'S33\U;NN.N@,#X"E+6"?"CF#IJ(VV\H&Y S5 M?.3TVZIR1M@)3SJ)*CR?;&[8E#4T5G'461=:$8Y4>;#]3+ 7$?%#B$\'OL7 MU_&\?;&C#O,I2 ;]>4#T9$!_6/3=^J9I5 [X%7 M>F \IPWJ8Z*X+1=&,39^/""&BZ^Q"'+YH->VD;+,O'O',O5%B;Q&;J^!8CU2 M=J,848SX8D;+/C*2\I*%*@7F>F#1CF@<*6P*S2'*9[DQLF%#R MIZ@D/5]RQA(+KX;I$=NQF_$7 .8CJ!H/7V0P+DXAL6=]BNJ,IN<3T2A_!::_ M@ <\WPU(U4D<*L>FV9;YG_BT/W4\%K_-GYB07]C0?-:2;C5+#_!""9:97&*2 M1 2_)L!=# W:&,:Q;3G 2UK"N1J+20O&/W)=(Z5Y:T H&9JZE-X=0XO K22 M$[C2"/.L$9Y!D!XA _3?G2L1\9#9O"Y )#L^IH)B X?P5FU^1S(FX,%<\-F M:USA$]G\US.JU+>>]&=@3/!;6& Z# 3F-;WE_AB8[:6- /S 0Q3@%(!7#3FP MBO*17Y1+%[*S!&R,9=AP?&&"T$J CWA0?V.3SV.=S6](*>ILR6EMC0WR8&67YM MO)6F&E"$K@?]"GC@60AD2%0:/XP,PQF-62 M<%*#^62Q9Y(#"4GSJ+DF$JS7DO#^45K/Y(3!02ASP((Y@/^M]0"KB6%I<.PE>#9B;UM:2XD#;97#MVFPP'FPJD$(D=]>> MA4$UH :2HI, ! 9)'%RJ9ILLEITD3;@*F0_F>LDN2;<>, #^(";1LCDUF MI.0QURXMZ9MMD'XQ0[H$LFMD4"2):\:W=:ED9B86(N_\N,,] M +A9K(/ HQ;7OE:V7XAT!H6]-W)KL/WF[C X?)&[I6[?K6ZW\&ZI+57LUA%W MJ[U]MWK%G<]J:WO0@-BLG3>K4V"SAH4W"RL!B7=['H#5_O=BF(BPU_P^!'>5^7'N=3&'.RV-\3'% B/.3C.7N1& M%; $>_F!3.TB&7=BHZHR OOY&S4<*.JQS#ZQ4V4MP/Z&; *YUQ4\51OS;Z#D M[U1'"+\:&7_Y4@Z^C7LBKT9%C4TC^\8\<8J,*.Y\W6+(5'#G$1A4^M,5.U>;(T<^W9*LX;VTKG^$>.2G?JVWQ>TYN!(J$' MQ6_7F8Q>',*YRU!F=QNV)5 M\N4!.=J>9CU:35+]\#PW77HXKU91KREWFVTE^><^Q4.2U4*Z5^_NE;5:G8=8 M1F78R9 ".Y8#25;9[-<=,9O*!GYE[BR[GFGA\GW)$G,]P$7W$*C8"G-=<9-3 MC15P,R#<* /U?5WPLZ.F6+_%64F4_\)F&M"(/;E=)@X@4&J-%+.2PALG6'*L>S\KK2[8C_/;3_;6?N)$K0/$G0H]O/<]K.3 ML9]]-"D'O_<$>Y[==G8SMG.@$GNJP^T&CMC/FNUG+VL_L7U [W>UWQ?[>;#] M3+L5>ERA=7LO"L/K]UF;"FW=L(EI(X0WFH7%*I13WQ@6"4 J42.N):NK=;-K M@FA! OO<;A5W&:JM3J\C2."\2*#(G5GQ"\YV2UZ+'ZT)H@4)[',15_S:M-?J M=U:;Q-0$T8($]LDL*7X7J\@M65YMQ%(33 L:V">"K,05;T;&?B]0)&;E>]G1VSGN6UGUCU/?WCL>QZQGY7>\_3X/4]'%OMYI'N>-G%,6ST/ M@S/9QV?]9-7GK9S^>/ UGT+4/E#E>5R$8V/=>2(]^#B#U2#@Z\?C='/N3JJH MX6H6<$==3X5+ E@:_D%3;A\6_F$^_!UYF)'*MR_\/1(8AX*_V]Y8I48Y//S# MP\*_(3GY*/ ?F/Z[_?QR!5VYWS\P_,-#TW]/R:=_@%\^//R'I?]>9P/\??70 M\F=X:/KO]?/A[_745]A'3<60%1< 7I*&S#8 MZ1VKSK\/Q6 MFIEV\\DT_.D;"8@6OJ%9)*I&[[O1FZ!.?<"/%76 \)UY^" ]9T3/A2.U>U&G MBK6N$!N;2JP@A"K"_Q4X_MN5]A'+'[8UL:BXTU#)@OS=]78BN>V'7OM& N'G MCMN'8 ;0+K",?H+[I"7[21'_%U!;CED_5DJXM&"O!N]1I)@1$ M@M,6G.UT.I31,"-^<^-)4^T1=!(>OU+Z?;9NE%\G WSQJ>Q3W M,!-<6X1KYRZ;:SSQ,91[A?DV[CVW;/F&;6]FVG>VTDDNV4S*GVI^V(4J[,$V M=USJC#5#IR?=;RMLJ5-XC5%'GA4H MB= BD60$;M13B#^V;$ '\HFW[@$T!9:/%7<""QE,5C883O &%]"YIR3 MS+EA-@/%@T2S2=Q4")%>$S@<&TYK'DJ5F@ TK@D<3,/6734!1BC)K4KRH^.B MGB#? SH\##;RL:.G&[80#16+OB1XTP/+TG*>>#]&F.([\\.VC-C)$+LNZN1B MXBW;&DF#EGJV8:M&#<:(94MB\#&GG[#?H$6:BT!"Q4BJB11LV(J.40<\;.<( MO[NH<@UF!&001]H']*'FNF2T+W4;UV6)T;D6AW_06L=.C0Q5/3I[<"P <:Z9 M1A,-:&V.!!9UJ4P"AMWS9J@>_\;^>%/7"2;396?(J,EJW,K5,LOH)M']D^E/>8OG")/ &,1=R:;3FLLB M_B,>0Z8]J!2(#.L%L;<7[B?-*SC[I7'V%R S<4&O'@L8X^@\N9T!A1,7HC) M-^,O]HK%QTSX@C<&#QOBXC$6F)A:WH))!DF^"S92@VRKXT/B3TTWA8/F7'/]Q;*!O.M@XV+7BSK%HTC%GMA. MX$E^V.R7K"E=#V8!MI_FW7^U6!2"884;"I([7J+G!X;)O+>2-T>7!5*!&Y// MQ&7<6_$V(J-H#@_>C5P3@+)@C,$GY*P ,'7FX3T?_H-W(# K? D4Q20O&*/A M25Z5I5,&!WFXN6]6L-MR>K_1G0M@&+3%@8?MQ",,-5=11.O.(A#O+;E[ HL0 M#MB#$= 33*K5FS,TM$E_(<.!*O-8#5+]E,>[ZPC[N@-#%R]+N&T7_OT%Z ZXG+,'% M64H@N6=I:HY^)]+DYA6<2>U82;2D.]B03#Y ?X8(B-R,Q>1=\$6,;5+%AW\MR=@U&):\9T Y73J!A4 W9CMW4D> M&F'=>,;+)WLAS5%T MD63@D+Z\Z]YM"BI2*WJF+\(9^3RF.5+Z'NT6" ON;/"9/K4=RYF@:.":B1R M!N,()S\!^E!-KP*CW792N-0L +W_!%H+"!W:N#%'HE,XP6$\NA/DB1.Z,*@ M5;\LDCEWCP6%=*;.;NNVKO!59,F#3S:%]X1!<BX\/@%^FQN.0O&'T'!'7\1'J91?^L,QB6?!WL&F]F> MA&J!)J)1*(0WY0>-;3&MD=O\R&@">U.S].A0GEQB MDD1BT1@'0'"Q,0]H65,@5RL6&(259?@#H&9J@C7ALM Q2P>G$;E)4R$3IOWH M6(^,RS9\+K!#'1>'0I!1,Y];H:V%A3=GB#TRLV+?21@S<9N%;%(O2X,VW!?:(\DAY$;;FEX0*9_D*2,Q M2/*P(4W!Y';TT$R R>@*S1F1'8&'?OH)EE<3F9\$0CH.&#DQO/412U_7^#O) MLTMRB%C+6 T'XJR_I/4;2X/7'_2I0W&@G*SFKHDQ['# ,EA\L9FP&R/#H0@D M//")&[#(^9Q^<08\DX.I!*8'W=0D(J9<-H'7R:RI*O\#,Y& *=YQ?-CA< MAQD$ ,7\F1VLYA6L#!K:"9%02HU!AQ$>P!RIQLAR M_4IV;73)E"3+"5CN(1H<+YJ0!WM%L1EZE(9(:C"Z'@P/'RX#.]9##8_O)\(Z MT!T3:H1$W')D@( A@Y>1R=- A/97!H67^3^UI/?+".8*U!V,DSJ$S^#!:8A" M3^+^O>.#(3VPN4_IG5);;DB(FE2H*F[5\:' I.9&VCG%@P MO$D91T>[A%#C M]RI)\N"N^ PBP8MD0&ODB2=WFXVV$U 'M@U2RB^<_)?W:YML=!P&1INN3_K M"(N.#EYTCV_#88-^B$U-DNST^WB#G2$XYZQ,QL_1-H,\Y'$.@G6V&8G M:'L-<]RC-YL'H1^#3J9H/\2/AK=S3V$=G&9D1J6\%Q0 3R41@!&711L2V521 M5?7>M&BN;%!2WMYHRMAR*S>7-+<".!WC?"@Q_O_VKKRW<2/9?Q7"2( -('M$ M4J2DR8L!CV>R\.[LV,AD7O#^"BBR9?.-1"H\;"N??JNZ>4ILB9)XR@T$$UGB MT57]J^JZNFOE!FR=W'B&&46)<^YS$$=0F-\9N\I?,9N?/&BQ3I\>/0S) /L2 MB_VB:&6JAJ07NE]LAIYP8%\FMX+9Z1%:JV44<(79H=&.@GP@.*5H8QA)M#8J M.]S<\C#(,2Z[?R'VL*.:$@,;Z&%I"MUBVWSTA&[JC:C(U$HB7)-HG<4'%$TN M+!:).+>#$^:"]P&% L;W$@&!823>:YR48DPWS]ST 3O+YV/->3&(V!X11=N*= M/FD\Q%++DD&6H2V!K+QZE>B&;4WL?KE@_[]H8*IX+.D9@+HPAO,'L0PNQ5@>]A_$E2R0FD;7Q@87R,XM MBDE98SX\30^)P& -+>_+'![CSG'O#<&M96MZ0;01F>Y@BXL$Q1HJU$^!^KGL MO]KI)G"Z,(9S!Z\R4!2E_P#NJ6/9M77S-IMM2A=+6M.P[V&)S]#G3"ZY4L[>-!G'HD]Z!NTHLMF'K@=:HLK9RMTF4 M]WY^F];N?B4F7$J/C-AJ'#>Y'(ZBQG'5-[:4^8T5Q]I&7\B3Z*J71].41]4W M/Y0G_.:!FM(.CT $Z$_%O)AL=DX.9[YMV8:W_FHLR/V8B=%?7W)5/,V*[)IK_%T]@Z=QR*&=88?ON2)'' MEZ%O75R76@O+T=0M]MPDS4$>#-NZQ/ID M>'BLHA^S*-ZKG]N3>.::[)$6T MCCI)ZR[8:CM@.^D);.LU=Z=]UX$'L^=(':@K0QZK%&4R/%=N[=>!NL);1YO4 M"X?#X!@=J"N\A;!=6G?!EK="(6Q;$?*:79RL4\/3;D?/5I5C/U(1C<9<120K M>OD9/<*"KY+Z_8IE-*Y["J-SA6@3?4,KG' M>C<:5X>H\J@WU)?P5K0F=45Z(UJ4.V:=H%*ZX. 5B5"C?OA55TG"9C M9VZX=JDQCK4QUT-2)]/M,>9>>/B )I>RLML2XRYSUXI>$+4Z<3QC-IXJ N-KD4M5K42=5IX*G#8IOO9&2*5]\)_JX>E5Z6N2#3P9??-7A=%B0J6YF M5BH0WRE??*>UT;5K/'SI552EP.DY?4059[55+EBJUX;UAC54+C94%42[)6H. ME5Y-W;$@J.JT^L6W\F@%G[1)HRO%GGB%RO?>Y5HDM]KH@\:WTFJ1W/J""1K? M*%-572YP^QJAYF#)W67*C52Y%ONAVA@!GS2NY,I:+3;J;A]R,IZV1@;\85W,IH45#4W M0LW!PCO:(;R3:0V>3^7U=7S2^'[$L#:Z=HV'+[RR7 M@*DYP\XVBMD9_K/#R M;2#XI%K6BCT4%T?7$#\M'VS86+_>R3 MO;F%R6IY,UF-8_1E=:PHVO#BNM1.[WAW=4"W)#OD1?)P2_+6WNEDI_&QC3FJ M:YL1N*O"HT6B)ZDZ]Q"PG8W&ZSKMH,PL5-)Z[,!M^A/>OO$C1WPE\1Y8<'99 MWZ?G:P4,0]FOX#%%35.Q'UJ^U])SN.A6A>WV&FCJ7H<&F@VSW*E<(&Q[- M9ILM["#L/1-+PI9GK(%\1T;:%8[1HR$=D[!F9 8V,1W"98:CZ0L8-DUT_U]CGS[5,]:*8E]_1]6=K?5O,^633OZWMSLGH,][-H MW?>["_I"^BTRB_:X2Z+?5&7]IB9J]_I-T3!0W%4JV_JX)"S._,3&@\B5CK(AN)BUV:6A-)W6K2\.Y=S/IL[G4 MMV6^3V?/=T;\V^_2,-8&TV$/Y/\\SIYO*,L:79^$I)OV%QX\PE:-MT M)3T;'=8M):=U]SC07_^\3H^=57; AA0\$>FOT/ "='W!4+4:2.6DB4M)!:6' MF9U!3C!?"+6>83"&(QF/CQYY1$1$R=UZ!S<=*H.A/L[-9F31P_O=<*,7(;;J MC0UW*7!3:WYSY.$*?T9V^\:22$Y(Z830\!,]X!/@#KW;"L,/(J MFLF[Y9B1.9;R(2;V!@BELNI?22Q>O_)NXS(7I MTG+L>S%\R5C! MG:^T?_)BW0!Y/ZA7N>"@!"*Z@-FX CJ)A$6�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
1@&"]Z%N! @\):2!1YB^?G+52 M957H"%*/O*8=U^7]OCMF>K"QSF6H=!OAUF'JI'1\6,M3\;3'W#=VD;W$;8YEBM?[CV@6@^MX[ >'5SM M,;=3^^)3*=I,(9>3, RR4X?I40Q!IE#QPNV]BL>(D8QF@>J%Z-D*/1E]9,QB M#69C4E@!Q\S>J&-V_N^<9#PNM7Y6&WR&4>VOR]BR<*RS\UX)/8$*XFG=&V^1 M7[PSL_*RT-&T=NV_4OG0\TCJ&Y%5H%\#D>ND[:O2-[A]#Y6./ LS%./LR$W, MCQ(@27^J1]0IJ D2R5"+)\9&+9;]^! E9<(@/-4UDAKJLDV;4,ZR9$8\B#MTC10A&MZ M89U>JE(54CGWH2[S]/2=W%W-]'VB]X9SX/M<99*:H3^\??WV[0F$!8O#\C_1 MR=NWL[?B/Q3DV88FY#<<_B?Z8?;#N^]F)S_\P)\DOI^]_=.?9M_]^7WI7$!X M5E/^6Z/JV@P%*8_W82S#C9KH_=L9 OH7#QO+XML3_NV?9Q!(#/E8V)4Z\I., MOW-YJ>R:C7RBZ*J'? ?"PG,4WK"EW;"S?,$T'GZ^J]<"EQY,YXE#&ZAMWO^E M43G[[*!R=HT<*K%#%7KFJXA;H(7IPN+_RN,&?=*:/KN2/D&)\H2JC4*5Z,6H1=JG%6.P;\ M*%[A%,NFUU%9R04HW??J,O"@524N$ M45!A_*.?)Q^;;$!=KNTW:UGZ!9/U)L/AXI'-=(WWGH[MVYEDH/NW.O5A:3V" M*V!_+O$,?2V00(' XM M@7&J4)RY(W-(HRA(TOI;CTD<';**'0N6_/I[NUT6 M3L35Y6KXHMG58_R=\W!DM]?/TL._ B_OV&__^M=)]/:;8#\EQQ;XV&"X'_-' MDYXB'YVMM I]'(UFW9"UP=P,@$2]2_V*'P8PMU7UHYF[K9$ G$^;O_3YJ ;2 MS3=4DJ03TZG2@0/C@B8K3"#&MHK:L*%<64+#EI9E&%T'L0& #H2*_3X5+EOL MHZ)Y6>4)SRJ8*,4EJW[MMS:E>HE1O:A=AN0/PN4";Z'&6RHYWAFZX+@EO&J=Z8I;<,JZ]#.BW+$_<94I/V85A_:D3H& MOA0C>4QMRUL5//\_4R/28!F3RI N'SA^.Q(UBJ1+*PZVUWW%Z1K7^E-,46,+ MBSA#3R$T@U2ERJ3RIOJ*XBTI01TXE: $M( E&+4RJFK+^Q=BQ!VZ"NM-RRDJRG.()>>E(U(HU\1>77,^%& M=$7CRK6J[2EUH*G.>VK'D$XL HP) *[R2ZHQG/6>4^%!.*@"NP)>MPW\R<5L M$+":2&N7\BI4C!]3$C(N"E$ )9-W-,:B R0(@4CM[/F/*?L%$@R+N; >'AY< MA[B+JI#?P>E)XO[3L^UWG=.S.8[UTU, \WAZME*-#I+"4GP!/.]WQ.>JQQ=( M#V8ROF 0J+/X@LOC^ +NX-$,ZQ8^+@5^Y@,,+!##=(#!,7V."CN68>\3"C"0 M9^VA /%)7)N).:9!:2TYO[&^N;AED$=:,T<:LEYOFS#??2D:D2:V,.CO"^O MR+JK^[RH"\>_#[O QY75V3CB.B;9"5!/PVK=S(;5Q'LO)=;#@""TJ 6HF@I\< M==A"^Z/-] -*#G9H.Z$C;2OHZ$&BI01SZV^ZCQ$N2BAW/D6X+Y_<3CO:2Q"W M6M(-KZ^>X' PWT1/2TU-I65$V[Q1@>Q+/-&:=R*F!^ZJ-&EFF%!,,.%E'^Q; M0:JP+",-/U6^E9LJ[ 2NG,*%]C(^?UIN0#(N:/)W'(1N8,R]1;0;\@'D#[""X0)3[-CQR5,O*=Y)WT"D01]^\3QJ$"N+Q MM/)@*3(E!=3&ZOD\UB2B+(8[&#GD7,9:')UUTPJWD*!XYZ$TE:"+^JV8A%=X M^"U_K]7H1WP^FO7 "<@"LF.PRGI=XI[(M[Z)O.CO4[7U*;^%5(XWI/WBJ0.I M;@9:ZVY%[:.ZLN]U@-#>/+;'N(1JD@NYPMOK'\O&8#DYDOI.6_OXB32'4U)I"+8U^,E,EVOG7]@;3FLAU,JCUN4MN MTJ7Y32B_B23U!S3 L5E./+\T#E3S-/W@* G.];OC %J3?WX'946E"?ZIQB-@NUSD;4.U\Y+8[4O$FFM5!5A^-AX.#PVV*6?B'@5D5NB[XYB#B] MA9A 6%L[]$,M/TZ/-=Y(AFHV]46CPG*H()I?TV_$PL+_]W>Q$8MIG)BVJO2 M<&U):4%E\M:3%IR=7FR-T,S/[L7_007NWCNJ,; CY(O05NJ3C#'P7'\M;"#>?9_U U^XX.X.D46$J^? M9O'4R(]T#UU\/M0>+"SMIX)C3:UQP0?7H8N(?KVL,] /['>*O77U*SDH'FTA MW ZR8F@UL_?[V295EX2.I+-C4S-;D:M@VQ;WTM=$UVS<&,JZ<1C>U "8C[B7 M7MI1&8+X80.1K&R $?8;C60%,9A#9O"1CVV @BT,T4:6D6$G=WE\2NB.W1.V MP66\9 U^N-[&Y"%/+\N':(#>G6-$:P"=D!(E0/9/J1@Q;&XX-C/$,'@-$4P_ MH (E5.&$.)=I)Q"Q/.O124,@CU,00]ZFONGSE[@B\E7X-62;((,WN"V!@HL; M+!ZI>7SLJN$# :Z \ 22,@SS#*)-FD.EO")QEI!EUO#JX@V"'4-Q28H"/Y#I MF35F\/@Y"P$M>4P.ORH?SROWPV(HN"[S^H\X(FN>_01O=Q%]QI@-$!(&AV$F M^D&.JSS*()^(AU 7/5FDXUG-[;ET7E#_#B>/9(G;[2!7E#\U86'M2/GUI/G[ M&4VS*YK] V=0Q7(=@[L:72M MC*FU&7&&JEGLI\68(4 ?4F6A9YRA>@8SM.#) +VH4VXEE'IE",=^'3@S4[-: M?R!=3P]E@$X"R,"6D8H\F=.I)#UB<:@YBO].- KQO')!D^(K:-?UUNH'B:GI M&*W(?O/*1NNL)J5U&**[$_6C4^VXJ:-P&]/X?:DA_=+L0A^18!7'SRO@_PJ\ M\HG$F'L3=KVD=#;4?30Y&M!%'JU& _ M&TPBT!2J[K)"%++"<%:F-:KJ%E)?)!J1-+]*E4_-$>1<3YE7VZ7AU>:?@TAV3'.CS=JX@MO#S+ M&X]'@90J(7]A+?;DYC,#DT@>Z^Q;+NUS!G6^W,[+6N3;G&\YU_ "#S-(\(9- M@CQB46FIU1-%N[]^\0LY.-9UK>NS2[3(LH0\Y!D7@HPR(>*^Y%Y*)^FO!!U- M7M=&)R8L&QJ%.$G/>>Z.(3?>P0[:1JBN@>T;HVK(?RPRF'ARR!TF+E6GV$C; MU$?\D(D20BELP:+B8YE^49Q=;78GA6XZ-B6)X6WSC2P>RL8@*W/3>-, /%"- M"--4BG*?)2YR+A*N9FC"E 5.?,$RV2MJBAXP/&D7A<.$?2L AS[NRO^2)I"< M(RN_>-5,D)'&I'L6<)YA18BQ;/.6-G081T'$M,#@;[?A! MZEU.E$1DDM(Q&!>>]@:&WS-D%W$H%?QC$Y2M-!$:*%F_Q?.4!0#:;R22U>54 MR5PP>HU\!)S+)2_H;3LJ'-U3R@(1\NWGUM]/S*,0\ GE*&"<3=+KU8V(HQ+\ M'X=W9!V3%5D&#,DJH7Z93W_H8<+$D)H,. :T;3[EN,$UL8D=?TIHX(=:ZA?X M?^@SLJ+4QC(Y#SP0VM4GFG:Y]K6VT0\7J,=2YT]V*7^@JA8C!A-%#)R6YCX. M7S5Y\HBHAB$.L!4@T4L ^JKCM62&^ 7$QZ34[TIR2V O/J1%T*@4/1RK996R MV)W'HK6-KAK6',OEG<%?*HMV\E$IFKA.GTT>@PPBF)?\BM'[CMS?6#L]=MN@ M]M-A3,QBZ-D:;R:&V^FIJE>!PM$()D MJZL2F49L\I1"D_NX<#@D>9#4(YU SI]PLB0I9N?9$O/J]B?=V90&&^LX?'0. M:EN$2L"(0T8<-#K13X9D<"*C$Q^!Q\"*)&F&<#G+'9\E-V)[\"(89AVJ1D;7 M*3(?4A*2('F^"\"KE;MH]5SZ+QT#!V9*#M#GG6Z8LE297(YY MJ48%'HBN5_>U=U#_>Z9T1UWN&@3@F,V\/C?*4YOJD]#X\?U.Y?A^9^/X?N?Q M^'YG\OC6GHB1XSO%C$G#Z9[?A[S3?7ZWTM&#.WSS.;\S;:A"CS$.\>TC>P\> M]&E\DZ'XH9>\#!D=^Y;N>USUO GVM-3U(CT>T94=H@6TCL'!R PT+ L57'\O M5WWL0!4HY);=A9=W!GEGP>G[#B_SA%LI>C=7R5Z:8C PNG77HQH\XI$6-0)^ M-UA9JE--4AK79=^KZ++O;>BR[SWJLN]-ZK+:$S&BRV8;DDQ8E3UDG6Y5MI6, MDW@M:M-X[7D)>"$2/P*U2I/ MC=V,-QO6<- M$'J=Z6K[.?E!,)M1NNX2[7SW3HG:OP!Q'1^;((57L%-4L8$MXJLTL2 M6R9V;0KA$;\$(,K]3GJM;339:6\LVZQ3 /.[-;53CTJ1Q%>"KT65Y>MF]C'-':UHO.TON6$M=K? R8\@5 MN5MO@PQ?QZ!>+^(0_H'D.X]!!&:,+L558PA=758!E'5[%<<%)*+*!YR &[?X MG"(JLIKXT6IUEH2:H+-CRWLK1B)G'M.8$LA!_!&+?[O,\!I#Z-KD%4"YL@:I MX*1C$K$[9UVCB!!7XE%"M=B.FJ"KXPBO<6?DZ7/[ 'WQ8O8AZD:?VBQ; MAZ;H,[#-P3I3#XLW!?D<3"LCV\VHI#A,]]+.[K,)U**6IOP@[]JJ5UW=CYA M;&G,C:6W.,7)(X:21!=YEB?X,DUS*.G+;XY=UWYCX^D\A(^!Z_(2+[ KO(5+ M_'AI$H$A*E%4OJ9[)XIFTLO@(8^"!(55QGQ.C:6@DZ@8G33IM!)T(@76/LJT MF.!Q:GR-7+M1;;"7TBV^1P3GG8Y>[Y>740T(6$ YQ^#LKF@>1P&GW%Z\\R+@YT:!VEM1QRJ(B07T1[5CJU+Q<3X>"*M-% M-WU1S]"NWA/Z<-!Y/S [)PUEXR:A2XS#X@PN[X@@H'L72E"XOPI_C'16-UL. MS]M6&B<9/J,ZA':>3,S'L& MN5ZR4A5:^>6<7H-V?V-#W./&>-W./SYMU@/$[>$A_YG#R_T?7GC*3?$Z$2D. M1&&JKH->NJ-VML(A ,X._4%,M(Y^"_,;K0!4QG2:H#)1AT!&*F[$6LY&:5ZC M^@2>@."M#G-.J@A?9V>3 G@$Q'[ZT"9_EO:@'N4TQJ*P_6J%$U'[*\UX^O4_ MG/S F_[AW9_@@62'(8X&1^:$UP!M# HPY)L_R+PZ'>'MYM4A 1X@LELAOL49 M.[]Q6+I#](8+]#?6%-+V06T+90FU]I;V&DHP0%FJ1BZOV154ZY$K44P:D6%=V[,!0.%P/[5$>[$8X(>^.Y\#6HG(X\[TU=I*32]''+)'72 M(N$U"KX+.3MKB_AU&J>G>$63HHSZ??"$TY])3!-V'ZO*Q\;A_BCBNO8SSC;@ M_OW(FFQ[(G8\8*#)V XQ=64L<3@EG8O;I"FN$>\!.* 'CG(1 8ZRX(E]$^,5 M\7/A\R%^= (K[&.;9>@70?.G8L5[M\3.UJ.VKZ-1W6XU1^#UMX4Q,_D@9A+C M=9#A4$V(+Z):J!>2R=(49EJD!.F5K&\43AKG,E';CO>O E:5Y[*D&8""BU4QTYO M@F<(:U/19MOZF51EF^.K\Y-6P>H2*MH)L,94UG%S,:B3-Q&9R.PT)+_$ KTL M\8!DA:A:O@(7GUN"O,@,:>G=U'7\5!,%:7J]*G+H72>W9+W)]I)=5S^FQ:_I M2==SSIBQ=)]\=& ZRRJD@YQ6>B$W5- 0:HX9.!F5N21I@CC\&3K(=%^W2:M& M?J[CX_B8&EV6">P&/9?UP?8FI=K%);V377U>UH>I/,1SOB_IK4CU7M4E>ICD M+3?7]A[N\GE_EZ'U$(1#9!5+Q61MN EF\?.@BB"FBV'ZK^*M*J/:E*8Y:%[E75Y-(UM!38I8_8* M+C#E5;;K9*8"6:@0->7[N ;S#^T@NNOF=H/Y"<P,HP/.HO6 / 2_\*DMKJDG D?)'&M0'D=M0FH5D(Y06T'(23)(*Y@K[Q@3H9_6%;7:,7@H?AW+ M&0.^Y7N\.+8+5TQ2H"YRPLGO+=,EG)&M>;E'REV%?T%).0KN)4" I_6 =8]Y M:=273,/?!4E6?O$*,04D3J$^*HU?HQ(+;1,63*@V%'D[(H%B_P7'<$ M[""%0A[Q;)Y%H1'VS1*3G;A6\"]V1=(M:,%'Y-E /9@"[6Z>U!UCCE81*Q!% M+#-'@38"FSF"A0,#+^W0>AJ-&DA/A=0 Z.0TT<),0[^T._\QX2MGS;UH66)7 M[E-=IX.T@=(?-XS>XN/*#K/4H9&'G7*<8%-SZ^,KTRELXFJ)3CM[C,YS>C2R MVV1+_$6O2KA4\^BAFC([2+;D.2%H]WJTY@,=(++;$_?O090?FOI&C^/@O.7P MIGC<.'*=!!+K'A&8N[#1W69!D.O//T ->DY@_,H!5BX\VN>DQZNM- M#L>A[+1L/9PK[0B#975[">IVG^3*>)QF"3\8&[MY;4WC3GI=H2K*_37W2VDX MKGQDI!'2D4.+L]789/G#;8W.##40*O_@%G6.DQ MX!:J2K:1YL7RE? 2GAMCS%]GH<#8_08?YDGO]O_2'D3'L*@,S+;(_-)X.*]1 MJLO6'671UW<2-"AD6:I"C-EVQ,@)3F25%Q;+L+8EZL'HX:[K66QR'[$QC4.?=@J9QNI-0UB_CKR74!_6@:D"HV3Q(1#0 RS4:&Q%-ASF76JZ_. M ]1!<(:#U3]3B50]3L;@:K?>0Q4_\TQVIVDI' ME2M76MZYV#']>DT?WX28B.L6^W!XRV)?_7/!J!_""EQ$P6$4:N?OBMQ_-([U MXA$E, 30G+) -\WH("$F%:+46Q-"J:^=<"4W6VBA-I"R,;J776S8$L!<2ZN;O& K6R(F"" M."J>$B2KK04=1V#GY9F8DKL!L\AC4=[B"F?7J_O@JS!1Q%-/07M2[ ,U:":6U'YG$(1X#0CVR#K+ O1WDA3(/8' MLRT##!HOW5S"FXDM^!E]*?[UO0]WT);*$%!+N6(TM''B//) MP=A^'$X.D!CO9#)Z5B8<2THD4(&%SQ3%<@S5Z4;22T_'NC2/]AG.9-;93E=# M/AS/E:@< =81#P/8:[MU%AZJ"DG%+,]!V7=3?0:V[A^=3$VEZ>3\5E&ZVLM* MKDP7_7M%Y]#V,\C4$1:S,D-?,R6?;^:2HGM[W5B#+*?\H%#DY7H^>;>^)]E1 M78N^)AK/"H=#V>8:#@24\9-W+]>ORH1LS\Z?&#I)2&7HXC@B2'"HM.U( M]M(-R^T?W7YH;@%^PON/[ )03:H:R-6T%^DK[L)=YENE/KH9E/K&MLU2XKY3 M(( X!NKV 2?STGOS_TC29433/.';;U";HW=BCBN:B&QGI*0!#U_WE)]&BLNH M%HFMGMYGX$@49Q>,V$'T#QPD3#G_&&1MI_A04XW3O&M(Z[J@@(L$8 20(9X/ M 6SG1_L@7:D*L7P:UTIWKEN&%2]-&=Y@M@!,\M==P23J Q@QN_4!\F.#Z\-H MO$'.['Q-6.=*C!"@-$,"*20[9R=F.BEN[+39R9/%I/E(U$ M#VVMO'/D:2;+V4O6-T,Q!E_Y-C4$OO[#GW0$URA--"1UGS -#-!P")*UF\DP M U(-"KH5O..*@^SZM M(^+&X1!6N6(LXO&;\F"S2%'F,J=A.HR)N"M0*8,%Q)9% 0VT+-3>0&+FED1Y)-_V%O!47P37P:TIT]J7 MD,/A(W[$$=WQTNT2[K<*/;5#7@>,7H!&'[?S"/TQ9JD0NARP#9@W*N?%)$ISJ4=+(MW90>)1U&Z]YV([:DO?&<;4C%L>7-5-U/32I-(N<7 M;[H5-CC ZQ.L-V/>G@K:$CWTK]!=(]OF(@$:5;!1"=QG%6T92E,-\DV"PWIK M:4OU,YK4Q-;7-<-L]@W:]6B0\X!U0Z]G)>MMJ(3"HE;"2 HP*ZP,P;PKW'L'H$!4<[!!WVR"*3O.4Q#AM,P;UM-+> M$?9&<[03<)BH!.II V@G(Y6DC0MNV. H&CHFVAKI\T)C,%>L " ]'P6M-*1R MA'&R\5_6R0<_,5Z\9+ISGZVXK_F(@Z%M6&<'10,X^@+@$8?O5O&4)C)5I9QK M-KJ'$B!R++37U S[\"']L X'/0FNV:=K-\>T$,O!X7-!(IR2]F$=[2EE($0%'0GPGG:7 1)35;KY MW&^N@BWN?0 8:FYD[ZF'=;P#S1" ]FOR'Z1PYW[413:W#/4+)NM-AL/%(TZ" M-;[B&=>O5SS.LA%F>1JD9 D.9B3*6>L.=ALWF"8SZ@&U7C2@P H% JVV:-PY M>@"D^.M"*-#R'J$[<@FIV75Q[3Q;%^1H%H?LX/:AYMINLNW#NO)Q[X(_MC*, MYER,5(81$31;$#2(L?%>&J:573I*PW33S4-6)IY6O$,>CAN,R4"(Y+6=Q0?U\UAL()$%2MS*X M"/^5IQD_,^[I(@P)6$N#Z"8@X65\%NQ(%D1%E2#("]&IPVN/HRF7RO"L:^Y5 M]2H.3I2M:@O?1/':O$F-4=VQ5,<9X5=#\HCOJBII MYT_+* ]Q***/M[M.ZL-A,=];_.^ MV15$1&,P=8BN8S[*7IEYCVT;66O&8-[> M;D7V ETNZ* DE26/ YYH=?3I^EF; M!]PX\A1K[\5SIY-D=(@.5A?Y$UX'D8#=XD;:TT)CJ0]&LKW:'!PJU]R]UV@? M\:@$11R_LY?1X&U1"?V-=-_;]P:S;YDH@_9]A!\,$)#*4<431URO+D@[)FCT%F M5K5I2ZV&[#[142CG+H]/"=UM@F0;7,9+UN"$P[W>\91M;&E:<\UJ]5649B48 MUL^E/$8,D1N."!0D6+Y&@ SBV""!#@)\)#//.IVK7E&=6[QCOP*/\H>G('[^ M8UH()!7SW<%\LTV0@1%^2UA#R(V_!CD%MW@FQB2&*@;PA"Q<=N-Y"J$W&23) M;PZ5SA#4/TC(,FO4O1+"OV-HL .30TS %9TU9O!X)"GDT,]CD@=C>2"I$]JHEU*@@CHO^)F)Q MHKJ[2,2KM3"ARZNY]Y7-\"!MZBQ(QY';V[7S+$@W%Q']FLI?-SN[C+]F'@WM M]'H)T!$'/Z%K93>UVZ^3 R1T\?HE7S58K9/^NYC'RL'E(YFXOMP)149@@:XG M4,!3<0FH'EV][6\^/8YH@"&!+0G)]][32C@X1PNV-<)^L@)K_QF]9>$85%'-X( MHTSAAEX])U2,FM;%D(>*:-@"H[E'F4;'-BLW\9VA/8RY":F)\_Y[5HTV:I2N M_N*[OHL7FOS*-H#" M]FK6IOH6.2VA_)-J^V@%2V+8W%6">& M48!$OE >;SG?*Z.((IS6WT4D>" 1#S/R8/3JX&0J03FWA^$5]^J]7EWO<,+7 MH>O)N;NAYH%T/*!M,140X;"H8?H_%WH(2^6IY=HH4#V??LP3QLDB^H>'_-0N MX]>KAN&VCOKK-!88&%/;B# "MBNOAE%(ZK@U.*:*Q@E68]&;=H KC,%RF4"D M/BGKW;,/=&*N$&9D@%I9PDGL,,(T:GB+41S4[!XC"=SS)B.)I<%=QAI=IK7- M> _Y-R03PWN.UH*ZW72X#_.07:>]D>:FL#^8*R'?AZHCM&/QUA!"X;O! ?LY MG#L6GLI1Q4,:PM/#F/U&-;/3Y[K)CE;UT>ASB)GKF?GT#*_SEA<9T/4S7:7#S'YA6<@1/) M34(?28C#T^?/#.W+N+"^QNO%,B./_-P;>+C4'TC7/*,,T'H:4G I6G&7(F!- MM"I183I7BB!Y.F%:,+(M/ V0 MJ#IF@L> 1/SFLJ*)<"V7/V>F2)HQ*5@+R+_O4[A/%@R>PH.KZ+A\0W'97L3A M+8]Q:/C6W>-DV['QR';3+(H\XVGALJ(-8=HX/86;U#&&6[:8KA MT/"NE+PA/'1DS_S<,IH%D9K4W4.7IK<7WU[2O1@,+#%%2Q(GS5Y4EZZ3./BX M0X'FN=?>UX(GC[-33PD9TYXYC@^]2:844>,T27^929QRMSAC*CX.RS3'B^4R MW^8\"OPC3V?;]8 @WU&[(M\0 -MBUX"(0@'24PT[:5)3??JYYKL4,U@;R*2- M'W%$=W I.W\"XV!WZ4>)/MKH^>.JR(NF-HFM%4H/F<@M<-E&!9$'4<>+@ ML2M"#9'9<7BA\-"/USRA&!.R0K*&7OBE^^D& Z-;SVBKT0 X0*RG]=Z>4)3 M;>JY93G(UB\?F#K06I.].D:US52\V/V4PCR'J$L52>8ZFX+P6NY7[#I::6=/ MV!O-U>7\ *Q>#5E=S,?5BBT\R[$,YM9R/;2S )6DCO,D(0>5:>O]7,1@#N<- M41Q /Y6()"#K#Y(;>'I+F>*(:'5R%Y&V<.]IF%S]G.,::]);K%B.T![,K3+/ M&,8?+OP]59AYG##R'*'Y"'B8_&F190EYR#/N:I=1=!- B/H,G8MT9:=!!(E5 MO ;P MJF30/LHYRI.V+=MS/[T\1)H^' :C"<_C19YM:$)^P^%G"-8[J,:2GC_A9$E2 M?).0);X%>V;Q#5ABBEBU7S!$T^!P\8B38(UO,<10"'GBQT >1!!>\ZZ+=:>% MW9B(5O^SL/\$+<(X\=.R0G&&OA;8H4"@AY(2/\CU4R*((K+"Z.4_<)!XC/WT MOT:M^\8T4/O=[%*-T+YV$NQU.<5K$@,]"J/@B8NMRA"*4]BO1D[%U:9%FZ&K M1WL6+G!$.T"2AU6%$!V8I%"\3818_0[V+5-L9VOS,LI+O^<=S*N>-1Z[;V+? M\JYG]6]9_P/4+ .,YFVGFJZ:=9291),$5SE8QZ]7QQIGWR;D#KK1]$3&L?1Q M69MH AY['#"8E,?RLG[#TOUYQQ1?_ND3V7;&Q;D .04Y/D#-MO#>E'>.@XO) M#.6 "#OE&1*3NZ78Y@-;TMR[N-^P")>[U+&NXO* [H8^!<'NQM*#EF\G?> $ M**.=#X:.(=*WL-=)2(EM)69H@;^9'?#T^7B2?<^F]B"YW]FZ,+*]BY50$0>+ M.%RO#[86%]6,(,JMU#3$7GT7*@8^Y"FH$X(C/P(G<_\A3:7U=;YU[96 MW[#8?:)?75_8.T!.01 /4/-W88\ D=_YA;V+#VQ);N_B'HIPD[R?V"?V9?D5 M^Q^\![!O_C]02P,$% @ )T!M3Z>D9(_^*P $O(# !4 !S;F)P+3(P M,3DP.3,P7W!R92YX;6SM?=F3VS:WY_M4S?_@\7UFG+9CQTY]N;=Z375-Q^KJ M;B?W/J4H$I(PH0A]!-ENY:\?@-1"J4G@@ M 0GC)TL)RSH]8SHY__=?+,GKS MC!**2?SKV[,??GS[!L4!"7$\__7MMT?O_/'R]O;M&YKZ<>A')$:_OHW)V__Z MS__]O_[U?SSO-Q2CQ$]1^&:Z?O.TR.(0)5=DB=[\]\7#W1OOS=G[7\Z^G/_^ MYMO3Y9OW/YY]\<[.O+,/GO>?_XIP_/??N M^_?O/[Q,D^@'DLS?O?_QQP_OMJW?;IKS7\-TUZ'<^..[XL==TU=#?_^0MSW[ M\N7+N_S775.*JQJR0<_>_??O=X_! BU]#\<%- E)$(/:/:&__O;P^W!G#2+IYBL M%GZR]'$R/(=A_['+Q]^?,=;OV.4IVB)XM2+28J\#QZ;"E./S+Q5@BC[>\X% MXRR?:)&@V:]O:3Q=>=MA."W_H39*NEZQE4/Q31OX41;^^K?NYH"GB:X@D&X@ZI>D.S?VHF/G\!=,*LFI: MJ%!6L4[87_[ZRCX*?2(W.&:;!OO1X_9ST?,I31,_2(_(4>RE"MX6NYE/I_G> MRZ@W]_U5 2"*4KK]RS&2FS__=<'7UV1V7UI=YW'XB. MWY,(!YAQPA;NQQ2/Q!7F 81H5F"=L34?%.%'B-GPWMOCI'=)F&G M*;IE_WF\T^4-#1+]Y$\C)"/XH)&(V/+9?YX$;TC"Y)-?WS(9A_TR0TF"PKMB MCMK[.+]=] M9PE9JI]Y! 8-F[@G6%(F-J([+=@ %BUIM#7[0T?/HA'=VT0F;8R=>_-IUNI $6?X??AQZ*%_T'HYGA/53 M\\H!!]*G\RD1U*,.>,Z("#DA-Y$_K]"V*G_O70N\S!*^,6[8@O2C_T%^[G=%G1( M;6Z"YBH= -)4&ZW%*JS?8,)VVJA\8A,)B"O_W#M-A?1UR:9-_.B6'M M:PUH->UT44F62Q(_INPN?V2W$J*3+,W#EW!<==S#.^FBOSC>']"*)-SJS*65 MRN,*TEP3S<.RJ!:37B]1,F> _):0[^F"?>"5']>O66%K313?X @EE^RLF9.D MGM+*5IHH?$!SS$7Q./WJ+ZM.)U$S330^+E 4R3YW52-=]"W]*+HX\GR$K"J ME1V^B$:4/:(@2]BD9^_G3SBME"_JFO1.VU/B\WOB<;VSL@$=PG8"@^V $%S!8& M1N4G.U"1*@I@0#[:! A$508C\\DF9 #:+QB8GVT"1J"&@0'Y;!,@<$,9&)\O M-N%3;UB "VZ6R++UEFHX%)8(L0"/ AP32Z18D+<-CHHE BW07PK'Q1*15N"5 MAV-AB30K-G1J#UD)"-/*8X8,_Z]-_ W[GZD?\0QYCRX02JD7%,*WM\J7M)?% M?A9BWJ[ 98%2S!:\0A)#+]/J"X?ID7R70-&/TZ)]G'1)>K[WDTF21Z*%?_A1 MAMA1GPO41^0WZ&F4K4(I.,_2!4GP/RB4LU/78P!LW%*:P5DX;#T \NL#'U2Z MZ&?D?GM'-]DH:IU-,P?<+K!.PV!&N&GD'8;!A'SK 'NY!"(UHDMAVO>$XER" M%R>^J71UF5'#2'* ?"KCZ5$N>D+_PCB]N F7 -0L1[")G&?=6E% 2"PTCCV$ MHCTR55+HV*,IVJ/2WKLW4/NS&C3*UI>Q!U@TAJ>C8V:@T14M86EUQ@PTKJ(E M)( #QJP;8]<@KR8;^'3AS2+RG?;GP6@\HW'G14O*G=]BJ'Z+>W^=?];)[ I- M4WZ,<2?5):%IG7$)T,,D&_D)I,;'ZRZNS&MS*]\E.QQN^-D M^[5=G%6O6'< M_*)/Y*QYSIKGK'G.FE=G>X"*"_TMD,%60U,10;1K37DEU_=>@NG?-*_LDS'2 MDI2=;2E&JB5II>-HKE +I,?I+=WK+:Y@K2M8:X21KW[*2)K,)BO^LA4[3NH4 MJ_J&3AMT2A14%'!%8UW16*=E.BW3:9DZB\;*[FXS:M1/7H3_G>&05T;E*L?V M>0QO%?FJ[S&"QM*L3BG0Y%0J;2K5)8DW[[_>L"W%S2]/I.2F_1TMIRBITJJ4 M.EJF^]60^"VF/#RIT[(/A//^%EAN@MKYT= MHX!O^#]QNF M/Y?(R">_]]?\FJEGH/5@/3*TR9G$;.8L"18^1>?S!.4+09TA M\& ],O2T8(L#/[/%?!_Y04-&I(,8R&**?$HGLPW%D^0!SQ=IQ:$(;C\0%BHO M'(4>!DPZ[$3?G_$7ZV\QN[W1%:)!@E>Y>%C_593ZFF:-%UD3?AY9S<%_ .SI#M$E#=$_$9E/*5&@_69?6@> "D+8WPT+*Y!RFC5V1;)J>3TF6 M_D9P/&>7;("26/;:G_H SF'@' ;.87#:#@.!*$Q4I4Z;,('K:415);(%)KF1 M@310YFU!1RYBD.;2JS4@R7UU,$G-&N>ERJJ!*&_6 "-=*4";IRV @$[?+NS< MUF7!UZX@F5G0EJ4CEOG:N-UL62OM-Y>B>\^ZH@K"3:;H!+%IWRGI%4TC"FQ9 M3>VWH:)3&@S<6 IX]!@&.)8B'2X,4"T,L*D=V4QXX$>/9LLETY=X<06*YS&> MX<#G#ZH' V3AYD* M,DU16'Y($JB=57?6K'^)B' :EC8-RV5K=4?B$TIR(.I!JV[1Q=0+Q-TFDHRP M^E9=YJH=.KL ^6FB#GUF/$D_EUK/@20&N=PF(V]E[?R5M4L*U-9T[I)+RQI: M6E:%#"N@7]#:=(*6RRH;H6W6$C9,FICO2#Q/-Q+#$YM=L ]$3SO_U(JL%,=:]9R%!/1.[MS M@]%Y63XUX-$7S089N5_=$C;]]FCW.._(!'['-0+T0P'>,<;T$PG'D2S=0Y"C#/*:3/*#M_9TP"X):#N"C%1@L^HZ-20CJ/9KP&DQ[DVG&MC3^)C%E]LE]AM M'+ &9_EFGN2YP>SB$T0^J_;MA=Q/DV6,IQF[O0,&$7Y&JC0#!FAMD*))6C)& ML?\[7JGL3W_][K_@9;:LIKWN=TVDX5A,6M7O>DA[X"$L%3N[\C>-)-5B5?&K M@;#Z[WX22DJ 5;8QZ3N:S"Y+M]H#BMBY&%X2FM)'MI_1!;_X[OUU?E1**Q1V M,^K(76F6L&'2(WC-I#NR1JAT\PF=@M+V!IR:[,+C9C7!65#5Q!RA0F=E=2,# M/J7=Z5$^7\JQN!?K5R=,?N;N#]XX!+'+P, Z]GTBE,H$MNZQ?W0QW_7N!_O]_]V% M0(RVZIP+@1"77.O2H: ],(+NWQOU_-V#H]YJ\^+H[C_@(1*J(^H+EFA&F0N; M."*KO[")"Q3G.;E^5"I#COR4[:W\"=QU\<\Z%U^K,3H@/R]G2FGF,YTJW_8 M)&.9\1T$[($;9"F MW4TP&%-&2U%3!,J4O(L!+[&?Q&SIT'N4Y$( C!=@+_WLW) $L2U^F3'9+684 ME6H(G<=A_K]1_@$D9U]GXQGP11\2(CD])*U'2K[)N(MMS2&V/J[0,XK(BM\\ MUR]<\-YLE!IF%'H.)6J@L#4Q@@_LM%3(9HN1G,_?OBSN;Y0IIM=$D,BY15Z9M@0; M+VFBPMJRB=3P$4DI8W?!J2'2@:G3%M^= F!JQE9;/'MJ>TQ920;#-/ WI]1@ M:JUD@V'[9!-L'=G[P.#];!-XS97[F:1:+41!PL49KQ4 MU3FC+,11QL6!1_Z8*4X9@=<'>U9L*:;?')U0/RZ65+JKK1*(B%>2;'94SJ[U1TSHPZ9X9X58W=/.E\&,Z'X7P8!P]C55]Y M1)^<948)K7X3IYFZ"1IK$&_^.!72K JYWTO\72P2YWEUW/*VM9.C MDCKT8GW]@I( 4_X&2X#RJB1P+/N>>("@[MF@YT&*G]G1 %*_NAMX&*"4BP"6 M:?_#C[)B"[&K?UG\K3% [2=QMAEGFW&V&?-:14=RBC//./.,,\\X\XPSSZAX MT'M5>6Q96BJ =B/"VY)#UP%R'6N,MB3;-4.V*ZW)C&'VO9=@^C?U_#CTLCA M25S-IMJ&]#F;K3:;+7]QI>K!E:OB^SP= M?IZR@5:M9P>D_DF2OW$\O_17.*TFZ;"%R0I3YTN2I/B?C>C!DX9YC5<>2WV? MH"7.EC5*L[2?2:8N?OF_^$.]SWZ$^,L\Z:6?)&N&.S^+Z^PLH+XFF?N* M4D[,3MZ+M;?V*US&T]6*/%Y /Q&^'E=R%)] "\VRV>1]WE'J("5?1NC MU#(T X1"RB-BMW[7R>SX:?4:-F"=32ZZ2@J31S]7+40M%H#\;WV#1:B:D@X%2+JPU+J"$(C\8).6R6H,%J9&9 8R3$$ M,).!T5 NC#4X-.!*DAFWP4]>A!DY(2>(F]"G&65L,$ED%?EQ2]=!H[$UNP]: MT.A<"-I<"*7*H6SO<9GPB93R)PX?_2N;ZY4Z=O2XTG[.\R!@APX3S-BQA&C* M)-OLE241VJV9L6W\+IEO,>7%"[CCF^.38J9:,CEEB2DER9J30^L_OW+G+GQ( M/G__.Z6W,9LT1GG9R#]QNF M/Y?(R">_]]=<5:YGH/5@/3*T+RIQGR7!PJ?H M?)Z@?#6H,P0>K$>&GA;H6"E09T0ZB &G6N13.IEM*)XD#WB^2"O.<'#[@;!0 M>3\J]!@(&P?A.;L?Z>97>J;"H&PLH[[=*H*_9GQO3&;[_7_I1Q$W:1S3K@(# M?%23@!S>^A?K;S$31=$5HD&"BQ+-]7M4J:]IUC8W%1=I*%/#^)E8A*YQ(P,* MZU:XVB##^9+\K7;AV21K;H:!/:Z2=5?=T#31)7%HCVU^#HK6%ZB_Z:6U)Q*T MM$3-300@ $0J6&.ST1.E!<)1!H1-'/487!B(/5$NA8TZU^GYFI_,2C7[A?L% MWM'%N%@:XU+(#U=,4(SG1=Y&(5=\1=_SG^I1AW0VNBNR*<4A]I-U:9D++G=I M>_TL;.7U\S@L!/9)EM+4CT.&]Q-*ZH)<9=U0S(QIR](1RWQM?.2VK)7VFTO1%V]+DCULDRGZ MJ&S:=TIZ1=-H)5M64_MMJ!A!TE]X]U"V87=Y1P-_$]GE'34-2%:V7I]@/E+/ MV2/V)"6IVMQ/,!.IDYBM$T],DCC53S$CJ=L0N%/+56H0?'^""4SM@O' @'VV M"K!&T65F$L&4'NAMEQ?6Q52:T\2Z(]EEC1V1=5J%YSH*[*DN13( )[XS9(U"TS>M*2@TCW&Y0B MGTS;2 ?ND' VTB8V4MW7G1G1_Y.'F40Z9;3EE0_:"?>PP32+[RI$.0%=FX#N MRCJ<;%D'[A#@\-1_X^H674R]0#QD0U(ZHKY5ET4M#@-M (4L1!WZ+(T@_5QJ M/0>2?>Z*( R%#5<$X42+(!RY\X39P<*VIK/^7?T&5[]A( Q,$CQGHES$_UJ( MF;!/5-'/]%=Q12F&7Y1BJ]%PBT:N.?#G[P*NQ<_K+-+P 8;#Y@AK;QQ25$3X MX6!CJ0)Q<=3'Y->XC8,$^91=DL6_;[E&S0^I;;1]#4/2?B:9NB-%<)R@HDBY MB6E2TPT=3VQVP8$L:FJ><.$F%C=V7DG[BH#L;"N O5C9UN2F=/4QG)?8>8E= M?8RAY+&IJH%-:1Q^RX8A2N M&(4&%6>P@=;*;N@3JD/1>XZR/14H.DBY/9E2%)KRN>VI0=$\9,&5I' E*09> M*L:>.A6]52&RM3*%),('C,\7:_ 1^?;A@J<]TKER !4 MJ+2I80>D=5?2N@=$VQBRK[+KG@K M-ZQ^BW&NJ*3KR>PF(@D._0>V2MAV6MRP@RC,%TM];EIG@YY6CN8#6?M1NJX( M(SO^V60$7"D=GPM]7TGL[_]2>ERC.M>SY2@N'M2^>%#N-)[,2@M"$.@L;.M" M)UWHY&F$3HJW >GHF+4%+;F+"'"LV.)UERZ=/B0X6\#3X6\=>#R"\[>J^A(% MUS#1Y(D>K 0K\ZNZQ44KQN5YG M"K3)% A[)*N6B28O;&EE3_8$\3%'L!>:G<7363QMMWBZC-_.WC97O6*M 4EN MN8*=M]98,U563:?OF0\=&)>JUWFJ'LRT8;^5O#M'P< S]IRCP+T2W!]0[I5@ MTYDA.CU67PK_S92_^\(#2W=OP[1T6BF/J]EOU9 ^Y[HZ(LNYKJ9^:2,.QF+2JW_60]L!#EBIV>.5O&DFJQ:KB M5P/QVOR!-$G]X,HV)MZFV%4/N_17.&6G8B[X\B"SY!F%-R2YR=(L05N)K\ZI MJ3J.2:? -9,ER!JA1T8:#E#U&WA?>;XX35&8?RGZ1!A/Y=\O"4W9A?(_*'U M 9G'^)\\09JI#HS7S9]XN[HJ^'J)L!+NTGU8M\VTS#T(SZ8O>^;_^(/MAYTMI.X(ZW(*HT[BIGQL]G\I M_[Y0\[O&JVZ>08-&A5\_%WWB$+2E^IS*$'!3^2J8'C-S_;+"2=ZXV#,BM+H8 MW[U4/XS GW'Y?EU8B0LKJ5P7E28#(E';Q\ZU6-U7>8B]]1UG"Y25N@"!">"V M8"#W]-9K3+9$2-2M@[:6:%OPD:\1@0W2%A"DYR[0'F)+E(SBIH&XG&R!IGZ_ M"+P=8]\G0JE,X'@:^T<7\UWO"[0_5*R[:+G15G)WT7+UT7)]&9=.,*"NM<_T M!&/K>C>A]W? VX+]U**]S(F[[K(,1RJ M\^6\G3^SYC:T]'Y[>@L=X(Y/:IJ5(\I.CP]8) 0M=7"AI:N0+/ETD_6^] .C[^&\\QN MN,YS$N!3#2;Q0)5D9WK39GIK[*Z0W ._;=YPJ2SMIG%F+_ZLPU#9Q=IOF7"A MNLG,6V'&9\CZR4'8%L*/(X1PHS8P'F8(<[&D[F#3,).#36FFAN?_,) [O,I^ M2PA5,S1W,M/X8"OI6K=QFN"8XB"/ >@)/.E\HX90S< MQGTGR"G8)YRKV+F*G:MX$*[B5?%Z<.HGZ1 =2;HL??TM-5L!ABIX+O6F=WWE M!!-P^K?F])!_\Z4 -69W7KII.Q!L33KL^BL%:>/JE1IRP7!^.@DX^]*EP3#_ M?!(PM_5W@>'\;,%IJ],=!@;VRTFLTU[-F' EHJ&:=AW;M8X58PG@^#;4TFS# M%^I/TAYM&9 X9'SD)L28D@B'_(SVIGZ4!X/2!4(I]8(LR0$L/HZ7Q7X68M8. M'FK9S3SZXBR[I-<%61Z1U4&093=NAO,@(!F[B]A6Y' M87B'_2DOK8 1E=(O;F^$A6S)Z_:A<)(N4,)/U00MV,;#S^@V9AL4W3&]ZBM* M)[,G_Z6>L2:C&& W#/,W ?SHWL?A;;R)R*]C2]S: /F4LD.OCMK\1Y,YW 4% MDCU0;C,88L^G-$W\ $3T<5L#!0)\NCB/0_ZOZW]G^-F/N#A_GE[Z2;)FDHTH M $RIK]':!T(N:IJ9(#AFRE"*V7W$7\Z&762P3OJ9*8YJ=D+S]*0 L=51[_L7 MMC5!>E'P#(2_N+%^XDL200W%I18F#\T2&>P0>2QES?/#)%W+J:_L-A"6Q(OF M=<-AD2VYP^0=]#.1"XO%Y?J5Q($0?F%;_:3?;VTJTKM*T-((V2LFR_*R<$RW M%B]X85O]I#_PR*D8A==^$C-!A9:4CJNB8D<-'_".+C90C>C)[ ;'?AQ@IB$1 MFNM*DE-(I:LU08]]$0N\?8=UW[ZF1KID9!WT,_&-'8CL"N('R#05GZ*BI@8) MOR/QG)=:Y53)**]J:T^0;Z.CR87MNK!=%[8[B+#=(3K? 09#6P 1LTI:61YM MV3Y@C JERU!Q&!, (9&J\I*@8$1NE)ZB-D=]C(!V(?Z"Z\=_C)IO#X&?K3" M[F.H\=.62QG ;WF% .(J;%DORLA (C9LN9/5P%'Q8MJ2EZ.&D-SV8\LUK88+ MQ/]JU66M!H_* M'9I7.,I*F^.(&6 O_>S\AF*V-B)&RGFXQ#'F=T3* -^X2VO8 ?8RE6W!!: ; M=AU>$K8-XRQ_N6E[O%V@&4E0R0'Z.XY)PC;KUH#&F#H4M#:8E;-9L1=L0<]JHYUK6ALM#K]=+.*->M3* M*,7L]-XOZQIZ#]J87-_E6[.@2 QT;?M!,B'9KN!^!M);MG1=$IIR965#&96P M!.YGD"7I[JAH:7)YB>P/-^R*P_.XL+$'ZRL)404^4G 8Q&OT#.*R(J#+.8%U,=E#]F79'-4\>J@ M2E.IEA!,L6HWF'T9%S))VR59N"0+EV3ADBQJ_/R*8K(MX,#9)@V-8+9LJ$9( M*8AZ_44%&'#"-0(+H.39LIA@9Y*B-<*6,PG.-E%Q^O2P=DR60E9""6H5M24T MJ1$X*C:&_@*5#)S6C= "VWW[BU8:"U0&/6,]Q#V-\-"#.;&L"H-JMJ=%3JC^ MHN''_]17>*IAA8&*><5!>O>416?_&:I?R735XO8D)J2FJ2?*L*7C8>QWO? M(2-YJFT^&66K>?]?D]D].YHPI219YQ1P6VB1WKV5V LZ=_17L=?=Z -EFC7X MTT_RE\#ZY;\T4:=0'#YD.)F5%AXG_D^<+O9DWR"?/W!4Q6F;<3I@@]>C M.'(.T+(#4O+/57XCCG_3ZY=@P=_<89+T XJ03]%>49ZS$W[S]LYD&N%YH3!7 MT=[QT!TPN\LQ/ES/MY1F1[3]P:XFDAS5SJABLJ,A3;R6L=5^Z!.I20;<[.&" MF9JX!^5QFAT(/3#]@)C\$N (':C93X07,6-?\QDSX>1B_8WR[[CSA9P7;[UC M:9Q?GU,9 &Y)V/'X3[XC)S-^1EYAFJ_D^P0M<;:L0P':SS1+FZJ@&P\9B)OJ M+A:^&'+\U+5=S'T<&G/%EDMKT0'YBR M.(FKJ:]AM0S>=*4X@!#8')3;O5J8T#=VB;CL%1,$LPP9+!!9&%QN9L)F;6, M5;8RDH)5)?ON1*J][%O#"7P HWE/8"IEB5"-!QH,TQ5ZC1JS%0,,\-NJ:XK- M!QI!ZJ1!4K>F,QZ,P6&,P]UVR4/\Y+F':OU-//A$ H3";1A+V819PQ2@AUDV MN(V(OP'-;0'N5L)P)&\LXF,M%5ATJ23&>!=EKKF1H6+,E%E!P^ MAW)SHSQ4/RY?PT%U8Y-JRKBS 2D63I0QYQ4^MM7^(B: 6Z[$67O>BR%UWV8EVF4$N5SA:T6N!0%P9M^083 M+JO^?$6Q#/WEUMF%+#A@ MSY:E"KNTFGH/>[B*3*;*-8!!""+,SVQ9DG77(#9RZ_:W?9]1,B6ZI:2N,96$ MK?28J:U?PNP!.TEHC%79V^W@:^XFMD6B:66, ,<.6&Z,@.!P\,02T(-JB[[7 M/6Q0-VT/%ZW18@F= EVKO9PR-F%GM"];M4]VPUVS4/N>JAZ,N*CL'DY8W3* FIO]MGB I*HY 3 M6[025>8K7]JNB.:WY%_]P("P)^YWQ$O]UO #[.7R+BU,5RST_'W@_'WD MQ\+% NAAX#')0G<3$E[9QIX,2@,R@9U"[X=;4E#T8RODJAJ2Z2Q9HP%@I(MIX*.J@(#W[A#KBI@P D%S 'OPW!D MQG3_A:D([*Z:^L5;,J74Z;J_H\V3ALWL]9W-I]E(WS'=SC)OWC+?V2<%F>,[ M7D!:[:-1/AL*JXLL5#^=TJRS?N8D#[<+;4E*?8W48R9+M+_2^-3\2JXW[P-Z M#(8-H6T>U,=$$4>*V#W/@Y&OT#.*R(I3!UEJ"CV=@=ZD@7Y<)B===Y:S$9^. MC1ARB;QZBAIT5-N"D%SI!E_$MIAB%!=- \G+%HN-(E+*@H,M*\H9]P9MW!MB M!E,3775H9CM21!1[9/^0=^>F.L <@S'/@6EU)CEM)KGK%Y0$F*+[! ?H@<>[ MGU4JO[#&O1#T7H6@]QH(^J!"T <-!/VD0M!/&@CZJ$+01PT$?5(AZ%/G!#50 MZP&'94MC-_@X-O\N2?Y7>IZE"Y+@?U#XC=T.22EKA\=TT(OUZT\I,+#V.-.H M8'O-BM"(EK'Q31,.7(@?R:\>.75P3*?^$*TR8Y3P>F M\MDM@7>R/_<-P%L_^\CA_;9:Z3X&:J8T!.2T(ZY>;\ _$9XO4A2>/Z/$GS/] MG=\>>97V.$_LS?R(5[![+\)\.-2-_/.\WL!' !QTN4!S'',T+OR(%[L\T_&- M.B+1]@]E=!^UI\XYV9V3O6\G.T17=H[UTW&L]VD\D#ZEU*&R;>I1:>I<^+9=TFTX>KT"U@W<[5ARO4A66-K V'>&A6 M86MD\P%^ A7GB34"O;G31A:/8(V KW^I=^7+U1Z 'A#&8%QX*V)*(ASRD/F] M6X/FQ>4X_PL2,2BHA_Z=,4'>"]$,!SCULMC/0LSZ;!F1!Z1W/Z>^ /6^:(<% MK-<$ARJ^[U"L\:H8T$8#O7KJKU6@:Y.W*CI@I7CSHADG'15F"()LF45\.>6/ M9?-3*4$+MMCP,RKRQ(1)YO&786-Q\#!4"P JQS%1!GQWGTD*?]>TTT_R=2[Y\#U&8@:Q,"E V%8_ MZ5]16ER9=X36[9Z#-I[!6+^ZZY[3=4,2IHC$EQG3U>)@_<26,F7:!]?GXC#_ MOZC0[G8[@;$UF3WY+S5<]S.92?@>>!16C,)M93])Z1Y18T-QGK1D::D+RSMN M=_S:[#B(_FB0Z*V*=W14B5[8 /5QT:=J1$]FCR7]ND#V^&&N.CX@?:T)K.WQ M>8E"&KK*$K8I"T&YV*OE]_I*^LF^KFHM"7#QAPJ& T_]6%?X\P=G/HB3@X:&A646I -$I5&'F$"NLY/)*NB M02"27"JU#A0ARP1L1K$NI@B*BX(YWKKX("A&$!N!=9$]X 74S$UE71@.%"^ M8=2ZPVB (;2K0G=)_22]&VHPB\B\U]\:&3HR4H&^OWMJL&_>-%/-^[NSQ@:4 M6+&U[JX20J37X]Y?&.@S2J9DF*M0Z&GL+VISP(CH\4*"H?WY5#:R>LP1&,// MME\:#9T98 "_V Y@,QLZ7/*%*P5?"@!C-.=Z[--0<>PTO@N.XUC4S-;8"4+# MX&C!M8K#53>D!==A\#@<.+B681=PU:'J<-RLT#J:>,[A$"DK#X41Y#H>U.(" MAU'!@5'6(88-C-1K"LG'VOS"_\%57/:7_P]02P$"% ,4 " G0&U/7EB5 ME6*% !*;@< $0 @ $ 1"FYCD( #.8@ M%0 @ $'D@ &UL4$L! A0# M% @ )T!M3\\EP,'W*0 +ZH# !4 ( ! @KSL $DQ P 5 M " 9W$ !S;F)P+3(P,3DP.3,P7VQA8BYX;6Q02P$"% ,4 M " G0&U/IZ1DC_XK 2\@, %0 @ %_ $ &UL4$L%!@ & 8 B@$ + L 0 $! end XML 27 R14.htm IDEA: XBRL DOCUMENT v3.19.3

Note 7 - Commitments and Contingencies
9 Months Ended

Sep. 30, 2019

Notes to Financial Statements

Commitments and Contingencies Disclosure [Text Block]

7
.

Commitments and Contingencies

License agreement

Subsequent to the end of the quarter, on
October 3, 2019,
the Company entered into a
second
amendment to its License Agreement
No.

A9672
with the University of Florida Research Foundation, Inc. (“UFRF”). The license agreement continues to entitle the Company to a worldwide exclusive license from UFRF for the polyamine analogue compound (“SBP-
101”
). The
second
amendment (i) eliminated the Company’s obligation to make any future milestone and minimum royalty payments to UFRF; (ii) clarified the obligation of the Company to make certain payments to UFRF in the event the Company sub-licenses SBP-
101
to another party; (iii) reduced the period during which the Company is required to pay royalties on future commercial sales of SBP-
101
to the shorter of
ten
years or the expiration of the period of regulatory exclusivity on a country-by-country basis; and (iv) extended the deadline for the
first
commercial sale of SBP-
101
to
December 31, 2025
before UFRF
may
exercise its termination rights under the license agreement.

X

- Definition
The entire disclosure for commitments and contingencies.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-URI http://asc.fasb.org/topic&trid=2127136

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 440
-URI http://asc.fasb.org/topic&trid=2144648
+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_DisclosureTextBlockAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 28 R10.htm IDEA: XBRL DOCUMENT v3.19.3

Note 3 - Basis of Presentation
9 Months Ended

Sep. 30, 2019

Notes to Financial Statements

Basis of Presentation and Significant Accounting Policies [Text Block]

3.

Basis of Presentation

We have prepared the accompanying interim condensed consolidated financial statements in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) for interim financial information and with the instructions to Form
10
-Q and Regulation S-
X
of the Securities and Exchange Commission (“SEC”). Accordingly, they do
not
include all of the information and footnotes required by U.S. GAAP for complete financial statements. These interim condensed consolidated financial statements reflect all adjustments consisting of normal recurring accruals, which, in the opinion of management, are necessary to present fairly our consolidated financial position, consolidated results of operations and consolidated cash flows for the periods and as of the dates presented. Our fiscal year ends on
December 31.
The condensed consolidated balance sheet as of
December 31, 2018
was derived from audited consolidated financial statements but does
not
include all disclosures required by U.S. GAAP. These interim condensed consolidated financial statements should be read in conjunction with the annual consolidated financial statements and the notes thereto included in our most recent filed Annual Report on Form
10
-K and our subsequent filings with the SEC. The nature of our business is such that the results of any interim period
may
not
be indicative of the results to be expected for the entire year.

Recently
Adopted
Accounting Pronouncement
s

In
June 2018,
the Financial Accounting Standards Board (the “FASB”) issued Accounting Standards Update (“ASU”)
2018
-
07,
“Compensation – Stock Compensation (Topic
718
).” ASU
2018
-
07
simplifies the accounting for nonemployee stock-based payment transactions. This ASU was adopted by the Company effective for the fiscal year beginning
January 1, 2019.
Historically, the ultimate stock-based compensation related to non-employee common stock options would fluctuate based on changes in the underlying option pricing model as the awards vest. Under the new guidance, the total compensation cost of non-employee options is determined at grant date. The Company has evaluated the impact of this new guidance on its financial statements and has determined that it has affected how the Company records stock-based compensation related to common stock options and other equity-based compensation, if any, granted to non-employees.

In
February 2016,
the FASB issued ASU
2016
-
02,
“Leases,” which created a new Topic, Accounting Standards Codification (“ASC”) Topic
842
and established the core principle that a lessee should recognize the assets, representing rights-of-use, and liabilities to make lease payments, that arise from leases. For leases with a term of
12
months or less, a lessee is permitted to make an election under which such assets and liabilities would
not
be recognized, and lease expense would be recognized generally on a straight-line basis over the lease term. This standard was adopted by the Company for the year beginning
January 1, 2019.
The Company has evaluated the impact of this revised guidance on its financial statements and determined it had
no
material impact, as the Company has
no
leasing arrangements with terms greater than
one
year.

X

- Definition
The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-URI http://asc.fasb.org/topic&trid=2122369
+ Details

Name: us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_DisclosureTextBlockAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 29 FilingSummary.xml IDEA: XBRL DOCUMENT 3.19.3 html 124 242 1 false 32 0 false 4 false false R1.htm 000 - Document - Document And Entity Information Sheet http://www.sunbiopharma.com/20190930/role/statement-document-and-entity-information Document And Entity Information Cover 1 false false R2.htm 001 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited) Sheet http://www.sunbiopharma.com/20190930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited Condensed Consolidated Balance Sheets (Current Period Unaudited) Statements 2 false false R3.htm 002 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) Sheet http://www.sunbiopharma.com/20190930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) Statements 3 false false R4.htm 003 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) Sheet http://www.sunbiopharma.com/20190930/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) Statements 4 false false R5.htm 004 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited) Sheet http://www.sunbiopharma.com/20190930/role/statement-condensed-consolidated-statements-of-stockholders-equity-deficit-unaudited Condensed Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited) Statements 5 false false R6.htm 005 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) Sheet http://www.sunbiopharma.com/20190930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited Condensed Consolidated Statements of Cash Flows (Unaudited) Statements 6 false false R7.htm 006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) (Parentheticals) Sheet http://www.sunbiopharma.com/20190930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-parentheticals Condensed Consolidated Statements of Cash Flows (Unaudited) (Parentheticals) Statements 7 false false R8.htm 007 - Disclosure - Note 1 - Business Sheet http://www.sunbiopharma.com/20190930/role/statement-note-1-business Note 1 - Business Notes 8 false false R9.htm 008 - Disclosure - Note 2 - Risks and Uncertainties Sheet http://www.sunbiopharma.com/20190930/role/statement-note-2-risks-and-uncertainties Note 2 - Risks and Uncertainties Notes 9 false false R10.htm 009 - Disclosure - Note 3 - Basis of Presentation Sheet http://www.sunbiopharma.com/20190930/role/statement-note-3-basis-of-presentation Note 3 - Basis of Presentation Notes 10 false false R11.htm 010 - Disclosure - Note 4 - Liquidity and Business Plan Sheet http://www.sunbiopharma.com/20190930/role/statement-note-4-liquidity-and-business-plan Note 4 - Liquidity and Business Plan Notes 11 false false R12.htm 011 - Disclosure - Note 5 - Summary of Significant Accounting Policies Sheet http://www.sunbiopharma.com/20190930/role/statement-note-5-summary-of-significant-accounting-policies Note 5 - Summary of Significant Accounting Policies Notes 12 false false R13.htm 012 - Disclosure - Note 6 - Indebtedness Sheet http://www.sunbiopharma.com/20190930/role/statement-note-6-indebtedness Note 6 - Indebtedness Notes 13 false false R14.htm 013 - Disclosure - Note 7 - Commitments and Contingencies Sheet http://www.sunbiopharma.com/20190930/role/statement-note-7-commitments-and-contingencies Note 7 - Commitments and Contingencies Notes 14 false false R15.htm 014 - Disclosure - Note 8 - Stockholders' Deficit Sheet http://www.sunbiopharma.com/20190930/role/statement-note-8-stockholders-deficit Note 8 - Stockholders' Deficit Notes 15 false false R16.htm 015 - Disclosure - Note 9 - Stock-based Compensation Sheet http://www.sunbiopharma.com/20190930/role/statement-note-9-stockbased-compensation Note 9 - Stock-based Compensation Notes 16 false false R17.htm 016 - Disclosure - Significant Accounting Policies (Policies) Sheet http://www.sunbiopharma.com/20190930/role/statement-significant-accounting-policies-policies Significant Accounting Policies (Policies) Policies http://www.sunbiopharma.com/20190930/role/statement-note-5-summary-of-significant-accounting-policies 17 false false R18.htm 017 - Disclosure - Note 5 - Summary of Significant Accounting Policies (Tables) Sheet http://www.sunbiopharma.com/20190930/role/statement-note-5-summary-of-significant-accounting-policies-tables Note 5 - Summary of Significant Accounting Policies (Tables) Tables http://www.sunbiopharma.com/20190930/role/statement-note-5-summary-of-significant-accounting-policies 18 false false R19.htm 018 - Disclosure - Note 8 - Stockholders' Deficit (Tables) Sheet http://www.sunbiopharma.com/20190930/role/statement-note-8-stockholders-deficit-tables Note 8 - Stockholders' Deficit (Tables) Tables http://www.sunbiopharma.com/20190930/role/statement-note-8-stockholders-deficit 19 false false R20.htm 019 - Disclosure - Note 9 - Stock-based Compensation (Tables) Sheet http://www.sunbiopharma.com/20190930/role/statement-note-9-stockbased-compensation-tables Note 9 - Stock-based Compensation (Tables) Tables http://www.sunbiopharma.com/20190930/role/statement-note-9-stockbased-compensation 20 false false R21.htm 020 - Disclosure - Note 2 - Risks and Uncertainties (Details Textual) Sheet http://www.sunbiopharma.com/20190930/role/statement-note-2-risks-and-uncertainties-details-textual Note 2 - Risks and Uncertainties (Details Textual) Details http://www.sunbiopharma.com/20190930/role/statement-note-2-risks-and-uncertainties 21 false false R22.htm 021 - Disclosure - Note 4 - Liquidity and Business Plan (Details Textual) Sheet http://www.sunbiopharma.com/20190930/role/statement-note-4-liquidity-and-business-plan-details-textual Note 4 - Liquidity and Business Plan (Details Textual) Details http://www.sunbiopharma.com/20190930/role/statement-note-4-liquidity-and-business-plan 22 false false R23.htm 022 - Disclosure - Note 5 - Summary of Significant Accounting Policies (Details Textual) Sheet http://www.sunbiopharma.com/20190930/role/statement-note-5-summary-of-significant-accounting-policies-details-textual Note 5 - Summary of Significant Accounting Policies (Details Textual) Details http://www.sunbiopharma.com/20190930/role/statement-note-5-summary-of-significant-accounting-policies-tables 23 false false R24.htm 023 - Disclosure - Note 5 - Summary of Significant Accounting Policies - Anti-dilutive Securities (Details) Sheet http://www.sunbiopharma.com/20190930/role/statement-note-5-summary-of-significant-accounting-policies-antidilutive-securities-details Note 5 - Summary of Significant Accounting Policies - Anti-dilutive Securities (Details) Details 24 false false R25.htm 024 - Disclosure - Note 6 - Indebtedness (Details Textual) Sheet http://www.sunbiopharma.com/20190930/role/statement-note-6-indebtedness-details-textual Note 6 - Indebtedness (Details Textual) Details http://www.sunbiopharma.com/20190930/role/statement-note-6-indebtedness 25 false false R26.htm 025 - Disclosure - Note 7 - Commitments and Contingencies (Details Textual) Sheet http://www.sunbiopharma.com/20190930/role/statement-note-7-commitments-and-contingencies-details-textual Note 7 - Commitments and Contingencies (Details Textual) Details http://www.sunbiopharma.com/20190930/role/statement-note-7-commitments-and-contingencies 26 false false R27.htm 026 - Disclosure - Note 8 - Stockholders' Deficit (Details Textual) Sheet http://www.sunbiopharma.com/20190930/role/statement-note-8-stockholders-deficit-details-textual Note 8 - Stockholders' Deficit (Details Textual) Details http://www.sunbiopharma.com/20190930/role/statement-note-8-stockholders-deficit-tables 27 false false R28.htm 027 - Disclosure - Note 8 - Stockholders' Deficit - Common Stock Reserved for Future Issuance (Details) Sheet http://www.sunbiopharma.com/20190930/role/statement-note-8-stockholders-deficit-common-stock-reserved-for-future-issuance-details Note 8 - Stockholders' Deficit - Common Stock Reserved for Future Issuance (Details) Details 28 false false R29.htm 028 - Disclosure - Note 9 - Stock-based Compensation (Details Textual) Sheet http://www.sunbiopharma.com/20190930/role/statement-note-9-stockbased-compensation-details-textual Note 9 - Stock-based Compensation (Details Textual) Details http://www.sunbiopharma.com/20190930/role/statement-note-9-stockbased-compensation-tables 29 false false R30.htm 029 - Disclosure - Note 9 - Stock-based Compensation - Stock-based Compensation Expense (Details) Sheet http://www.sunbiopharma.com/20190930/role/statement-note-9-stockbased-compensation-stockbased-compensation-expense-details Note 9 - Stock-based Compensation - Stock-based Compensation Expense (Details) Details 30 false false R31.htm 030 - Disclosure - Note 9 - Stock-based Compensation - Summary of Option Activity (Details) Sheet http://www.sunbiopharma.com/20190930/role/statement-note-9-stockbased-compensation-summary-of-option-activity-details Note 9 - Stock-based Compensation - Summary of Option Activity (Details) Details 31 false false R32.htm 031 - Disclosure - Note 9 - Stock-based Compensation - Options Outstanding (Details) Sheet http://www.sunbiopharma.com/20190930/role/statement-note-9-stockbased-compensation-options-outstanding-details Note 9 - Stock-based Compensation - Options Outstanding (Details) Details 32 false false R33.htm 032 - Disclosure - Note 9 - Stock-based Compensation - Assumptions Used in Calculating Fair Value of Options (Details) Sheet http://www.sunbiopharma.com/20190930/role/statement-note-9-stockbased-compensation-assumptions-used-in-calculating-fair-value-of-options-details Note 9 - Stock-based Compensation - Assumptions Used in Calculating Fair Value of Options (Details) Details 33 false false All Reports Book All Reports snbp-20190930.xml snbp-20190930.xsd snbp-20190930_cal.xml snbp-20190930_def.xml snbp-20190930_lab.xml snbp-20190930_pre.xml http://xbrl.sec.gov/dei/2019-01-31 http://fasb.org/srt/2019-01-31 http://fasb.org/us-gaap/2019-01-31 true true XML 30 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 31 R33.htm IDEA: XBRL DOCUMENT v3.19.3

Note 9 - Stock-based Compensation - Assumptions Used in Calculating Fair Value of Options (Details)
3 Months Ended 9 Months Ended

Sep. 30, 2019

$ / shares

Sep. 30, 2019

$ / shares

Expected dividend yield 0.00% 0.00%

Expected stock price volatility 72.00%

Minimum [Member]

Common stock fair value (in dollars per share) $ 4.50 $ 4.50

Risk-free interest rate 1.55%

Expected Option life (years) (Year) 5 years

Maximum [Member]

Common stock fair value (in dollars per share) $ 5 $ 5

Risk-free interest rate 1.57%

Expected Option life (years) (Year) 5 years 182 days

X

- Definition
The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iii)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(ii)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
The risk-free interest rate assumption that is used in valuing an option on its own shares.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iv)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Price of a single share of a number of saleable stocks of a company.
+ References
No definition available.
+ Details

Name: us-gaap_SharePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(i)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 14.D.2)
-URI http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Details

Name: srt_RangeAxis=srt_MinimumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_RangeAxis=srt_MaximumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

EXCEL 32 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 33 R24.htm IDEA: XBRL DOCUMENT v3.19.3

Note 5 - Summary of Significant Accounting Policies - Anti-dilutive Securities (Details) - shares
9 Months Ended

Sep. 30, 2019

Sep. 30, 2018

Anti-dilutive securities (in shares) 5,123,055 2,398,911

Share-based Payment Arrangement [Member]

Anti-dilutive securities (in shares) 1,711,511 1,130,710

Convertible Debt Securities [Member]

Anti-dilutive securities (in shares) 2,222

Warrant [Member]

Anti-dilutive securities (in shares) 3,411,544 1,265,979

X

- Definition
Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockCompensationPlanMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 34 R20.htm IDEA: XBRL DOCUMENT v3.19.3

Note 9 - Stock-based Compensation (Tables)
9 Months Ended

Sep. 30, 2019

Notes Tables

Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]

Nine Months Ended September 30,

2019

2018

General and Administrative
$
573
$
1,404

Research and Development

385

892

$
958
$
2,296

Share-based Payment Arrangement, Option, Activity [Table Text Block]

Shares

Available

for Grant

Shares

Underlying

Options

Weighted Average

Exercise Price

Per Share

Aggregate

Intrinsic Value

Balance at December 31, 2018

732,149

1,032,211
$
8.90
$
169,495

Granted

(700,100
)
700,100

3.41

Exercised

-

-

-

Cancelled

-

-

-

Forfeitures

20,800

(20,800
)
15.10

Balance at September 30, 2019

52,849

1,711,511
$
6.58
$
1,674,675

Share-based Payment Arrangement, Option, Exercise Price Range [Table Text Block]

Outstanding, Vested and Expected to Vest

Options Vested and Excercisable

Per Share Exercise Price

Shares

Weighted Average

Remaining Contractual Life

(Years)

Weighted Average

Exercise Price

Options

Excercisable

Weighted Average

Remaining Contractual Life

(Years)

$0.875
-

$1.10

26,360

3.25
$
1.029

26,360

3.25

$2.275
-

$2.50

38,000

4.37
$
2.464

38,000

4.37

$2.95
-

$3.175

740,800

8.50
$
3.011

398,125

7.52

$4.50
-

$8.10

538,300

8.04
$
6.742

506,500

8.18

$10.00
-

$10.10

54,000

7.80
$
10.007

54,000

7.80

$15.10

314,051

6.66
$
15.100

307,051

6.76

Totals

1,711,511

7.88
$
6.581

1,330,036

7.43

Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]

2019

Common stock fair value

4.50

-

5.00

Risk-free interest rate

1.55%

-

1.57%

Expected dividend yield

0%

Expected Option life (years)
5.0

-

5.5

Expected stock price volatility

72%

X

- Definition
Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (h)(1)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 14.F)
-URI http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901
+ Details

Name: us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (f)(2)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_TableTextBlock

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 35 R28.htm IDEA: XBRL DOCUMENT v3.19.3

Note 8 - Stockholders' Deficit - Common Stock Reserved for Future Issuance (Details) - shares

Sep. 30, 2019

Dec. 31, 2018

Stock options outstanding (in shares) 1,711,511

Shares available for grant under equity incentive plan (in shares) 52,849 732,149

Common shares issuable under outstanding common stock purchase warrants (in shares) 3,411,544

(in shares) 5,175,904

X

- Definition
Number of warrants or rights outstanding.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(i))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690
+ Details

Name: us-gaap_ClassOfWarrantOrRightOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Aggregate number of common shares reserved for future issuance.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockCapitalSharesReservedForFutureIssuance

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)-(ii)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

XML 36 R31.htm IDEA: XBRL DOCUMENT v3.19.3

Note 9 - Stock-based Compensation - Summary of Option Activity (Details) - USD ($)
9 Months Ended

Sep. 30, 2019

Dec. 31, 2018

Balance, shares available for grant (in shares) 732,149

Balance, shares underlying options (in shares) 1,032,211

Balance, weighted average exercise price per share (in dollars per share) $ 6.58 $ 8.90

Aggregate intrinsic value $ 1,674,675 $ 169,495

Granted, shares available for grant (in shares) (700,100)

Granted, shares underlying options (in shares) 700,100

Granted, weighted average exercise price per share (in dollars per share) $ 3.41

Forfeitures , shares available for grant (in shares) 20,800

Forfeited, shares underlying options (in shares) (20,800)

Forfeited, weighted average exercise price per share (in dollars per share) $ 15.10

Balance, shares available for grant (in shares) 52,849

Balance, shares underlying options (in shares) 1,711,511

X

- Definition
Represents the number of available shares granted during the period.
+ References
No definition available.
+ Details

Name: snbp_SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfSharesAvailableForGrantGrantsInPeriod

Namespace Prefix: snbp_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(3)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Gross number of share options (or share units) granted during the period.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Number of options outstanding, including both vested and non-vested options.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)-(ii)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

XML 37 R5.htm IDEA: XBRL DOCUMENT v3.19.3

Condensed Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited) - USD ($)
shares in Thousands, $ in Thousands

Common Stock [Member]

Additional Paid-in Capital [Member]

Retained Earnings [Member]

AOCI Attributable to Parent [Member]

Total

Balances (in shares) at Dec. 31, 2017 3,842

Balances at Dec. 31, 2017 $ 4 $ 25,625 $ (29,153) $ (165) $ (3,689)

Stock Issued During Period, Shares, New Issues 252

Sale of common stock and warrants 1,261 1,261

Stock-based compensation 1,792 1,792

Net loss (1,753) (1,753)

Foreign currency translation adjustment 69 69

Sale of common stock and warrants (in shares) 252

Balances (in shares) at Mar. 31, 2018 4,094

Balances at Mar. 31, 2018 $ 4 28,678 (30,906) (96) (2,320)

Balances (in shares) at Dec. 31, 2017 3,842

Balances at Dec. 31, 2017 $ 4 25,625 (29,153) (165) (3,689)

Net loss (5,165)

Foreign currency translation adjustment 324

Warrants issued with sale of convertible notes payable

Common stock converted into convertible notes payable

Balances (in shares) at Sep. 30, 2018 5,061

Balances at Sep. 30, 2018 $ 5 33,612 (34,318) 159 (542)

Balances (in shares) at Mar. 31, 2018 4,094

Balances at Mar. 31, 2018 $ 4 28,678 (30,906) (96) (2,320)

Stock Issued During Period, Shares, New Issues 216

Sale of common stock and warrants 1,080 1,080

Stock-based compensation 358 358

Net loss (2,487) (2,487)

Foreign currency translation adjustment 100 100

Beneficial conversion feature 121 121

Conversion of convertible notes payable and accrued interest into common stock and warrants (in shares) 751

Conversion of convertible notes payable and accrued interest into common stock and warrants $ 1 3,257 3,258

Sale of common stock and warrants (in shares) 216

Balances (in shares) at Jun. 30, 2018 5,061

Balances at Jun. 30, 2018 $ 5 33,494 (33,393) 4 110

Stock-based compensation 146 146

Net loss (925) (925)

Foreign currency translation adjustment 155 155

Sale of common stock and warrants (28) (28)

Balances (in shares) at Sep. 30, 2018 5,061

Balances at Sep. 30, 2018 $ 5 33,612 (34,318) 159 (542)

Balances (in shares) at Dec. 31, 2018 5,077

Balances at Dec. 31, 2018 $ 5 35,038 (35,058) 283 268

Stock-based compensation 10 10

Net loss (1,581) (1,581)

Foreign currency translation adjustment (32) (32)

Beneficial conversion feature 353 353

Warrants issued with sale of convertible notes payable 419 419

Common stock converted into convertible notes payable (in shares) (7)

Common stock converted into convertible notes payable (25) (25)

Balances (in shares) at Mar. 31, 2019 5,070

Balances at Mar. 31, 2019 $ 5 35,795 (36,639) 251 (588)

Balances (in shares) at Dec. 31, 2018 5,077

Balances at Dec. 31, 2018 $ 5 35,038 (35,058) 283 268

Net loss (5,226)

Foreign currency translation adjustment 219

Warrants issued with sale of convertible notes payable 419

Common stock converted into convertible notes payable (25)

Balances (in shares) at Sep. 30, 2019 6,624

Balances at Sep. 30, 2019 $ 7 42,164 (40,284) 502 2,389

Balances (in shares) at Mar. 31, 2019 5,070

Balances at Mar. 31, 2019 $ 5 35,795 (36,639) 251 (588)

Stock-based compensation 412 412

Net loss (2,271) (2,271)

Foreign currency translation adjustment 49 49

Conversion of convertible notes payable and accrued interest into common stock and warrants (in shares) 652

Conversion of convertible notes payable and accrued interest into common stock and warrants $ 1 2,280 2,281

Balances (in shares) at Jun. 30, 2019 5,722

Balances at Jun. 30, 2019 $ 6 38,487 (38,910) 300 (117)

Stock Issued During Period, Shares, New Issues 902

Sale of common stock and warrants $ 1 3,141 3,142

Stock-based compensation 536 536

Net loss (1,374) (1,374)

Foreign currency translation adjustment 202 202

Sale of common stock and warrants (in shares) 902

Balances (in shares) at Sep. 30, 2019 6,624

Balances at Sep. 30, 2019 $ 7 $ 42,164 $ (40,284) $ 502 $ 2,389

X

- Definition
Represents number of common stock converted into convertible notes payable.
+ References
No definition available.
+ Details

Name: snbp_CommonStockConvertedIntoConvertibleNotesPayableShares

Namespace Prefix: snbp_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Represents the value of common stock converted into convertible notes payable.
+ References
No definition available.
+ Details

Name: snbp_CommonStockConvertedIntoConvertibleNotesPayableValue

Namespace Prefix: snbp_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of increase (decrease) in additional paid in capital (APIC) resulting from recognition of deferred taxes for convertible debt with a beneficial conversion feature.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 55
-Paragraph 51
-URI http://asc.fasb.org/extlink&oid=117331294&loc=d3e34017-109320
+ Details

Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 20
-Section 55
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=118258462&loc=d3e11149-113907

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 20
-Section 55
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=118258462&loc=d3e11178-113907

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 35
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=116855982&loc=d3e4534-113899
+ Details

Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770
+ Details

Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 25
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109126253&loc=d3e4724-112606

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770
+ Details

Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 10A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section 45
-Paragraph 20
-Subparagraph (b,c)
-URI http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900
+ Details

Name: us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Number of shares issued which are neither cancelled nor held in the treasury.
+ References
No definition available.
+ Details

Name: us-gaap_SharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of shares issued during the period as a result of the conversion of convertible securities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-30)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of new stock issued during the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The gross value of stock issued during the period upon the conversion of convertible securities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-31)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_StockIssuedDuringPeriodValueNewIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 38 R1.htm IDEA: XBRL DOCUMENT v3.19.3

Document And Entity Information - shares
9 Months Ended

Sep. 30, 2019

Nov. 08, 2019

Document Information [Line Items]

Entity Registrant Name Sun BioPharma, Inc.

Entity Central Index Key 0001029125

Trading Symbol snbp

Current Fiscal Year End Date --12-31

Entity Filer Category Non-accelerated Filer

Entity Current Reporting Status Yes

Entity Emerging Growth Company false

Entity Small Business true

Entity Common Stock, Shares Outstanding (in shares) 6,631,308

Entity Shell Company false

Document Type 10-Q

Document Period End Date Sep. 30, 2019

Document Fiscal Year Focus 2019

Document Fiscal Period Focus Q3

Amendment Flag false

Title of 12(g) Security Common Stock, $0.001 par value

X

- Definition
Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
No definition available.
+ Details

Name: dei_AmendmentFlag

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
End date of current fiscal year in the format --MM-DD.
+ References
No definition available.
+ Details

Name: dei_CurrentFiscalYearEndDate

Namespace Prefix: dei_

Data Type: xbrli:gMonthDayItemType

Balance Type: na

Period Type: duration

X

- Definition
Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.
+ References
No definition available.
+ Details

Name: dei_DocumentFiscalPeriodFocus

Namespace Prefix: dei_

Data Type: dei:fiscalPeriodItemType

Balance Type: na

Period Type: duration

X

- Definition
This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.
+ References
No definition available.
+ Details

Name: dei_DocumentFiscalYearFocus

Namespace Prefix: dei_

Data Type: xbrli:gYearItemType

Balance Type: na

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: dei_DocumentInformationLineItems

Namespace Prefix: dei_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.
+ References
No definition available.
+ Details

Name: dei_DocumentPeriodEndDate

Namespace Prefix: dei_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition
The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
No definition available.
+ Details

Name: dei_DocumentType

Namespace Prefix: dei_

Data Type: dei:submissionTypeItemType

Balance Type: na

Period Type: duration

X

- Definition
A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityCentralIndexKey

Namespace Prefix: dei_

Data Type: dei:centralIndexKeyItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.
+ References
No definition available.
+ Details

Name: dei_EntityCommonStockSharesOutstanding

Namespace Prefix: dei_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.
+ References
No definition available.
+ Details

Name: dei_EntityCurrentReportingStatus

Namespace Prefix: dei_

Data Type: dei:yesNoItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate if registrant meets the emerging growth company criteria.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityEmergingGrowthCompany

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityFilerCategory

Namespace Prefix: dei_

Data Type: dei:filerCategoryItemType

Balance Type: na

Period Type: duration

X

- Definition
The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityRegistrantName

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition
Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityShellCompany

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicates that the company is a Smaller Reporting Company (SRC).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntitySmallBusiness

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
Title of a 12(g) registered security.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection g
+ Details

Name: dei_Security12gTitle

Namespace Prefix: dei_

Data Type: dei:securityTitleItemType

Balance Type: na

Period Type: duration

X

- Definition
Trading symbol of an instrument as listed on an exchange.
+ References
No definition available.
+ Details

Name: dei_TradingSymbol

Namespace Prefix: dei_

Data Type: dei:tradingSymbolItemType

Balance Type: na

Period Type: duration

XML 39 R9.htm IDEA: XBRL DOCUMENT v3.19.3

Note 2 - Risks and Uncertainties
9 Months Ended

Sep. 30, 2019

Notes to Financial Statements

Nature of Operations [Text Block]

2.

Risks and Uncertainties

The Company operates in a highly regulated and competitive environment. The development, manufacturing and marketing of pharmaceutical products require approval from, and are subject to ongoing oversight by, the Food and Drug Administration (“FDA”) in the United States, the Therapeutic Goods Administration in Australia, the European Medicines Agency in the European Union, and comparable agencies in other countries. Obtaining approval for a new pharmaceutical product is never certain,
may
take many years, and is normally expected to involve substantial expenditures.

We have incurred losses of
$40.3
million since our inception in
2011.
For the
nine
months ended
September 30, 2019,
we incurred a net loss of
$5.2
million, which includes the amortization of discount on debt of
$2.1
million. We also incurred negative cash flows from operating activities of
$1.9
million during this period. During this same period, we raised
$3.1
million from sales of common stock and warrants and
$0.8
million from the sale of convertible promissory notes and warrants, as discussed in Note
4
titled “Liquidity and Business Plan”. The notes sold in
January 2019,
along with similar ones sold in
December 2018
converted into common stock on
June 30, 2019.
As we continue to pursue development activities and seek commercialization of our initial product candidate, SBP-
101,
we expect to incur substantial losses, which are likely to generate negative net cash flows from operating activities. As of
September 30, 2019,
we had cash of
$3.4
million, working capital (current assets less current liabilities) of
$3.1
million and stockholders’ equity of
$2.4
million. The Company’s principal sources of cash have historically included the issuance of convertible debt and equity securities.

The accompanying condensed consolidated financial statements have been prepared assuming that we will continue as a going concern, which contemplates the realization of assets and liquidation of liabilities in the normal course of business. The condensed

consolidated financial statements do
not
include any adjustments relating to the recoverability or classification of assets or the amounts of liabilities that might result from the outcome of these uncertainties. Our current independent registered public accounting firm included a paragraph emphasizing this going concern uncertainty in their audit report regarding our
2018
financial statements dated
March 22, 2019.
Our ability to continue as a going concern, realize the carrying value of our assets and discharge our liabilities in the ordinary course of business is dependent upon a number of factors, including our ability to obtain additional financing, the success of our development efforts, our ability to obtain marketing approval for our SBP-
101
product candidate in the United States, Australia, the European Union or other markets and ultimately our ability to market and sell our SBP-
101
product candidate. These factors, among others, raise substantial doubt about our ability to continue operations as a going concern. See Note
4
titled “Liquidity and Business Plan.”

X

- References
No definition available.
+ Details

Name: us-gaap_DisclosureTextBlockAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-URI http://asc.fasb.org/topic&trid=2134479
+ Details

Name: us-gaap_NatureOfOperations

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 40 R16.htm IDEA: XBRL DOCUMENT v3.19.3

Note 9 - Stock-based Compensation
9 Months Ended

Sep. 30, 2019

Notes to Financial Statements

Share-based Payment Arrangement [Text Block]

9
.

S
tock
-based
Compensation

2016
Omnibus Incentive Plan

The Sun BioPharma, Inc.
2016
Omnibus Incentive Plan (the
“2016
Plan”) was adopted by our Board of Directors in
March 2016
and approved by our stockholders in
May 2016.
The
2016
Plan permits the granting of incentive and non-statutory stock options, restricted stock, stock appreciation rights, performance units, performance shares and other stock awards to eligible employees, directors and consultants. We grant options to purchase shares of common stock under the
2016
Plan at
no
less than the fair market value of the underlying common stock as of the date of grant. Options granted under the
2016
Plan have a maximum term of
ten
years. Under the
2016
Plan, a total of
1,500,000
shares of common stock were initially reserved for issuance. As of
September 30, 2019,
options to purchase
1,447,151
shares of common stock were outstanding under the
2016
Plan
52,849
shares remained available for future awards.

2011
Stock Option Plan

Our Board of Directors ceased making awards under the Sun BioPharma, Inc.
2011
Stock Option Plan (the
“2011
Plan”) upon the receipt of stockholder approval for the
2016
Plan. Awards outstanding under the
2011
Plan remain outstanding in accordance with and pursuant to the terms thereof. Options granted under the
2011
Plan have a maximum term of
ten
years and generally vest over
zero
to
two
years for employees. As of
September 30, 2019,
options to purchase
264,360
shares of common stock remained outstanding under the
2011
Plan.

Stock
-based Compensation
Expense

General and administrative (“G&A”) and research and development (“R&D”) expenses include non-cash stock-based compensation expense as a result of our issuance of stock options. The terms and vesting schedules for stock-based awards vary by type of grant and the employment status of the grantee. The awards granted through
September 30, 2019
vest based upon time-based and performance conditions. There was approximately
$0.6
million unamortized stock-based compensation expense related to options granted to employees and non-employees as of
September 30, 2019
which will be amortized over the next
eleven
quarters.

Stock-based compensation expense for each of the periods presented is as follows (in thousands):

Nine Months Ended September 30,

2019

2018

General and Administrative
$
573
$
1,404

Research and Development

385

892

$
958
$
2,296

A summary of stock option activity for the
nine
months ended
September 30, 2019
is as follows:

Shares

Available

for Grant

Shares

Underlying

Options

Weighted Average

Exercise Price

Per Share

Aggregate

Intrinsic Value

Balance at December 31, 2018

732,149

1,032,211
$
8.90
$
169,495

Granted

(700,100
)
700,100

3.41

Exercised

-

-

-

Cancelled

-

-

-

Forfeitures

20,800

(20,800
)
15.10

Balance at September 30, 2019

52,849

1,711,511
$
6.58
$
1,674,675

Information about stock options outstanding, vested and expected to vest as of
September 30, 2019,
is as follows:

Outstanding, Vested and Expected to Vest

Options Vested and Excercisable

Per Share Exercise Price

Shares

Weighted Average

Remaining Contractual Life

(Years)

Weighted Average

Exercise Price

Options

Excercisable

Weighted Average

Remaining Contractual Life

(Years)

$0.875
-

$1.10

26,360

3.25
$
1.029

26,360

3.25

$2.275
-

$2.50

38,000

4.37
$
2.464

38,000

4.37

$2.95
-

$3.175

740,800

8.50
$
3.011

398,125

7.52

$4.50
-

$8.10

538,300

8.04
$
6.742

506,500

8.18

$10.00
-

$10.10

54,000

7.80
$
10.007

54,000

7.80

$15.10

314,051

6.66
$
15.100

307,051

6.76

Totals

1,711,511

7.88
$
6.581

1,330,036

7.43

Key assumptions

The estimated grant-date fair values of the stock options were calculated using the Black-Scholes valuation model, based on the following assumptions for the
three
months ended
September 30, 2019:

2019

Common stock fair value

4.50

-

5.00

Risk-free interest rate

1.55%

-

1.57%

Expected dividend yield

0%

Expected Option life (years)
5.0

-

5.5

Expected stock price volatility

72%

X

- Definition
The entire disclosure for share-based payment arrangement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-URI http://asc.fasb.org/topic&trid=2228938
+ Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_DisclosureTextBlockAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 41 R12.htm IDEA: XBRL DOCUMENT v3.19.3

Note 5 - Summary of Significant Accounting Policies
9 Months Ended

Sep. 30, 2019

Notes to Financial Statements

Significant Accounting Policies [Text Block]

5.

Summary of Significant Accounting Policies

Principles of consolidation

The accompanying condensed consolidated financial statements include the assets, liabilities and expenses of the Company. All significant intercompany transactions and balances have been eliminated in consolidation.

Use of estimates

The preparation of condensed consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amount of expenses during the reporting period. Actual results could differ from those estimates.

Beneficial
c
onversion
f
eature
s

For convertible debt where the rate of conversion is below fair market value for our common stock, the Company records a beneficial conversion feature and related debt discount that is presented as a direct deduction from the carrying amount of the related debt and as an increase to additional paid-in capital. The debt discount is amortized through interest expense over the life of the related debt.

Debt issuance costs

Costs associated with the issuance of debt instruments are capitalized and presented as a direct deduction from the carrying amount of the related debt liability. These costs are amortized through interest expense over the life of the related debt.

Research and development costs

Research and development costs include expenses incurred in the conduct of our
second
Phase
1
human clinical trial, for
third
-party service providers performing various testing and accumulating data related to our preclinical studies; sponsored research agreements; developing and scaling the manufacturing process necessary to produce sufficient amounts of the SBP-
101
compound for use in our pre-clinical studies and human clinical trials; consulting resources with specialized expertise related to execution of our development plan for our SBP-
101
product candidate; personnel costs, including salaries, benefits and share-based compensation; and costs to license and maintain our licensed intellectual property.

We charge research and development costs, including clinical trial costs, to expense when incurred. Our human clinical trials are, and will be, performed at clinical trial sites and are administered jointly by us with assistance from contract research organizations (“CROs”). Costs of setting up clinical trial sites are accrued upon execution of the study agreement. Expenses related to the performance of clinical trials generally are accrued based on contracted amounts and the achievement of agreed upon milestones, such as patient enrollment, patient follow-up, etc. We monitor levels of performance under each significant contract, including the extent of patient enrollment and other activities through communications with the clinical trial sites and CROs, and adjust the estimates, if required, on a quarterly basis so that clinical expenses reflect the actual effort expended at each clinical trial site and by each CRO.

All material CRO contracts are terminable by us upon written notice and we are generally only liable for actual effort expended by the CROs and certain non-cancelable expenses incurred at any point of termination.

We expense costs associated with obtaining licenses for patented technologies when it is determined there is
no
alternative future use of the intellectual property subject to the license.

Stock
-based compensation

In accounting for stock-based incentive awards, we measure and recognize the cost of employee and non-employee services received in exchange for awards of equity instruments based on the fair value of those awards on the grant date. Calculating stock-based compensation expense requires the input of highly subjective assumptions, which represent our best estimates and involve inherent uncertainties and the application of management’s judgment. Compensation cost is recognized ratably using the straight-line attribution method over the vesting period, which is considered to be the requisite service period. Compensation expense for performance-based stock option awards is recognized when “performance” has occurred or is probable of occurring.

The fair value of stock-based awards is estimated at the date of grant using the Black-Scholes option pricing model. The determination of the fair value of stock-based awards is affected by our stock price, as well as assumptions regarding a number of complex and subjective variables. Risk free interest rates are based upon U.S. Treasury rates appropriate for the expected term of each award. Expected volatility rates are based primarily on the volatility rates of a set of guideline companies, which consist of public and recently public biotechnology companies. The assumed dividend yield is zero, as we do
not
expect to declare any dividends in the foreseeable future. The expected term of options granted is determined using the “simplified” method. Under this approach, the expected term is presumed to be the mid-point between the average vesting date and the end of the contractual term. Forfeitures of unvested stock options are recognized as they occur.

Foreign currency translation adjustments

The functional currency of Sun BioPharma Australia Pty Ltd is the Australian Dollar. Accordingly, assets and liabilities, and equity transactions of Sun BioPharma Australia Pty Ltd are translated into U.S. dollars at period-end exchange rates. Revenues and expenses are translated at the average exchange rate in effect for the period. The resulting translation gains and losses are recorded as a component of accumulated comprehensive loss presented within the statements of stockholders’ equity (deficit). During the
nine
-month periods ended
September 30, 2019
and
2018,
any reclassification adjustments from accumulated other comprehensive loss to operations were inconsequential.

Comprehensive loss

Comprehensive loss consists of our net loss and the effects of foreign currency translation.

Net loss per share

Basic net loss per share is computed by dividing net loss by the weighted-average number of common shares outstanding during the period. Diluted net loss per share is based on the weighted average of common shares outstanding during the period plus dilutive potential common shares calculated using the treasury stock method. Such potentially dilutive shares are excluded when the effect would be anti-dilutive or reduce a net loss per share. The Company’s potential dilutive shares, which include convertible debt, outstanding common stock options, and warrants, have
not
been included in the computation of diluted net loss per share for all periods as the result would be anti-dilutive.

The following table sets forth the potential shares of common stock that were
not
included in the calculation of diluted net loss per share as their effects would have been anti-dilutive as of:

September 30,

2019

2018

Employee and non-employee stock options

1,711,511

1,130,710

Estimated common shares issuable upon conversion of notes payable and accrued interest

-

2,222

Common stock issuable under common stock purchase warrants

3,411,544

1,265,979

5,123,055

2,398,911

X

- References
No definition available.
+ Details

Name: us-gaap_DisclosureTextBlockAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for all significant accounting policies of the reporting entity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-URI http://asc.fasb.org/topic&trid=2122369
+ Details

Name: us-gaap_SignificantAccountingPoliciesTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 43 R30.htm IDEA: XBRL DOCUMENT v3.19.3

Note 9 - Stock-based Compensation - Stock-based Compensation Expense (Details) - USD ($)
$ in Thousands
9 Months Ended

Sep. 30, 2019

Sep. 30, 2018

Share-based compensation expense $ 958 $ 2,296

General and Administrative Expense [Member]

Share-based compensation expense 573 1,404

Research and Development Expense [Member]

Share-based compensation expense $ 385 $ 892

X

- Definition
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 14.F)
-URI http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (h)(1)(i)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_AllocatedShareBasedCompensationExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 44 R8.htm IDEA: XBRL DOCUMENT v3.19.3

Note 1 - Business
9 Months Ended

Sep. 30, 2019

Notes to Financial Statements

Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]

1.

Business

Sun BioPharma, Inc. together with its wholly-owned subsidiary Sun BioPharma Australia Pty Ltd. (collectively “we,” “us,” “our,” and the “Company”), exists for the primary purpose of advancing the commercial development of a proprietary polyamine analogue (the “compound”) for the treatment of patients with pancreatic cancer. We have exclusively licensed the worldwide rights to this compound, which has been designated as SBP-
101,
from the University of Florida Research Foundation, Inc. (“UFRF”).

X

- References
No definition available.
+ Details

Name: us-gaap_DisclosureTextBlockAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-URI http://asc.fasb.org/topic&trid=2122149

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-URI http://asc.fasb.org/topic&trid=2197479
+ Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 45 R17.htm IDEA: XBRL DOCUMENT v3.19.3

Significant Accounting Policies (Policies)
9 Months Ended

Sep. 30, 2019

Accounting Policies [Abstract]

Consolidation, Policy [Policy Text Block]
Principles of consolidation

The accompanying condensed consolidated financial statements include the assets, liabilities and expenses of the Company. All significant intercompany transactions and balances have been eliminated in consolidation.

Use of Estimates, Policy [Policy Text Block]
Use of estimates

The preparation of condensed consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amount of expenses during the reporting period. Actual results could differ from those estimates.

Beneficial Conversion Feature, Policy [Policy Text Block]
Beneficial
c
onversion
f
eature
s

For convertible debt where the rate of conversion is below fair market value for our common stock, the Company records a beneficial conversion feature and related debt discount that is presented as a direct deduction from the carrying amount of the related debt and as an increase to additional paid-in capital. The debt discount is amortized through interest expense over the life of the related debt.

Debt Issuance Costs [Policy Text Block]
Debt issuance costs

Costs associated with the issuance of debt instruments are capitalized and presented as a direct deduction from the carrying amount of the related debt liability. These costs are amortized through interest expense over the life of the related debt.

Research and Development Expense, Policy [Policy Text Block]
Research and development costs

Research and development costs include expenses incurred in the conduct of our
second
Phase
1
human clinical trial, for
third
-party service providers performing various testing and accumulating data related to our preclinical studies; sponsored research agreements; developing and scaling the manufacturing process necessary to produce sufficient amounts of the SBP-
101
compound for use in our pre-clinical studies and human clinical trials; consulting resources with specialized expertise related to execution of our development plan for our SBP-
101
product candidate; personnel costs, including salaries, benefits and share-based compensation; and costs to license and maintain our licensed intellectual property.

We charge research and development costs, including clinical trial costs, to expense when incurred. Our human clinical trials are, and will be, performed at clinical trial sites and are administered jointly by us with assistance from contract research organizations (“CROs”). Costs of setting up clinical trial sites are accrued upon execution of the study agreement. Expenses related to the performance of clinical trials generally are accrued based on contracted amounts and the achievement of agreed upon milestones, such as patient enrollment, patient follow-up, etc. We monitor levels of performance under each significant contract, including the extent of patient enrollment and other activities through communications with the clinical trial sites and CROs, and adjust the estimates, if required, on a quarterly basis so that clinical expenses reflect the actual effort expended at each clinical trial site and by each CRO.

All material CRO contracts are terminable by us upon written notice and we are generally only liable for actual effort expended by the CROs and certain non-cancelable expenses incurred at any point of termination.

We expense costs associated with obtaining licenses for patented technologies when it is determined there is
no
alternative future use of the intellectual property subject to the license.

Share-based Payment Arrangement [Policy Text Block]
Stock
-based compensation

In accounting for stock-based incentive awards, we measure and recognize the cost of employee and non-employee services received in exchange for awards of equity instruments based on the fair value of those awards on the grant date. Calculating stock-based compensation expense requires the input of highly subjective assumptions, which represent our best estimates and involve inherent uncertainties and the application of management’s judgment. Compensation cost is recognized ratably using the straight-line attribution method over the vesting period, which is considered to be the requisite service period. Compensation expense for performance-based stock option awards is recognized when “performance” has occurred or is probable of occurring.

The fair value of stock-based awards is estimated at the date of grant using the Black-Scholes option pricing model. The determination of the fair value of stock-based awards is affected by our stock price, as well as assumptions regarding a number of complex and subjective variables. Risk free interest rates are based upon U.S. Treasury rates appropriate for the expected term of each award. Expected volatility rates are based primarily on the volatility rates of a set of guideline companies, which consist of public and recently public biotechnology companies. The assumed dividend yield is
zero
, as we do
not
expect to declare any dividends in the foreseeable future. The expected term of options granted is determined using the “simplified” method. Under this approach, the expected term is presumed to be the mid-point between the average vesting date and the end of the contractual term. Forfeitures of unvested stock options are recognized as they occur.

Foreign Currency Transactions and Translations Policy [Policy Text Block]
Foreign currency translation adjustments

The functional currency of Sun BioPharma Australia Pty Ltd is the Australian Dollar. Accordingly, assets and liabilities, and equity transactions of Sun BioPharma Australia Pty Ltd are translated into U.S. dollars at period-end exchange rates. Revenues and expenses are translated at the average exchange rate in effect for the period. The resulting translation gains and losses are recorded as a component of accumulated comprehensive loss presented within the statements of stockholders’ equity (deficit). During the
nine
-month periods ended
September 30, 2019
and
2018,
any reclassification adjustments from accumulated other comprehensive loss to operations were inconsequential.

Comprehensive Income, Policy [Policy Text Block]
Comprehensive loss

Comprehensive loss consists of our net loss and the effects of foreign currency translation.

Earnings Per Share, Policy [Policy Text Block]
Net loss per share

Basic net loss per share is computed by dividing net loss by the weighted-average number of common shares outstanding during the period. Diluted net loss per share is based on the weighted average of common shares outstanding during the period plus dilutive potential common shares calculated using the treasury stock method. Such potentially dilutive shares are excluded when the effect would be anti-dilutive or reduce a net loss per share. The Company’s potential dilutive shares, which include convertible debt, outstanding common stock options, and warrants, have
not
been included in the computation of diluted net loss per share for all periods as the result would be anti-dilutive.

The following table sets forth the potential shares of common stock that were
not
included in the calculation of diluted net loss per share as their effects would have been anti-dilutive as of:

September 30,

2019

2018

Employee and non-employee stock options

1,711,511

1,130,710

Estimated common shares issuable upon conversion of notes payable and accrued interest

-

2,222

Common stock issuable under common stock purchase warrants

3,411,544

1,265,979

5,123,055

2,398,911

X

- Definition
Disclosure of accounting policy for beneficial conversion feature.
+ References
No definition available.
+ Details

Name: snbp_BeneficialConversionFeaturePolicyPolicyTextBlock

Namespace Prefix: snbp_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for debt issuance costs.
+ References
No definition available.
+ Details

Name: snbp_DebtIssuanceCostsPolicyTextBlock

Namespace Prefix: snbp_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for comprehensive income.
+ References
No definition available.
+ Details

Name: us-gaap_ComprehensiveIncomePolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.3A-02)
-URI http://asc.fasb.org/extlink&oid=116822174&loc=d3e355033-122828

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section S99
-Paragraph 3
-Subparagraph (SX 210.3A-03)
-URI http://asc.fasb.org/extlink&oid=116822174&loc=d3e355100-122828

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684
+ Details

Name: us-gaap_ConsolidationPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257
+ Details

Name: us-gaap_EarningsPerSharePolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6450222&loc=d3e30840-110895
+ Details

Name: us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373
+ Details

Name: us-gaap_ResearchAndDevelopmentExpensePolicy

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (b),(f)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901
+ Details

Name: us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592
+ Details

Name: us-gaap_UseOfEstimates

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 46 R13.htm IDEA: XBRL DOCUMENT v3.19.3

Note 6 - Indebtedness
9 Months Ended

Sep. 30, 2019

Notes to Financial Statements

Debt Disclosure [Text Block]

6.

Indebtedness

Notes

On
June 30, 2019,
all
$2.2
million aggregate principal balance of Notes outstanding plus
$105,000
of accrued interest was converted at a conversion rate of
$3.50
per share of common stock into
651,758
shares of common stock per the terms of the Notes. The Notes were issued in
December 2018
and
January 2019
and bore interest at a rate of
10.0%
per year. Both the relative value of the Warrants and the beneficial conversion feature of the Notes were recorded as a debt discount at the times the Notes were sold which was presented as a direct deduction from the carrying value of the Notes. The discount was fully amortized through interest expense immediately prior to the conversion on
June 30, 2019.

Term debt

Effective
April 5, 2019
the terms of our unsecured loan (the “Term Debt”) payable to the Institute for Commercialization of Public Research, Inc. (the “Institute”) were amended to extend the maturity date from
May 1, 2019
to
December 31, 2019.
The Institute agreed to the amendment in exchange for a warrant to purchase
5,555
shares of common stock at an exercise price of
$4.50.
The warrant expires
five
years from issuance. The fair market value of the warrant was nominal and as such has
not
been given any accounting treatment. The amendment requires the continuation of monthly payments of principal and interest totaling
$10,000.
The unpaid principal balance at
September 30, 2019
was
$204,000.

Unsecured Promissory Notes

On
May 17, 2019
the Company executed an unsecured promissory note with a vendor that relieved the Company’s immediate obligation to pay the outstanding vendor invoices. The outstanding vendor invoices totaling approximately
$742,000
were removed from the Company’s accounts payable as consideration for the promissory note. The promissory note is unsecured, does
not
bear interest and the balance is payable in full on the earlier of (
1
)
December 31, 2020
or (
2
) the date the Company’s stock is registered on a national exchange.

X

- Definition
The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-URI http://asc.fasb.org/topic&trid=2208564
+ Details

Name: us-gaap_DebtDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_DisclosureTextBlockAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 47 R4.htm IDEA: XBRL DOCUMENT v3.19.3

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended

Sep. 30, 2019

Sep. 30, 2018

Sep. 30, 2019

Sep. 30, 2018

Operating expenses:

General and administrative $ 622 $ 467 $ 1,505 $ 1,779

Research and development 720 450 1,578 1,475

Operating loss (1,342) (917) (3,083) (3,254)

Other (expense) income:

Grant income 29 51

Interest expense (3) (3) (2,187) (1,763)

Other expense (219) (89) (287) (362)

Total other expense (222) (63) (2,474) (2,074)

Loss before income tax benefit (1,564) (980) (5,557) (5,328)

Income tax benefit 190 55 331 163

Net loss (1,374) (925) (5,226) (5,165)

Foreign currency translation adjustment 202 155 219 324

Comprehensive loss $ (1,172) $ (770) $ (5,007) $ (4,841)

Basic and diluted net loss per share (in dollars per share) $ (0.23) $ (0.18) $ (0.97) $ (1.14)

Weighted average shares outstanding - basic and diluted (in shares) 6,009,904 5,060,594 5,385,986 4,522,606

X

- Definition
The aggregate amount of income from grants not considered a component of the entity's core operations.
+ References
No definition available.
+ Details

Name: snbp_GrantIncomeNonoperating

Namespace Prefix: snbp_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=118930883&loc=d3e557-108580

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580
+ Details

Name: us-gaap_ComprehensiveIncomeNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256
+ Details

Name: us-gaap_EarningsPerShareBasicAndDiluted

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.4)
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227
+ Details

Name: us-gaap_GeneralAndAdministrativeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(h)(1)(i))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690
+ Details

Name: us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (h)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 20
-Section 45
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109238882&loc=d3e38679-109324
+ Details

Name: us-gaap_IncomeTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of the cost of borrowed funds accounted for as interest expense.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=114775744&loc=d3e28555-108399

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (210.5-03(11))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04.9)
-URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260
+ Details

Name: us-gaap_InterestExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.7)
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227
+ Details

Name: us-gaap_NonoperatingIncomeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NonoperatingIncomeExpenseAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_OperatingCostsAndExpensesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The net result for the period of deducting operating expenses from operating revenues.
+ References
No definition available.
+ Details

Name: us-gaap_OperatingIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 10A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section 45
-Paragraph 20
-Subparagraph (b,c)
-URI http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900
+ Details

Name: us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of income (expense) related to nonoperating activities, classified as other.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.9)
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227
+ Details

Name: us-gaap_OtherNonoperatingIncomeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 985
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373
+ Details

Name: us-gaap_ResearchAndDevelopmentExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).
+ References
No definition available.
+ Details

Name: us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 48 R29.htm IDEA: XBRL DOCUMENT v3.19.3

Note 9 - Stock-based Compensation (Details Textual) - USD ($)
$ in Millions
9 Months Ended

May 31, 2016

Sep. 30, 2019

Dec. 31, 2018

Common Stock, Capital Shares Reserved for Future Issuance 5,175,904

Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance 1,711,511 1,032,211

Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount $ 0.6

Share-based Payment Arrangement, Option [Member]

Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition 2 years 270 days

Sun BioPharma, Inc. 2016 Omnibus Incentive Plan [Member]

Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period 10 years

Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance 1,447,151

Sun BioPharma, Inc. 2016 Omnibus Incentive Plan [Member] | Share-based Payment Arrangement, Option [Member]

Common Stock, Capital Shares Reserved for Future Issuance 1,500,000 52,849

Sun BioPharma, Inc. 2011 Stock Option Plan [Member]

Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period 10 years

Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance 264,360

Sun BioPharma, Inc. 2011 Stock Option Plan [Member] | Share-based Payment Arrangement, Option [Member] | Minimum [Member]

Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period 0 years

Sun BioPharma, Inc. 2011 Stock Option Plan [Member] | Share-based Payment Arrangement, Option [Member] | Maximum [Member]

Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period 2 years

X

- Definition
Aggregate number of common shares reserved for future issuance.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockCapitalSharesReservedForFutureIssuance

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (i)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cost to be recognized for option under share-based payment arrangement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (i)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of options outstanding, including both vested and non-vested options.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)-(ii)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (a)(2)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PlanNameAxis=snbp_SunBiopharmaInc2016OmnibusIncentivePlanMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PlanNameAxis=snbp_SunBiopharmaInc2011StockOptionPlanMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_RangeAxis=srt_MinimumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_RangeAxis=srt_MaximumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 49 R25.htm IDEA: XBRL DOCUMENT v3.19.3

Note 6 - Indebtedness (Details Textual) - USD ($)
9 Months Ended

Jun. 30, 2019

May 17, 2019

Apr. 05, 2019

Sep. 30, 2019

Sep. 30, 2018

Dec. 31, 2018

Increase (Decrease) in Accounts Payable, Total $ 742,000 $ 179,000 $ 186,000

Unsecured Long-term Debt, Noncurrent 742,000

Warrants In Connection with Term Debt [Member]

Class of Warrant or Right, Number of Securities Called by Warrants or Rights 5,555

Class of Warrant or Right, Exercise Price of Warrants or Rights $ 4.50

Warrants and Rights Outstanding, Term 5 years

Term Debt [Member]

Debt Instrument, Periodic Payment, Total $ 10,000

Long-term Debt, Total $ 204,000

Unsecured Promissory Note [Member]

Unsecured Long-term Debt, Noncurrent $ 742,000

Convertible Debt [Member] | The 2018 Notes [Member]

Debt Instrument, Interest Rate, Stated Percentage 10.00%

Conversion from Debt to Common Stock [Member]

Debt Conversion, Original Debt, Amount $ 2,200,000

Debt Conversion, Accrued Interest, Amount $ 105,000

Debt Instrument, Convertible, Conversion Price $ 3.50

Debt Conversion, Converted Instrument, Shares Issued 651,758

X

- Definition
The amount of the acrrued interest being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.
+ References
No definition available.
+ Details

Name: snbp_DebtConversionAccruedInterestAmount

Namespace Prefix: snbp_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Exercise price per share or per unit of warrants or rights outstanding.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(i)(4))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690
+ Details

Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(i)(2))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690
+ Details

Name: us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4332-108586

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4304-108586
+ Details

Name: us-gaap_DebtConversionConvertedInstrumentSharesIssued1

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount of the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4304-108586

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4332-108586
+ Details

Name: us-gaap_DebtConversionOriginalDebtAmount1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The price per share of the conversion feature embedded in the debt instrument.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 5
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109500613&loc=SL6031898-161870
+ Details

Name: us-gaap_DebtInstrumentConvertibleConversionPrice1

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Contractual interest rate for funds borrowed, under the debt agreement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22(a)(1))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_DebtInstrumentInterestRateStatedPercentage

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
Amount of the required periodic payments including both interest and principal payments.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 470
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823
+ Details

Name: us-gaap_DebtInstrumentPeriodicPayment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInAccountsPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 4
-Subparagraph (b)(3)
-URI http://asc.fasb.org/extlink&oid=109500613&loc=SL6031897-161870

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(16))
-URI http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(16))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(22))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_LongTermDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Carrying value as of the balance sheet date of uncollateralized debt obligation (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_UnsecuredLongTermDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (bbb)(2)
-URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258
+ Details

Name: us-gaap_WarrantsAndRightsOutstandingTerm

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: instant

X

- Details

Name: us-gaap_ClassOfWarrantOrRightAxis=snbp_WarrantsInConnectionWithTermDebtMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentAxis=snbp_TermDebtMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentAxis=snbp_UnsecuredPromissoryNoteMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentAxis=snbp_The2018NotesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtConversionByUniqueDescriptionAxis=snbp_ConversionFromDebtToCommonStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 50 R21.htm IDEA: XBRL DOCUMENT v3.19.3

Note 2 - Risks and Uncertainties (Details Textual) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended 105 Months Ended

Sep. 30, 2019

Jun. 30, 2019

Mar. 31, 2019

Sep. 30, 2018

Jun. 30, 2018

Mar. 31, 2018

Sep. 30, 2019

Sep. 30, 2018

Sep. 30, 2019

Dec. 31, 2018

Dec. 31, 2017

Net Income (Loss) Attributable to Parent, Total $ (1,374) $ (2,271) $ (1,581) $ (925) $ (2,487) $ (1,753) $ (5,226) $ (5,165) $ (40,300)

Amortization of Debt Discount (Premium) 2,061 1,687

Net Cash Provided by (Used in) Operating Activities, Total (1,867) (2,225)

Proceeds from Issuance of Private Placement 3,142 2,314

Proceeds from Issuance or Sale of Equity, Total 800

Cash and Cash Equivalents, at Carrying Value, Ending Balance 3,377 239 3,377 239 3,377 $ 1,405 $ 152

Working Capital 3,100 3,100 3,100

Stockholders' Equity Attributable to Parent, Ending Balance $ 2,389 $ (117) $ (588) $ (542) $ 110 $ (2,320) $ 2,389 $ (542) $ 2,389 $ 268 $ (3,689)

X

- Definition
Represents current assets less current liabilities.
+ References
No definition available.
+ Details

Name: snbp_WorkingCapital

Namespace Prefix: snbp_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=114775744&loc=d3e28541-108399

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.8)
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227
+ Details

Name: us-gaap_AmortizationOfDebtDiscountPremium

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3044-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.1)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 25
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3521-108585

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585
+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585
+ Details

Name: us-gaap_ProceedsFromIssuanceOfPrivatePlacement

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585
+ Details

Name: us-gaap_ProceedsFromIssuanceOrSaleOfEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

Note 9 - Stock-based Compensation - Assumptions Used in Calculating Fair Value of Options (Details)	3 Months Ended	9 Months Ended
	Sep. 30, 2019 $ / shares	Sep. 30, 2019 $ / shares
Expected dividend yield	0.00%	0.00%
Expected stock price volatility	72.00%
Minimum [Member]
Common stock fair value (in dollars per share)	$ 4.50	$ 4.50
Risk-free interest rate	1.55%
Expected Option life (years) (Year)	5 years
Maximum [Member]
Common stock fair value (in dollars per share)	$ 5	$ 5
Risk-free interest rate	1.57%
Expected Option life (years) (Year)	5 years 182 days

Note 5 - Summary of Significant Accounting Policies - Anti-dilutive Securities (Details) - shares	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Anti-dilutive securities (in shares)	5,123,055	2,398,911
Share-based Payment Arrangement [Member]
Anti-dilutive securities (in shares)	1,711,511	1,130,710
Convertible Debt Securities [Member]
Anti-dilutive securities (in shares)		2,222
Warrant [Member]
Anti-dilutive securities (in shares)	3,411,544	1,265,979

Note 8 - Stockholders' Deficit - Common Stock Reserved for Future Issuance (Details) - shares	Sep. 30, 2019	Dec. 31, 2018
Stock options outstanding (in shares)	1,711,511
Shares available for grant under equity incentive plan (in shares)	52,849	732,149
Common shares issuable under outstanding common stock purchase warrants (in shares)	3,411,544
(in shares)	5,175,904

Note 9 - Stock-based Compensation - Summary of Option Activity (Details) - USD ($)	9 Months Ended
	Sep. 30, 2019	Dec. 31, 2018
Balance, shares available for grant (in shares)	732,149
Balance, shares underlying options (in shares)	1,032,211
Balance, weighted average exercise price per share (in dollars per share)	$ 6.58	$ 8.90
Aggregate intrinsic value	$ 1,674,675	$ 169,495
Granted, shares available for grant (in shares)	(700,100)
Granted, shares underlying options (in shares)	700,100
Granted, weighted average exercise price per share (in dollars per share)	$ 3.41
Forfeitures , shares available for grant (in shares)	20,800
Forfeited, shares underlying options (in shares)	(20,800)
Forfeited, weighted average exercise price per share (in dollars per share)	$ 15.10
Balance, shares available for grant (in shares)	52,849
Balance, shares underlying options (in shares)	1,711,511

Condensed Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited) - USD ($) shares in Thousands, $ in Thousands	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]	Total
Balances (in shares) at Dec. 31, 2017	3,842
Balances at Dec. 31, 2017	$ 4	$ 25,625	$ (29,153)	$ (165)	$ (3,689)
Stock Issued During Period, Shares, New Issues	252
Sale of common stock and warrants		1,261			1,261
Stock-based compensation		1,792			1,792
Net loss			(1,753)		(1,753)
Foreign currency translation adjustment				69	69
Sale of common stock and warrants (in shares)	252
Balances (in shares) at Mar. 31, 2018	4,094
Balances at Mar. 31, 2018	$ 4	28,678	(30,906)	(96)	(2,320)
Balances (in shares) at Dec. 31, 2017	3,842
Balances at Dec. 31, 2017	$ 4	25,625	(29,153)	(165)	(3,689)
Net loss					(5,165)
Foreign currency translation adjustment					324
Warrants issued with sale of convertible notes payable
Common stock converted into convertible notes payable
Balances (in shares) at Sep. 30, 2018	5,061
Balances at Sep. 30, 2018	$ 5	33,612	(34,318)	159	(542)
Balances (in shares) at Mar. 31, 2018	4,094
Balances at Mar. 31, 2018	$ 4	28,678	(30,906)	(96)	(2,320)
Stock Issued During Period, Shares, New Issues	216
Sale of common stock and warrants		1,080			1,080
Stock-based compensation		358			358
Net loss			(2,487)		(2,487)
Foreign currency translation adjustment				100	100
Beneficial conversion feature		121			121
Conversion of convertible notes payable and accrued interest into common stock and warrants (in shares)	751
Conversion of convertible notes payable and accrued interest into common stock and warrants	$ 1	3,257			3,258
Sale of common stock and warrants (in shares)	216
Balances (in shares) at Jun. 30, 2018	5,061
Balances at Jun. 30, 2018	$ 5	33,494	(33,393)	4	110
Stock-based compensation		146			146
Net loss			(925)		(925)
Foreign currency translation adjustment				155	155
Sale of common stock and warrants		(28)			(28)
Balances (in shares) at Sep. 30, 2018	5,061
Balances at Sep. 30, 2018	$ 5	33,612	(34,318)	159	(542)
Balances (in shares) at Dec. 31, 2018	5,077
Balances at Dec. 31, 2018	$ 5	35,038	(35,058)	283	268
Stock-based compensation		10			10
Net loss			(1,581)		(1,581)
Foreign currency translation adjustment				(32)	(32)
Beneficial conversion feature		353			353
Warrants issued with sale of convertible notes payable		419			419
Common stock converted into convertible notes payable (in shares)	(7)
Common stock converted into convertible notes payable		(25)			(25)
Balances (in shares) at Mar. 31, 2019	5,070
Balances at Mar. 31, 2019	$ 5	35,795	(36,639)	251	(588)
Balances (in shares) at Dec. 31, 2018	5,077
Balances at Dec. 31, 2018	$ 5	35,038	(35,058)	283	268
Net loss					(5,226)
Foreign currency translation adjustment					219
Warrants issued with sale of convertible notes payable					419
Common stock converted into convertible notes payable					(25)
Balances (in shares) at Sep. 30, 2019	6,624
Balances at Sep. 30, 2019	$ 7	42,164	(40,284)	502	2,389
Balances (in shares) at Mar. 31, 2019	5,070
Balances at Mar. 31, 2019	$ 5	35,795	(36,639)	251	(588)
Stock-based compensation		412			412
Net loss			(2,271)		(2,271)
Foreign currency translation adjustment				49	49
Conversion of convertible notes payable and accrued interest into common stock and warrants (in shares)	652
Conversion of convertible notes payable and accrued interest into common stock and warrants	$ 1	2,280			2,281
Balances (in shares) at Jun. 30, 2019	5,722
Balances at Jun. 30, 2019	$ 6	38,487	(38,910)	300	(117)
Stock Issued During Period, Shares, New Issues	902
Sale of common stock and warrants	$ 1	3,141			3,142
Stock-based compensation		536			536
Net loss			(1,374)		(1,374)
Foreign currency translation adjustment				202	202
Sale of common stock and warrants (in shares)	902
Balances (in shares) at Sep. 30, 2019	6,624
Balances at Sep. 30, 2019	$ 7	$ 42,164	$ (40,284)	$ 502	$ 2,389

Document And Entity Information - shares	9 Months Ended
Document And Entity Information - shares	Sep. 30, 2019	Nov. 08, 2019
Document Information [Line Items]
Entity Registrant Name	Sun BioPharma, Inc.
Entity Central Index Key	0001029125
Trading Symbol	snbp
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Current Reporting Status	Yes
Entity Emerging Growth Company	false
Entity Small Business	true
Entity Common Stock, Shares Outstanding (in shares)		6,631,308
Entity Shell Company	false
Document Type	10-Q
Document Period End Date	Sep. 30, 2019
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	Q3
Amendment Flag	false
Title of 12(g) Security	Common Stock, $0.001 par value

Note 9 - Stock-based Compensation - Stock-based Compensation Expense (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Share-based compensation expense	$ 958	$ 2,296
General and Administrative Expense [Member]
Share-based compensation expense	573	1,404
Research and Development Expense [Member]
Share-based compensation expense	$ 385	$ 892

Note 9 - Stock-based Compensation (Details Textual) - USD ($) $ in Millions		9 Months Ended
	May 31, 2016	Sep. 30, 2019	Dec. 31, 2018
Common Stock, Capital Shares Reserved for Future Issuance		5,175,904
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance		1,711,511	1,032,211
Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount		$ 0.6
Share-based Payment Arrangement, Option [Member]
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition		2 years 270 days
Sun BioPharma, Inc. 2016 Omnibus Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period	10 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance		1,447,151
Sun BioPharma, Inc. 2016 Omnibus Incentive Plan [Member] \| Share-based Payment Arrangement, Option [Member]
Common Stock, Capital Shares Reserved for Future Issuance	1,500,000	52,849
Sun BioPharma, Inc. 2011 Stock Option Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period		10 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance		264,360
Sun BioPharma, Inc. 2011 Stock Option Plan [Member] \| Share-based Payment Arrangement, Option [Member] \| Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period		0 years
Sun BioPharma, Inc. 2011 Stock Option Plan [Member] \| Share-based Payment Arrangement, Option [Member] \| Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period		2 years

Note 6 - Indebtedness (Details Textual) - USD ($)				9 Months Ended
Note 6 - Indebtedness (Details Textual) - USD ($)	Jun. 30, 2019	May 17, 2019	Apr. 05, 2019	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2018
Increase (Decrease) in Accounts Payable, Total		$ 742,000		$ 179,000	$ 186,000
Unsecured Long-term Debt, Noncurrent				742,000
Warrants In Connection with Term Debt [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights			5,555
Class of Warrant or Right, Exercise Price of Warrants or Rights			$ 4.50
Warrants and Rights Outstanding, Term			5 years
Term Debt [Member]
Debt Instrument, Periodic Payment, Total			$ 10,000
Long-term Debt, Total				$ 204,000
Unsecured Promissory Note [Member]
Unsecured Long-term Debt, Noncurrent		$ 742,000
Convertible Debt [Member] \| The 2018 Notes [Member]
Debt Instrument, Interest Rate, Stated Percentage	10.00%
Conversion from Debt to Common Stock [Member]
Debt Conversion, Original Debt, Amount	$ 2,200,000
Debt Conversion, Accrued Interest, Amount	$ 105,000
Debt Instrument, Convertible, Conversion Price	$ 3.50
Debt Conversion, Converted Instrument, Shares Issued	651,758

Note 2 - Risks and Uncertainties (Details Textual) - USD ($) $ in Thousands	3 Months Ended						9 Months Ended		105 Months Ended
	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Dec. 31, 2018	Dec. 31, 2017
Net Income (Loss) Attributable to Parent, Total	$ (1,374)	$ (2,271)	$ (1,581)	$ (925)	$ (2,487)	$ (1,753)	$ (5,226)	$ (5,165)	$ (40,300)
Amortization of Debt Discount (Premium)							2,061	1,687
Net Cash Provided by (Used in) Operating Activities, Total							(1,867)	(2,225)
Proceeds from Issuance of Private Placement							3,142	2,314
Proceeds from Issuance or Sale of Equity, Total							800
Cash and Cash Equivalents, at Carrying Value, Ending Balance	3,377			239			3,377	239	3,377	$ 1,405	$ 152
Working Capital	3,100						3,100		3,100
Stockholders' Equity Attributable to Parent, Ending Balance	$ 2,389	$ (117)	$ (588)	$ (542)	$ 110	$ (2,320)	$ 2,389	$ (542)	$ 2,389	$ 268	$ (3,689)